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Abstract 
Cardiovascular disease is a leading cause of death in the United States, and while mortality rates from 
acute myocardial infarctions (MI) are declining, many of these surviving patients will develop heart failure 
as a result of adverse left ventricular remodeling initiated by the ischemic attack. Cell therapies have been 
broadly explored in the clinic to promote cardiac repair after MI, but low engraftment of delivered cells has 
limited their translation and clinical efficacy. Additionally, the positive benefits of cell therapies may be 
due to paracrine signals that cells produce rather than the cells themselves, which has motivated the 
direct delivery of cell-derived therapies, such as growth factors, cytokines, and extracellular vesicles 
(EVs). However, with all of these therapies, new strategies to improve their engraftment and sustained 
presentation after MI are needed. 
To address this concern, this dissertation engineers an injectable hydrogel through the mixing of 
hyaluronic acid functionalized with either adamantane or -cyclodextrin groups. This supramolecular 
assembly imparts shear-thinning and self-healing properties into the hydrogel that allows injection into 
the myocardium. After a thorough characterization of the hydrogel properties, select formulations are 
explored for the delivery of various cell-based therapeutics, including endothelial progenitor cells (EPCs), 
interleukin-10 (IL-1), and mesenchymal stromal cell (MSC)-derived EVs. These therapeutics are intended 
to improve outcomes after MI, through alterations in vascularization and the inflammatory response 
during remodeling. 
Hydrogel delivery of EPCs significantly improves EPC retention when compared to the direct injection of 
EPCs in saline. This enhanced cell retention is correlated with improved cardiac function, reduced scar 
fraction, and increased vascular density in a rat MI model. IL-10 is delivered from the same hydrogel, 
using a degradable microgel carrier that allows decoupling of the hydrogel injectability from IL-10 release 
behavior. Delivery of this composite hydrogel with IL-10 to the heart in a rat MI model significantly 
reduced the presence of inflammatory cells and improved cardiac function and remodeling when 
compared to saline. 
Finally, an injectable guest-host hydrogel is utilized to deliver EVs isolated from MSCs that are pre-
conditioned to be pro-vasculogenic. EVs isolated from MSCs treated with different pre-conditioning 
regimens have varied protein content, and the delivery of pre-conditioned EVs using an injectable hydrogel 
improves EV retention in the heart and increases vascularization in the infarct region after MI. These 
findings indicate that a shear-thinning hydrogel can be used to deliver and enhance the retention of cells, 
cytokines, and EVs in the heart and enhanced therapeutic retention can result in improved outcomes for 
cardiac repair after MI. Overall, this thesis highlights the use of an injectable hydrogel as a therapeutic 
delivery vehicle toward translation of these therapeutics for clinical use. 
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ABSTRACT 
 
INJECTABLE HYALURONIC ACID HYDROGELS FOR THE DELIVERY OF CELL-
BASED THERAPEUTICS TO THE HEART 
Minna H. Chen 
Jason A. Burdick 
 
Cardiovascular disease is a leading cause of death in the United States, and 
while mortality rates from acute myocardial infarctions (MI) are declining, many of these 
surviving patients will develop heart failure as a result of adverse left ventricular 
remodeling initiated by the ischemic attack. Cell therapies have been broadly explored in 
the clinic to promote cardiac repair after MI, but low engraftment of delivered cells has 
limited their translation and clinical efficacy. Additionally, the positive benefits of cell 
therapies may be due to paracrine signals that cells produce rather than the cells 
themselves, which has motivated the direct delivery of cell-derived therapies, such as 
growth factors, cytokines, and extracellular vesicles (EVs). However, with all of these 
therapies, new strategies to improve their engraftment and sustained presentation after 
MI are needed.  
 To address this concern, this dissertation engineers an injectable hydrogel 
through the mixing of hyaluronic acid functionalized with either adamantane or b-
cyclodextrin groups. This supramolecular assembly imparts shear-thinning and self-
healing properties into the hydrogel that allows injection into the myocardium. After a 
thorough characterization of the hydrogel properties, select formulations are explored for 
the delivery of various cell-based therapeutics, including endothelial progenitor cells 
(EPCs), interleukin-10 (IL-1), and mesenchymal stromal cell (MSC)-derived EVs.  These 
v 
therapeutics are intended to improve outcomes after MI, through alterations in 
vascularization and the inflammatory response during remodeling. 
 Hydrogel delivery of EPCs significantly improves EPC retention when compared 
to the direct injection of EPCs in saline. This enhanced cell retention is correlated with 
improved cardiac function, reduced scar fraction, and increased vascular density in a rat 
MI model.  IL-10 is delivered from the same hydrogel, using a degradable microgel 
carrier that allows decoupling of the hydrogel injectability from IL-10 release behavior.  
Delivery of this composite hydrogel with IL-10 to the heart in a rat MI model significantly 
reduced the presence of inflammatory cells and improved cardiac function and 
remodeling when compared to saline.  
 Finally, an injectable guest-host hydrogel is utilized to deliver EVs isolated from 
MSCs that are pre-conditioned to be pro-vasculogenic. EVs isolated from MSCs treated 
with different pre-conditioning regimens have varied protein content, and the delivery of 
pre-conditioned EVs using an injectable hydrogel improves EV retention in the heart and 
increases vascularization in the infarct region after MI. These findings indicate that a 
shear-thinning hydrogel can be used to deliver and enhance the retention of cells, 
cytokines, and EVs in the heart and enhanced therapeutic retention can result in 
improved outcomes for cardiac repair after MI. Overall, this thesis highlights the use of 
an injectable hydrogel as a therapeutic delivery vehicle toward translation of these 
therapeutics for clinical use.  
 
 
 
 
 
 
vi 
TABLE OF CONTENTS 
ACKNOWLEDGMENT ..................................................................................................... II 
ABSTRACT ..................................................................................................................... IV 
TABLE OF CONTENTS .................................................................................................. VI 
LIST OF TABLES .......................................................................................................... VIII 
LIST OF FIGURES .......................................................................................................... IX 
CHAPTER 1 ...................................................................................................................... 1 
INTRODUCTION .............................................................................................................. 1 
1.1 SIGNIFICANCE ....................................................................................................................................... 1 
1.2 LEFT VENTRICULAR REMODELING AFTER MI ....................................................................................... 3 
1.3 CELLULAR AND CELL-DERIVED THERAPEUTICS FOR CARDIAC REPAIR ................................................. 6 
1.4 INJECTABLE HYDROGELS FOR MI ....................................................................................................... 21 
1.5 CONCLUSIONS .................................................................................................................................... 30 
1.6 REFERENCES ....................................................................................................................................... 31 
CHAPTER 2 .................................................................................................................... 46 
RESEARCH OVERVIEW ............................................................................................... 46 
2.1 SPECIFIC AIMS .................................................................................................................................... 46 
2.2 CHAPTER OUTLINE ............................................................................................................................. 52 
2.3 REFERENCES ....................................................................................................................................... 53 
CHAPTER 3 .................................................................................................................... 56 
METHODS TO CHARACTERIZE INJECTABLE HYDROGELS FOR BIOMEDICAL 
APPLICATIONS ............................................................................................................. 56 
3.1 INTRODUCTION .................................................................................................................................. 56 
3.2 SYNTHESIS OF HYDROGEL COMPONENTS ......................................................................................... 59 
3.3 RHEOLOGICAL CHARACTERIZATION OF HYDROGELS ......................................................................... 78 
3.4 MEASUREMENT OF HYDROGEL INJECTION FORCES .......................................................................... 88 
3.5 ENCAPSULATED CELL VIABILITY AFTER INJECTION ............................................................................ 94 
3.6 INJECTION OF HYDROGELS IN RAT MI MODELS ............................................................................... 103 
3.7 SUMMARY ........................................................................................................................................ 113 
3.8 REFERENCES ..................................................................................................................................... 115 
CHAPTER 4 .................................................................................................................. 120 
INJECTABLE HYDROGELS FOR ENDOTHELIAL PROGENITOR CELL DELIVERY 
TO THE HEART ........................................................................................................... 120 
vii 
4.1 INTRODUCTION ................................................................................................................................ 120 
4.2 METHODS ......................................................................................................................................... 123 
4.3 RESULTS ........................................................................................................................................... 128 
4.4 DISCUSSION ..................................................................................................................................... 135 
4.5 CONCLUSION .................................................................................................................................... 138 
4.6 REFERENCES ..................................................................................................................................... 139 
CHAPTER 5 .................................................................................................................. 144 
INJECTABLE SUPRAMOLECULAR HYDROGEL/MICROGEL COMPOSITES FOR 
THERAPEUTIC DELIVERY ......................................................................................... 144 
5.1 INTRODUCTION ................................................................................................................................ 144 
5.2 EXPERIMENTAL SECTION ................................................................................................................. 146 
5.3 RESULTS AND DISCUSSION ............................................................................................................... 156 
5.4 CONCLUSIONS .................................................................................................................................. 171 
5.5 REFERENCES ..................................................................................................................................... 172 
CHAPTER 6 .................................................................................................................. 178 
INJECTABLE HYDROGEL DELIVERY OF EXTRACELLULAR VESICLES ISOLATED 
FROM PRE-CONDITIONED MSCS TO THE HEART .................................................. 178 
6.1 INTRODUCTION ................................................................................................................................ 178 
6.2 METHODS ......................................................................................................................................... 181 
6.3 RESULTS AND DISCUSSION ............................................................................................................... 191 
6.4 CONCLUSION .................................................................................................................................... 210 
6.5 REFERENCES ..................................................................................................................................... 211 
CHAPTER 7 .................................................................................................................. 215 
CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS .................................. 215 
7.1 OVERVIEW ........................................................................................................................................ 215 
7.2 SPECIFIC AIM 1 ................................................................................................................................. 216 
7.3 SPECIFIC AIM 2 ................................................................................................................................. 219 
7.4 SPECIFIC AIM 3 ................................................................................................................................. 221 
7.5 SPECIFIC AIM 4 ................................................................................................................................. 223 
7.6 OVERALL SUMMARY ........................................................................................................................ 225 
7.7 REFERENCES ..................................................................................................................................... 226 
 
 
 
 
 
 
 
viii 
LIST OF TABLES 
Table 1.1. Main growth factors applicable to cardiac repair. ........................................... 19 
Table 1.2. Therapeutic angiogenesis clinical trials. ........................................................ 20 
Table 1.3. Fold-increase in cell retention over intramyocardial saline delivery reported 
with various injectable hydrogels. ................................................................................... 25 
Table 4.1. Left ventricular function. ............................................................................... 133 
Table 6.1. Exosome size and protein content for all pre-conditioning regimens. .......... 195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
LIST OF FIGURES 
Figure 1.1. Blockages in coronary arteries can cause MI. ................................................ 2 
Figure 1.2. Local cardiac remodeling after MI. .................................................................. 4 
Figure 1.3. Global ventricular remodeling after MI. ........................................................... 5 
Figure 1.4. Goals of cellular therapies. ............................................................................. 7 
Figure 1.5. Delivery methods for cells to the heart. .......................................................... 8 
Figure 1.6. Clinical trials for cell therapies. ..................................................................... 13 
Figure 1.7. EVs produced by cells. ................................................................................. 15 
Figure 1.8. Exosome biogenesis. .................................................................................... 16 
Figure 1.9. Clinical trials for EV or exosome therapies. .................................................. 18 
Figure 1.10. Left ventricular end-diastolic myofiber stress distribution after hydrogel 
injection. .......................................................................................................................... 22 
Figure 1.11. Relative hydrogel mesh size to drug size mediates diffusion of encapsulated 
therapeutics. ................................................................................................................... 29 
Figure 3.1. Guest-host material synthesis and assembly. .............................................. 59 
Figure 3.2. Synthetic route for preparation of CD-Tos and CD-HDA. ............................. 66 
Figure 3.3. Reaction setup for synthesis of CD-Tos and CD-HDA. ................................ 67 
Figure 3.4. 1H NMR spectrum of CD-Tos in DMSO-d6. ................................................... 73 
Figure 3.5. 1H NMR spectra of HA-TBA in D2O. ............................................................. 74 
Figure 3.6. 1H NMR spectrum of CD-Tos in DMSO-d6. ................................................... 75 
Figure 3.7. 1H NMR spectrum of CD-HDA in DMSO-d6. ................................................. 76 
Figure 3.8. 1H NMR spectra of CD-HA in D2O. ............................................................... 77 
Figure 3.9. 1H NMR spectra of Ad-HA in D2O. ................................................................ 78 
Figure 3.10. Hydrogel loading onto the rheometer stage. ............................................... 83 
Figure 3.11. Rheological characterization of guest-host hydrogels. ............................... 86 
Figure 3.12. Additional rheological characterization of guest-host hydrogels. ................ 88 
Figure 3.13. Injection force using a force sensor. ........................................................... 91 
Figure 3.14. Injection force using a mechanical testing machine. .................................. 92 
Figure 3.15. Agarose molds. ........................................................................................... 98 
x 
Figure 3.16. Techniques for mixing guest-host hydrogels. ........................................... 100 
Figure 3.17. Cell viability depends on material concentration. ...................................... 102 
Figure 3.18. Effect of increasing flow rate on injection force and cell viability. ............. 102 
Figure 3.19. Intramyocardial hydrogel injections in rat MI models. ............................... 107 
Figure 3.20. Hydrogel and tissue preservation after embedding, sectioning, and staining.
 ...................................................................................................................................... 112 
Figure 4.1. Overview of hydrogel composition. ............................................................. 124 
Figure 4.2. EPC viability after injectable hydrogel encapsulation. ................................ 129 
Figure 4.3. EPC engraftment after 48 hours. ................................................................ 130 
Figure 4.4. EPC tracking over time. .............................................................................. 130 
Figure 4.5. Ejection fraction. ......................................................................................... 132 
Figure 4.6. Cardiac remodeling. .................................................................................... 134 
Figure 4.7. Formation of new vascular structures. ........................................................ 135 
Figure 5.1. NMR Spectra. ............................................................................................. 147 
Figure 5.2. Material synthesis. ...................................................................................... 157 
Figure 5.3. Microgel formation. ..................................................................................... 158 
Figure 5.4. Effect of HepSH. ......................................................................................... 159 
Figure 5.5. Microgel degradation and IL-10 release. .................................................... 160 
Figure 5.6. Composite hydrogels. ................................................................................. 161 
Figure 5.7. Rheology of composite hydrogels. .............................................................. 163 
Figure 5.8. IL-10 release from composite hydrogels. .................................................... 164 
Figure 5.9. Rat MI model. ............................................................................................. 165 
Figure 5.10. Inflammatory response. ............................................................................ 166 
Figure 5.11. Cardiac remodeling. .................................................................................. 167 
Figure 5.12. Composite hydrogel in cardiac tissue. ...................................................... 167 
Figure 5.13. Cardiac function. ....................................................................................... 169 
Figure 5.14. Formation of new vascular structures. ...................................................... 170 
Figure 6.1. rMSC pre-conditioning regimen. ................................................................. 183 
xi 
Figure 6.2. MSC number and morphology after pre-conditioning. ................................ 192 
Figure 6.3. EV characterization: size, yield, protein content. ........................................ 195 
Figure 6.4. Matrigel angiogenesis assay. ..................................................................... 196 
Figure 6.5. Exploratory proteomics analysis. ................................................................ 198 
Figure 6.6. Enrichment proteomics analysis. ................................................................ 200 
Figure 6.7. in vivo EV retention. .................................................................................... 202 
Figure 6.8. in vivo EV biodistribution. ............................................................................ 203 
Figure 6.9. Cardiac remodeling. .................................................................................... 205 
Figure 6.10. Quantification of cardiac remodeling. ....................................................... 206 
Figure 6.11. Vascular structures. .................................................................................. 207 
Figure 6.12. Quantification of vascular structures. ........................................................ 208 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1  
INTRODUCTION 
 
1.1 SIGNIFICANCE 
Cardiovascular disease (CVD) is the leading cause of death globally and in the 
United States, where it is responsible for almost 1 in every 3 deaths - more than all types 
of cancer combined.1 More than 121.5 million adults in the United States have some 
form of CVD, and from 2014-2015 the total costs associated with CVD and stroke were 
more than $350 billion, accounting for 14% of total healthcare expenditures and more 
than any other major diagnostic group.1 While the etiology of the disease is not certain, 
CVD can be preventable by reducing risk factors such as smoking and high body weight 
through physical activity and a healthy diet, as well as maintenance of healthy 
cholesterol, blood pressure, and blood sugar levels.1  
Every 40 seconds an American adult suffers from a heart attack or myocardial 
infarction (MI).1 An MI most commonly occurs when a coronary artery becomes 
occluded, usually due to the rupture of atherosclerotic plaques and subsequent clot 
formation (Figure 1.1).2 If diagnosed and treated quickly, medications and surgical 
interventions can restore blood flow and limit heart muscle damage. Thrombolytic 
medications such as aspirin, heparin, and antiplatelet drugs can break up the existing 
clot and prevent new clots from forming.2 Percutaneous coronary intervention 
procedures, where stents are used to open narrow or blocked arteries, as well as 
coronary artery bypass surgery can be used to restore blood flow to the heart.2 However, 
if blood flow is not restored quickly, the lack of oxygen and nutrients cause muscle 
damage and tissue death, which triggers an inflammatory response and a loss of 
2 
cardiomyocytes, the contractile cell of the heart. Over time, this leads to a remodeling 
process that replaces healthy tissue with scar tissue and can result in diminished cardiac 
function and potentially heart failure (HF). 
 
 
Figure 1.1. Blockages in coronary arteries can cause MI. A-B) Cholesterol and fatty 
acid deposits (plaques) inside coronary arteries, which can rupture and attract platelets 
to form C) a blood clot which occludes the artery. D) Downstream of the blockage, the 
heart muscle becomes ischemic due to the lack of oxygen and nutrients, eventually 
leading to heart muscle death. Adapted from Cleveland Clinic Foundation.2  
 
The prognosis for patients who develop HF is grim- over 50% will die within 5 
years.3,4 About 5.7 million American adults suffer from HF, with 915,000 more diagnosed 
each year.3 HF costs Americans an estimated $30.7 billion per year due to 
hospitalizations, medications, and lost productivity.3 Current treatments for HF focus on 
improving cardiac function and blood flow through the use of medications (angiotensin 
converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, 
aldosterone antagonists) or surgeries (coronary artery bypass graft surgery, valve repair 
or replacements).5 Pacemakers and implantable cardiac defibrillators can be used to 
3 
regulate cardiac contractions. In advanced HF, ventricular assist devices and heart 
transplants may be considered. Besides heart transplantation, which suffers from an 
extremely limited donor supply, all other treatments are merely palliative and do not 
address the irreversible loss of cardiac muscle tissue that occurs as a result of the 
ischemic attack. Thus, there exists a great need to develop therapeutics that can target 
this damaged tissue to restore cardiac function and limit adverse cardiac remodeling to 
improve outcomes for patients with HF. 
 
1.2 LEFT VENTRICULAR REMODELING AFTER MI  
MI can lead to the loss of a billion or more cardiomyocytes6, which leads to a 
series of regional and global changes in the myocardium that can eventually result in 
HF. These changes to the myocardium are broadly termed cardiac remodeling, whereby 
biochemical, cellular, and matrix changes result in modifications to the size, shape, and 
function of the heart over time.7 The initial phase of acute inflammation evolves into 
granulation tissue formation and eventually scar formation (Figure 1.2).8 The process of 
cardiac remodeling starts immediately after infarction and continues for a period of 
months and even years. Over time, the replacement of healthy myocardium with scar 
tissue reduces cardiac function.  
Cardiomyocyte necrosis and apoptosis starts as quickly as an hour after 
occlusion of a coronary artery, and leads to a localized inflammatory response that is 
prominent during the first 4 days.8 At this time, inflammatory cells such as neutrophils 
and monocytes infiltrate the infarct region and clear necrotic cardiomyocytes and other 
cellular debris.8,9 Matrix metalloproteinases begin to degrade the extracellular matrix 
(ECM) and cytokines and chemokines modulate the inflammatory response.8 
4 
Following this stage is a proliferative phase. In this stage, which occurs 2-3 days 
later and lasts for up to 2 weeks, granulation tissue begins to form and endothelial cells 
migrate into the infarct region and create new vasculature.8 Fibroblasts and 
myofibroblasts start to produce ECM, and the infarct begins to expand as greater wall 
stresses lead to ventricular dilation and wall thinning.10 In this stage, formation of new 
vasculature, ECM deposition, and macrophage function are crucial to control infarct 
expansion, which ultimately has an adverse effect on ventricular function.11 Infarct 
expansion is particularly pronounced if the infarct region is transmural.  
 
Figure 1.2. Local cardiac remodeling after MI. Following cardiomyocyte death, phases 
of acute inflammation, granulation tissue formation, and scar formation contribute to the 
local remodeling of cardiac tissue after MI. During these phases, macrophage activation, 
new vessel formation, and collagen deposition are important determinants of infarct 
expansion and subsequent cardiac function. Adapted from Matsui, et al.8 
 
In the next phase, the granulation tissue matures to form scar tissue over a 
period of weeks to months. Fibroblasts and myofibroblasts undergo apoptosis and 
vascular structures start to regress.11 The remaining cardiomyocytes realign themselves 
in the dense, cross-linked collagen matrix of the scar tissue, which often exhibits 
5 
reduced regional wall motion.10 This promotes greater levels of loading on the viable 
myocardium, which leads to further ventricular dilation and cardiac hypertrophy (Figure 
1.3).11,12 This ventricular dilation preserves the stroke volume, but does not improve the 
ejection fraction, and changes the shape of the ventricle to be more spherical, which is 
detrimental to cardiac function and ultimately can lead to HF.7,10  
 
Figure 1.3. Global ventricular remodeling after MI. After MI, changes to the infarct, 
border zone, and remote regions of the myocardium result in infarct expansion, 
ventricular dilation, and ventricular wall thinning, which decreases cardiac function. 
Adapted from Jessup, et al.12 
 
The process of adverse cardiac remodeling after MI lends itself to targets to 
potentially modulate the remodeling process and improve cardiac function. Anti-
inflammatory cytokines can be used to mitigate the initial acute inflammatory response, 
as well as the response of immune cells in the proliferative phase. The delivery of cells 
and cell-derived therapeutics that can increase vascularization can help to control infarct 
expansion. Finally, the use of biomaterials can improve the localization and retention of 
delivered therapeutics, as well as bulk the ventricular wall, which can ameliorate the 
increased wall stresses by increasing ventricular wall thickness.  
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1.3 CELLULAR AND CELL-DERIVED THERAPEUTICS FOR CARDIAC REPAIR 
The delivery of cells for cardiac repair is motivated by two overarching theories. 
In the first theory, cardiac regeneration is mediated by the delivered cells, which are 
intended to engraft, differentiate, and integrate with existing cardiomyocytes.13 Because 
adult cardiomyocytes are both difficult to isolate14–17 and have very little proliferative 
capacity18,19, the delivery of alternate cell types has been explored to replace 
cardiomyocytes lost as a result of MI. These cell types include skeletal myoblasts, 
cardiac stem cells, and induced pluripotent stem cells.  
In the second theory, cardiac regeneration is mediated through stimulation of 
cells in the existing tissue, and the delivered cells release paracrine signaling factors to 
promote endogenous repair.13 These paracrine signaling factors may act on 
cardiomyocytes to promote proliferation, but also can target other cells and mechanisms 
of cardiac repair, such as increasing vascularization or reducing fibrosis. This theory 
gained traction when it was discovered that a very small percentage of delivered cells 
engraft to the myocardium and are present at even short timepoints after delivery.20–24 
Along these lines, the delivery of cell-derived therapeutics has become popular. 
Additionally, instead of delivering cells, the factors that the cells produce can be 
delivered instead, such as exosomes, growth factors, and cytokines.  The following 
sections will outline the various cellular and cell-derived therapeutics that have been 
explored, including mention of clinical trials that have been completed or are under 
development. 
1.3.1. CELLULAR THERAPIES 
A wide variety of cell types have been delivered to the heart to promote cardiac 
repair and regeneration. Immediately after MI, cell therapies can help to limit cardiac 
deterioration largely through the formation of new vascular structures, which, in the long-
7 
term, allows for restoration of pumping capacity (Figure 1.4). While hundreds of pre-
clinical studies have shown that cell delivery is promising for limiting adverse 
remodeling, reducing scar, and promoting cardiac function, in general, clinical trials have 
been less encouraging.13,25,26 Overall, clinical trials for cellular therapies have had mixed 
results, with some suggesting that cellular therapies can significantly improve global 
cardiac function, while others show no significant differences between treatment and 
control groups.  
 
Figure 1.4. Goals of cellular therapies. Cellular therapies for cardiac repair after MI 
aim to limit cardiac deterioration in the days and weeks following MI and restore 
pumping capacity in the long term. Adapted from Mummery, et al.27 
 
Many cellular therapies are still undergoing clinical trials with larger patient 
populations. For the majority of these clinical trials, cell suspensions are delivered to the 
heart in a saline solution injected either systemically (intravenous), to coronary arteries 
(intracoronary), or to the myocardium (intramyocardial) (Figure 1.5). 
1.3.1.1. SKELETAL MYOBLASTS 
Skeletal myoblasts were the first cell type to be investigated in both pre-clinical 
and clinical trials for cardiac repair starting in 2001. Easily isolated from autologous 
muscle tissue biopsies, these cells were attractive because of their ease of expansion, 
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myogenic capacity, survival in ischemic conditions, and low tumorigenicity.28 Skeletal 
myoblasts were delivered in pre-clinical animal models in mice29, rats30,31, rabbits32,33, 
sheep34,35, dogs36,37, and pigs38–40 where they showed differentiation into myotubes, 
decreased fibrosis, mitigated adverse left ventricular remodeling, and improved cardiac 
function. Phase 2 clinical trials started in 2005 and showed that intramyocardial delivery 
of skeletal myoblasts resulted in some improvements in left ventricular ejection fraction, 
left ventricular remodeling, regional wall motion, and HF severity, but not compared to 
the placebo group.41,42 Safety concerns from an increased number of ventricular 
arrhythmias ultimately resulted in the termination of the trials. Contrary to what was 
previously believed, skeletal myoblasts were found not to transdifferentiate into 
cardiomyocytes or form gap junctions to electromechanically couple with existing 
cardiomyocytes.43–45 Another Phase 2/3 clinical trial started in 2007 and is currently 
ongoing, but inconsistent efficacy coupled with increased risk of arrhythmias has 
diminished interest in this cell type. 
 
Figure 1.5. Delivery methods for cells to the heart. Summary of A) intracoronary and 
B) intramyocardial methods for cell delivery practiced in clinical trials. RCA: right 
coronary artery, CFX: circumflex artery, LAD: left anterior descending artery, LV: left 
ventricle. Adapted from Strauer, et al.46 
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1.3.1.2. BONE MARROW-DERIVED MONONUCLEAR CELLS (BMMNCs) 
 Bone marrow-derived mononuclear cells (BMMNCs) are the most prolific cell 
type investigated for cardiac repair. This cell population consists mostly of cells derived 
from hematopoietic stem cells at various differentiation stages, but likely also consists of 
hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stromal cells.47 
Intracoronary48–55 and intramyocardial56–59 delivery of BMMNCs have been extensively 
investigated in numerous randomized, controlled clinical trials and have been shown to 
be safe and feasible. However, the efficacy of this therapy is varied and there have been 
no consistent short-term or long-term benefits shown for cardiac remodeling, cardiac 
function, or HF class, leading to the investigation of more specified cell types.  
1.3.1.3. ENDOTHELIAL PROGENITOR CELLS (EPCs) 
 Endothelial progenitor cells (EPCs) are a sub-population of hematopoietic stem 
cells that can be isolated in limited quantities from bone marrow and peripheral blood 
and have been shown to promote neovascularization in multiple animal models.60,61 
Typically, these cells are characterized by their expression of CD34 and CD133, 
although a widely accepted definition of this cell type has yet to be determined.62,63 Both 
CD34+ and CD133+ autologous cells have been investigated in clinical trials with mixed 
results. Intramyocardial64,65 and intracoronary66–69 delivery of CD34+ cells, as well as 
intramyocardial70,71 and intracoronary72 delivery of CD133+ cells have shown trends for 
improved left ventricular ejection fraction and increased myocardial perfusion. In general, 
while safety and feasibility studies have been positive, there is no consensus regarding 
efficacy and most studies have shown no effect on global cardiac function, although 
trials are ongoing.73–77 
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1.3.1.4. MESENCHYMAL STROMAL CELLS 
 Bone marrow-derived mesenchymal stromal cells (BMMSCs) are non-
hematopoietic stem cells that are multipotent, plastic-adherent, and typically 
characterized by their ability to differentiate into osteoblasts, adipocytes, and 
chondrocytes.78,79 These cells express CD73, CD105, and CD90 but not CD34, CD45, 
CD14, or HLA-DR.79 BMMSCs are widely thought to be immune-privileged and 
immunosuppressive, allowing for allogeneic delivery and the development of off-the-
shelf therapies.80 A recent meta-analysis of 58 pre-clinical studies showed that the 
delivery of BMMSCs reduced adverse remodeling and improved cardiac function in 
animal models of acute MI and chronic ischemic cardiomyopathy.81 However, clinical 
studies of BMMSC efficacy have been inconsistent. While many groups have shown that 
BMMSC delivery results in significant improvements in LVEF, others have found that 
there is no significant difference in cardiac function between cell delivery and control 
groups.26,82,83 
A similar cell type, adipose-derived mesenchymal stromal cells have also been 
explored for cardiac repair. In preclinical MI models, these cells have been shown to be 
pro-angiogenic, increasing perfusion and the formation of new vascular structures in the 
infarct region.84,85 In clinical trials, this cell type has generally been found to be safe and 
feasible, but its impact on cardiac function is questionable. The PRECISE trial found no 
improvements in left ventricular ejection fraction but an alleviation of patient symptoms 
and increased exercise tolerance was observed.86 The ATHENA trial similarly found 
positive changes in VO2 max, but no difference in LV function or volumes with cell 
delivery.87 In another trial, cells were pre-treated with vascular endothelial growth factor 
and delivered intramyocardially to patients with refractory angina. This trial also found no 
improvements in exercise capacity between patients treated with cells or with a control.88 
11 
1.3.1.5. CARDIAC STEM CELLS  
 Although the regenerative capacity of cardiomyocytes is limited, recently 
researchers have discovered the presence of cardiac stem cells (CSCs) or cardiac 
progenitor cells. These cells can be isolated from biopsies of the myocardium either 
using antibodies for specific cell surface markers89,90 or by culturing as cardiospheres91. 
Reports have suggested that these cells can differentiate into cardiomyocytes as well as 
endothelial cells and vascular smooth muscle cells.89–91 In a very promising Phase 1 
clinical trial that used intracoronary injections to deliver autologous c-kit+ CSCs to 
patients with ischemic cardiomyopathy, a significant increase in LVEF and decrease in 
scar size was reported, but these results were later retracted due to concerns over 
misrepresentation of the CSC phenotype.92,93 For instance, other groups showed that c-
kit+ cells cannot generate cardiomyocytes at significant levels, and instead abundantly 
generate cardiac endothelial cells.94 Additionally, researchers have observed that c-kit+ 
cells may only be able to generate cardiomyocytes in neonatal hearts and that their role 
in adult hearts is primarily revascularization.95,96 Phase 1 and Phase 2 clinical trials 
exploring the intracoronary delivery of autologous cardiosphere-derived cells (CDCs), 
which are isolated differently than c-kit+ CSCs, have reported improvements in both 
cardiac remodeling and cardiac function with treatment.97,98 
1.3.1.6. PLURIPOTENT STEM CELLS 
 Finally, pluripotent stem cells have been explored for cardiac repair and are 
attractive because of their capability to differentiate into cardiomyocytes and hopefully 
integrate with existing cells. The first pluripotent cell type explored were embryonic stem 
cells (ESCs). The risk of tumorigenicity from delivering an undifferentiated cell99,100 has 
led researchers to differentiate ESCs into cardiomyocytes prior to implantation, although 
it can be difficult to generate pure and mature cardiomyocytes in large enough 
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quantities.101,102 The ESCORT Phase 1 clinical trial explored the epicardial delivery of 
human ESC-derived cardiac progenitor cells in a fibrin patch. Although the therapy was 
deemed to be safe with no patients developing tumors, arrhythmias, or immune 
rejection, no follow-up studies have been conducted largely due to ethical concerns.103  
 Another pluripotent cell type that has been explored is induced pluripotent stem 
cells (iPSCs). Like ESCs, iPSCs can be differentiated into cardiomyocytes104–107, but 
similar challenges exist for obtaining genetically-stable, adult cardiomyocytes in large 
numbers.108,109 However, there are fewer ethical concerns with iPSCs compared to 
ESCs. Interestingly, even though iPSCs can be delivered autologously, genetic 
instabilities have been found to lead to immunologic rejection which has led researchers 
to modify differentiation techniques.110–112 Currently, there have been no completed 
clinical trials with iPSC-derived cardiomyocytes for heart disease. 
1.3.1.7. SUMMARY OF CELLULAR THERAPIES FOR CARDIAC REPAIR 
Numerous cell types have been explored as therapeutics for cardiac repair after 
MI (Figure 1.6). While generally deemed to be safe, there is currently no cell type that 
consistently displays significant improvements in remodeling or function compared to a 
control therapy. Cell therapies also suffer from manufacturing challenges related to the 
isolation, culture, and storage of cells prior to delivery. In addition, cell sourcing 
(allogeneic vs autologous) and reproducibility are huge hurdles for regulatory approval. 
Other challenges that have been explored but still need further investigation and 
standardization for the clinic are cell dosage and timing of delivery after MI.  
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Figure 1.6. Clinical trials for cell therapies. Various cell types, ranging from 
unselected BMMNCs to specific cell types and cardiac stem cells, have been 
investigated in clinical trials for almost two decades. Adapted from Hastings, et al.25 
 
Finally, one of the leading factors for the inconsistency in the efficacy of cell 
therapies is the low engraftment of delivered cells. Almost all of the clinical studies 
mentioned here deliver cells in a saline solution, which has little to no capacity to retain 
cells at the injection site. Cell washout or mechanical ejection due to muscle beating, as 
well as cell death due to the ischemic and inflammatory infarct environment, are 
particularly prevalent in cell therapies delivered to the heart.25,113 Multiple groups have 
reported catastrophically low levels of cell retention, regardless of mode of 
delivery.20,22,24,114,115 For instance, it has been reported that after four weeks less than 1% 
of delivered cells are retained.116 This strongly supports the hypothesis that paracrine 
factors that cells produce are the therapeutic element of cellular delivery rather than 
functional integration of delivered cells as cardiomyocytes. In response, this has 
triggered the investigation of cell-derived products, such as growth factors, cytokines, 
and extracellular vesicles (EVs), as therapeutics instead of the cells themselves. 
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1.3.2. CELL-DERIVED THERAPIES  
The delivery of cell-derived therapies consists of two major strategies- delivering 
the entire cell secretome, such as in the form of isolated EVs or exosomes, or delivering 
one or more specific factors that are produced by cells. In both cases, cardiac repair is 
mediated through the stimulation of resident cells, which can occur through a number of 
mechanisms such as modulating inflammation, reducing apoptosis or promoting cell 
cycle re-entry, increasing angiogenesis, or recruiting and activating progenitor cells.  
1.3.2.1. EXTRACELLULAR VESICLES 
 EVs are membrane-bound vesicles released by cells that can transport cargo 
such as DNAs, RNAs, proteins, and lipids to other cells as a form of cellular 
communication (Figure 1.7).117 There are varying types of EVs, differentiated by their 
biogenesis. These include exosomes, microvesicles, apoptotic bodies, and oncosomes. 
Microvesicles are about 100-1000 nm in diameter and are formed directly from budding 
of the plasma membrane and contain cytoplasmic cargo.118 Apoptotic bodies are formed 
by blebbing of the plasma membrane in dying cells and are can be up to 2 µm in 
diameter with varied content depending on cell type.119,120 Oncosomes are formed by 
plasma membrane protrusions in cancer cells and are generally larger, around 1-10 µm 
in diameter.121,122 Common EV isolation methods include ultracentrifugation, density 
gradient ultracentrifugation, size-exclusion chromatography, and polymer precipitation.123 
These methods rely primarily on size to enrich but not distinctly separate isolation of 
these different subpopulations of EVs, and most EV research has focused on exosomes.  
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Figure 1.7. EVs produced by cells. A) Exosomes and microvesicles are produced by 
normal and diseased cells. Apoptosis triggers the release of apoptotic bodies. Some 
cancer cells were reported to generate large EVs, termed oncosomes. B) EVs can be 
taken up via different mechanisms, including endocytosis, membrane fusion, or 
phagocytosis. Ligand–receptor interactions on the cell surface can also result in 
biological effects and help to target vesicles to specific cell types. Adapted from 
Zaborowski, et al.117 
 
 Exosomes are small vesicles (about 100 nm in diameter) formed from the 
invagination of membranes of multivesicular bodies inside the cell (Figure 1.8).124 
Exosomes are present in all bodily fluids and their payload is cell-specific, but almost all 
cell types produce exosomes. Exosomes are released from cells when these 
endosomes fuse with the plasma membrane of the cell, releasing their cargo to affect 
neighboring or distant cells. Exosomes can contain miRNAs, mRNAs, and proteins from 
inside the cell and are used for intercellular communication and signaling.125 Recently, 
exosomes have become popular as they can be easily isolated in large quantities from 
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cells, are amenable to freezing and storage, and can be used as therapeutics directly or 
altered to encapsulate other cargo.126  
 
Figure 1.8. Exosome biogenesis. Exosomes form from invaginations of multivesicular 
bodies within the cell and contain proteins and RNAs (mRNA: messenger RNA, MiRNA: 
microRNA, lncRNA: long noncoding RNA). These vesicles are then either secreted from 
the cell or degraded by lysosomes within the cell. Adapted from Marbán, et al.124 
 
 Exosomes isolated from mesenchymal stromal cells, CSCs, iPSCs, and ESCs 
have been investigated as therapeutics for cardiac repair in numerous preclinical studies 
which have been previously reviewed.127,128 In 2010, Lai, et al published one of the first 
studies utilizing exosomes as a therapeutic for cardiac repair and showed that exosomes 
isolated from human ESC-derived mesenchymal stem cells reduced infarct size after 
systemic delivery in a mouse model of myocardial ischemia/reperfusion injury.129 Since 
then, many groups have investigated the benefits of mesenchymal stromal cell-derived 
exosomes, including Teng, et al, who found that the intramyocardial delivery of these 
exosomes in a rat model of MI reduced infarct size and improved vascularization.130 
Exosomes isolated from human cardiosphere-derived cells have been evaluated in more 
clinically relevant large-animal models such as pigs, and intramyocardial delivery of 
these exosomes 4 weeks after MI was shown to decrease scarring and improve left 
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ventricular ejection fraction.131 In mice, Adamiak, et al found that the intramyocardial 
injection of EVs derived from mouse iPSCs 48 hours after MI was able to improve 
cardiac function and increase perfusion in the infarct region, even more so than the 
delivery of IPSCs.132 In addition, teratomas formed after iPSC delivery while none were 
observed with EV delivery, indicating that iPSC-derived EVs may be safer and more 
effective than iPSCs.132  
Additionally, exosomes can be altered to encapsulate additional cargo or to 
facilitate targeting to various tissues in the body. Alvarez-Erviti, et al engineered brain-
targeted exosomes by transfecting primary dendritic cells with a targeting peptide 
expressing plasmid, and then altered the cargo of these isolated exosomes using 
electroporation to introduce brain-specific siRNAs.133 After intravenous injection of these 
targeted exosomes in mice, they observed a knockdown of the same brain-specific 
genes.133 Electroporation was also used to load mesenchymal stromal cell-derived 
exosomes with miR-132, which were then delivered after MI through intramyocardial 
injections in mice.134 The delivery of these loaded exosomes were shown to increase the 
formation of new vasculature structures and improve ejection fraction compared to the 
delivery of non-loaded exosomes or miR-132 alone.134 For cardiac targeting, Vandergriff, 
et al conjugated cardiac stem cell-derived exosomes with a cardiac homing peptide and 
showed that they were able to deliver these exosomes systemically in rats at 1/50 of the 
dosage they utilized in a previous paper with similar improvements for cardiac 
remodeling and angiogenesis after myocardial ischemia/reperfusion injury.135 
Currently, there are 147 clinical trials involving EVs or exosomes reported on 
ClinicalTrials.gov taking place around the world, with 49 trials in the United States alone 
(Figure 1.9). Not all of these trials involve EVs as a therapeutic; some study the effects 
of other drugs or disease states on EV production or EV content. At this time, there are 
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no trials investigating EV therapies for cardiac disease, although EVs are being explored 
as therapeutics for other indications, such as stroke, diabetes, and cancer.136,137  
 
Figure 1.9. Clinical trials for EV or exosome therapies. As of July 8, 2019, there are 
147 clinical trials globally that involve EVs or exosomes, with 49 of these trials taking 
place in the United States. Studies with multiple locations are represented in each region 
containing these locations. Adapted from ClinicalTrials.gov. 
 
1.3.2.2. GROWTH FACTORS 
Exosomes contain varied proteins and RNAs, which can make it challenging to 
understanding the influence of specific contents on tissue repair and molecular 
pathways. In contrast, a more direct approach is the delivery of one or more factors in a 
more targeted method. At stated above, the cardiac remodeling process following MI 
lends itself to a wide variety of targets, such as inflammation, angiogenesis, extracellular 
matrix remodeling, and cardiomyocyte proliferation. A summary of key growth factors or 
cytokines relevant to cardiac regeneration and their targets is shown in the table below 
(Table 1.1). 
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Table 1.1. Main growth factors applicable to cardiac repair. 
 
Factor* Mechanisms 
VEGF Angiogenesis 
FGF Angiogenesis 
HGF Anti-apoptosis, cardiac stem cell chemotaxis 
SDF-1 Hematopoietic stem cell mobilization and homing 
IGF-1 Stem and progenitor cell viability, differentiation 
PDGF Anti-apoptosis 
Erythropoietin Anti-apoptosis 
G-CSF Anti-apoptosis, hematopoietic stem cell mobilization and homing 
Intermedin Angiogenesis 
Angiopoietin Angiogenesis, remodeling, and vascular stabilization 
Periostin Cardiomyocyte proliferation 
Neuregulin-1 Cardiomyocyte proliferation 
 
*VEGF: vascular endothelium growth factor isoforms; FGF: fibroblast growth factor; HGF: 
Hepatocyte growth factor; SDF-1: stromal cell-derived factor; IGF-1: Insulin-like growth factor 1; 
PDGF: platelet-derived growth factor; G-CSF: granulocyte colony stimulating factor. Adapted from 
Rebouças, et al.138 
 
 Most of these growth factors have been evaluated in numerous preclinical 
studies, and, in general, positive preclinical results have not translated into clinical 
success. For instance, perhaps the most commonly explored target for growth factor 
therapies for cardiac repair is angiogenesis, and clinical trials first started in 1994 with 
intramyocardial injection of recombinant FGF-1.139 While neovascularization was 
observed at the injection site, there were no measurements of improved cardiac 
function. Subsequent studies with FGF and VEGF are summarized in the table below 
(Table 1.2).  
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Table 1.2. Therapeutic angiogenesis clinical trials. 
 
VEGF      
Phase Author/trial name (year) Product Route n Outcome 
Phase 1/2 Hendel (2000) VEGF-165 i.c. 14 - 
Phase 1/2 Henry (2001) VEGF-165 i.c. 15 - 
Phase 2 VIVA (2003) VEGF-165 i.c./i.v. 178 - (Except: ETT 
high-dose only) 
FGF      
Phase Author/trial name (year) Product Route n Outcome 
Phase 1/2 Schumacher (1998) FGF-1 i.m. 40 - 
Phase 1/2 Pecher (2000) FGF-1 i.m. 40 - 
Phase 1/2 Selke (1998) FGF-2 i.m. 8 - 
Phase 1/2 Ruel (2002) FGF-2 i.m. 24 - 
Phase 1/2 Laham (2000) FGF-2 i.c. 52 + 
Phase 1/2 Udelson (2000) FGF-2 i.c./i.v. 59 + 
Phase 1/2 Unger (2000) FGF-2 i.c. 25 - 
Phase 2 FIRST (2002) FGF-2 i.c. 337 - 
 
ETT: exercise tolerance test; FGF: fibroblast growth factor; i.c.: intracoronary; i.m.: 
intramyocardial; i.v.: intravenous; VEGF: vascular endothelial growth factor; -: negative outcome; 
+: positive outcome. Adapted from Rubanyi, et al.140 
 
 While some initial Phase 1/2 clinical trials showed promise, larger Phase 2 
controlled clinical studies of both VEGF141 and FGF142 delivery showed no clinical 
benefit. Simply increasing dosage is not an option, since there are serious off-target 
effects of VEGF and FGF delivery related to aberrant angiogenesis, including tumor 
growth.143,144 For periostin and neuregulin, off-target effects of cardiomyocyte 
proliferation raise concerns for cardiac hypertrophy and ventricular arrhythmias.145 Other 
factors, such as SDF-1, are susceptible to degradation by matrix metalloproteinases like 
MMP-2, which is upregulated after MI.146 
 The delivery of growth factors and cytokines for cardiac repair suffers from two 
major challenges. First, protein instability can render some therapeutics inactive mere 
hours after delivery. Second, because protein therapies are being delivered in saline 
solutions even in clinical trials, they are rarely retained in the ischemic myocardium, 
leading to off-target effects. Biomaterials can be used to address both of these concerns, 
by sequestering protein molecules to both protect and control their release in a targeted 
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manner. In summary, the retention of cellular and cell-derived therapeutics at the 
delivery site of cardiac tissue is a major concern. Mechanical forces in the heart lead to 
the distribution of these therapeutics away from the delivery site.  As one approach to 
address this concern, biomaterials either applied as patches or injected (intracoronary or 
intramyocardial) are being developed to retain these therapeutics at the desired delivery 
site.  
 
1.4 INJECTABLE HYDROGELS FOR MI 
One class of biomaterials of great interest in treating cardiac tissues are 
hydrogels (i.e., water-swollen polymer networks).  The use of hydrogels to deliver cells 
or cell-derived therapeutics is attractive because hydrogels can be designed to be 
injectable through minimally-invasive methods utilizing catheter technologies, which 
reduces risks for patients, lowers hospital costs compared to open-heart procedures, 
and can potentially be applied at multiple timepoints. For injectability, the hydrogel or 
precursor must flow through the syringe or catheter, but then gel with the appropriate 
kinetics at the injection site for material retention. This is generally achieved either by 
using shear-thinning and rapidly self-healing hydrogels or by hydrogels that crosslink in 
situ after injection. For both preclinical and clinical trials, hydrogels are typically delivered 
via three methods: intracoronary or intramyocardial, either from the epicardial or 
endocardial side. 
1.4.1. HYDROGELS ALONE 
In addition to the delivery of cellular or cell-derived therapeutics, there are 
therapeutic advantages to the delivery hydrogels alone. This is due to their ability to 
increase the thickness of the left ventricular wall, thereby reducing wall stress, restoring 
ventricular geometry, and preserving cardiac function. LaPlace’s law (T = (P*R)/t) states 
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that tension in the myocardial wall (T) is directly proportional to intraventricular pressure 
(P) and radius of curvature (R) and inversely proportional to wall thickness (t). Therefore, 
increasing wall thickness through the injection of bulking agents such as hydrogels can 
decrease wall stress. Finite element models have shown that multiple hydrogel injections 
into the border zone region of the infarct can reduce myofiber stresses, which is further 
improved using stiffer materials.147 These results were later confirmed in an ovine model 
using hydrogels of 8 kPa and 43 kPa stiffness.148 In addition to increasing hydrogel 
stiffness, larger hydrogel injection volumes were also found to be beneficial for 
decreasing wall stresses in a finite element model (Figure 1.10)149  
 
Figure 1.10. Left ventricular end-diastolic myofiber stress distribution after 
hydrogel injection. 150 μL injections (A-C) and 300 μL injections (D-F) of hydrogels of 
stiffness 0.1 kPa (A, D), 25 kPa (B, E), and 100 kPa (C, F) show that myofiber stress 
near the injection site decreases with increasing hydrogel stiffness and increasing 
hydrogel volumes. Adapted from Wang, et al.149 
 
Numerous natural and synthetic injectable hydrogels have been evaluated in 
preclinical models with improvements in cardiac remodeling and function. In 2004, one 
of the first studies using injectable hydrogels as bulking agents was conducted by 
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Christman et al, who found that a fibrin glue preserved infarct wall thickness and cardiac 
function in rats.150,151 Since then, other naturally-derived hydrogels such as collagen152, 
alginate153–155, chitosan156, matrix derivatives157,158, and hyaluronic acid159 have been 
explored. Synthetic hydrogels based on poly(N-isopropylacrylamide) (PNIPAAm)160,161 
and poly(ethylene glycol) (PEG)162–164 have also been tested. These materials have 
varied gelation methods, ranging from peptide-self-assembly and self-assembly for fibrin 
gels and PEG gels, respectively, to ionic mechanisms for alginate gels and thermal 
mechanisms for collagen, chitosan, Matrigel, and PNIPAAm. Hyaluronic acid and PEG 
have also been modified with functional groups to allow for covalent crosslinking. 
Hydrogels have been injected at different timepoints after MI, ranging from immediately 
to 8 weeks later and with varied injection volumes even within similar animal models.165 
Data collection timepoints have also varied within animal models; for example, rat MI 
models have evaluated outcomes at timepoints ranging from 2 to 16 weeks.165 In 
addition to the bulking due to initial material properties, the biological response to 
injected materials and changes in local extracellular matrix properties likely has a 
positive effect as well.165  
Hydrogels have also been evaluated in clinical trials. In 2011, LoneStar Heart 
Inc. started the AUGMENT-HF Phase 2/3 clinical trial for Algisyl-LVRTM, an injectable 
calcium alginate hydrogel delivered intramyocardially to patients with HF. Evaluations at 
6 months166 and 1 year167 after injection showed improvements in exercise capacity and 
clinical status for patients who received the alginate hydrogel injections compared to 
those who did not. A larger follow-up study, AUGMENT-HFII, is planned but not yet 
recruiting.  
In 2010, Bellerophon BCM LLC started the PRESERVATION-1 clinical trial for 
the intracoronary delivery of IK-5001, an injectable sodium alginate calcium gluconate 
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solution that was delivered to patients 2-5 days after MI.168,169 The study included 303 
patients and found that, after 6 months, there was no significant improvement in adverse 
left ventricular remodeling, exercise capacity, or heart failure classification for the 
alginate injection compared to saline, likely because vascular occlusion prevented the 
therapy from perfusing the infarct region.169 
In 2014, Ventrix, Inc. commenced enrollment in a Phase 1 clinical trial for 
VentriGel, an injectable hydrogel derived from decellularized porcine myocardium.157 
VentriGel is currently being evaluated using intramyocardial/transendocardial catheter 
delivery to patients 60 days to 3 years after MI and results have not yet been reported.  
 Challenges still remain for hydrogel therapies to promote cardiac repair after MI 
and prevent HF. For instance, even though preclinical studies suggest that stiffer 
hydrogels provide more therapeutic benefit, clinical trials for hydrogels either do not 
report hydrogel stiffness or utilize notably soft hydrogels. Some studies have 
investigated delivery parameters such as hydrogel volume, injection pattern, injection 
location, and timing of delivery, but a consensus of these parameters still needs to be 
obtained. Also, in most cases hydrogels are not inert materials so further investigation 
into the biological mechanisms (and not just the mechanical mechanisms) of hydrogel 
delivery should be explored.  
1.4.2. HYDROGELS AS DELIVERY VEHICLES 
1.4.2.1. CELL DELIVERY WITH HYDROGELS 
As delivery vehicles, both natural and synthetic injectable hydrogels have been 
used by multiple groups to deliver various cell types to the heart for improved retention 
and cardiac repair in preclinical trials. For example, in 2004, Christman, et al delivered 
skeletal myoblasts in a rat MI model in an injectable fibrin gel and showed that hydrogel 
delivery increased cell survival, decreased infarct size, and increased blood flow to the 
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myocardium.150 Since then, many other groups have also used fibrin-based gels to 
deliver MSCs170, embryonic stem cell-derived cardiomyocytes171, and endothelial 
progenitor cells.172 Other naturally-derived hydrogels made from alginate173, 
chitosan174,175, or peptides176 have also been used to deliver MSCs and adipose-derived 
stem cells. Synthetic hydrogels or combinations of natural and synthetic hydrogels have 
also been tested. Oligo (poly (ethylene glycol) fumarate) was used to encapsulate 
mouse embryonic stem cells and delivered in a rat MI model with improved cardiac 
outcomes.177 Cai, et al combined a star-shaped peptide-PEG-PNIPAAm copolymer with 
an engineered recombinant protein to form a hydrogel with an initial weak, physical 
network between peptides that was later stabilized via thermo-responsive crosslinking in 
situ, and used this hydrogel to deliver adipose-derived stem cells in mice.178 In addition 
to assessing relevant functional or remodeling outcomes, many groups also showed that 
the use of biomaterials can improve the retention and localization of delivered cells 
compared to saline and, interestingly, these increases in cell retention can become more 
pronounced over time (Table 1.3).  
Table 1.3. Fold-increase in cell retention over intramyocardial saline delivery 
reported with various injectable hydrogels. 
 
Hydrogel Cell type Time(s) of analysis Fold-increase  
Fibrin150 Skeletal myoblast 5 weeks ~2 
PEG diacrylate171 ESC-CM 48 hours ~2.5 
Fibrin170 MSC 90 min 1.77 
Chitosan/b-glycerol 
phosphate/hydroxyethyl 
cellulose175 
ADSC 24 hours 
4 weeks 
1.5 
8 
 
PEG: poly(ethylene glycol); ESC-CM: embryonic stem cell-derived cardiomyocyte; MSC: 
mesenchymal stromal cell; ADSC: adipose-derived stem cell. Adapted from Hastings, et al.25 
 
Hydrogels can also change the local environment of encapsulated cells, 
potentially influencing cell viability, behavior, and differentiation.174 For instance, 
hydrogels can shield cells from ischemia and inflammation, and prevent anoikis-related 
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cell death.25 Injectable hydrogels can also be protective to cells during syringe 
ejection.179,180 Aguado, et al observed that the viability of human umbilical vein 
endothelial cells after ejection in an alginate hydrogel (G’=29.6 Pa) was 88.9% ± 5.0%, 
compared to 58.7% ± 8.1% after ejection in saline.179 However, hydrogels of higher and 
lower stiffness were not as protective, indicating that mechanical and flow properties of 
hydrogels should be tuned for high cell viability. Other considerations for translation that 
affect cell viability after injection include needle gauge, needle length, and flow rate. 
Currently, there are no clinical trials for cell therapy for MI that use injectable hydrogel 
carriers.  
1.4.2.2. EXTRACELLULAR VESICLE DELIVERY WITH HYDROGELS 
 Injectable hydrogels have been investigated to some extent in preclinical trials for 
their ability to increase the retention and stability of EVs at the delivery site. Human 
placenta MSC-derived exosomes were delivered with an injectable chitosan hydrogel in 
a mouse model of hindlimb ischemia, and the chitosan hydrogel was shown to increase 
the stability of proteins and miRNAs in exosomes, as well as increase exosome retention 
in vivo and increase perfusion.181 In another mouse hindlimb ischemia model, human 
umbilical cord MSC-derived exosomes were delivered in an injectable silk fibroin 
hydrogel and showed increased perfusion after 4 weeks compared to exosomes 
delivered in saline.182  
 In a rat MI model, the delivery of iPSC-derived cardiomyocytes in an implantable 
collagen gelfoam mesh was shown to permit the sustained delivery of EVs for at least 1 
week in vivo and, after 4 weeks, increased ejection fraction and reduced infarct size.183 
For improved EV retention, Han, et al delivered human umbilical cord MSC-derived 
exosomes in an injectable peptide hydrogel, since peptide hydrogels can be engineered 
to have much smaller mesh sizes than hydrogels made of other naturally-derived 
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materials.184 After delivery in a rat MI model, the delivery of exosomes with the peptide 
hydrogel showed enhanced exosome retention and improved cardiac function, 
remodeling, and vascularization compared to the delivery of exosomes in saline.184 Our 
group has also previously investigated the delivery of EPC-derived EVs in a rat MI model 
using an injectable hyaluronic acid hydrogel and showed that hydrogel delivery of EVs 
can improve outcomes of cardiac repair185, and that the timing of EV delivery may be 
important for better cardiac outcomes.186 
1.4.2.3. GROWTH FACTOR DELIVERY WITH HYDROGELS 
In preclinical animal MI models, injectable hydrogels have also been used to 
deliver proteins, growth factors, and cytokines, all of which benefit from hydrogel carriers 
because improved retention and sustained delivery of these therapeutics can decrease 
the need to deliver supraphysiological doses, which can often have detrimental off-target 
effects.143,144 Many different natural and synthetic injectable hydrogels have been used to 
deliver a spectrum of growth factors to the heart, and there are recent reviews that 
highlight many of these studies.165,187,188 
For instance, growth factor delivery can encourage the recruitment of 
endogenous cells for cardiac repair. An injectable, hydrolytically degradable, hyaluronic 
acid-based hydrogel was used for the delivery of a synthetic analog of chemokine SDF-
1a called engineered stromal cell-derived factor analog or ESA. In prior studies, ESA 
has been shown to be more effective than native SDF-1a for EPC migration.189 In a rat 
MI model, delivery of ESA with the injectable hydrogel allowed for the sustained release 
of ESA for 4 weeks in vivo, and increased EPC chemotaxis, improved vascularity, 
preserved ventricular geometry, and improved cardiac function.190 
Growth factors are also commonly delivered for angiogenesis. As one example, 
VEGF and HGF were encapsulated in an injectable, protease-degradable, PEG-based 
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hydrogel and delivered to the heart after ischemia/reperfusion injury in rats. The delivery 
of the combination growth factor therapy with the injectable hydrogel led to significant 
improvements in angiogenesis, cardiac progenitor cell recruitment, myocardial fibrosis, 
and cardiac function after 3 weeks.191 
The delivery of MMP inhibitors can also be useful, especially for MI since the 
upregulation of MMPs contributes to adverse ventricular remodeling.192 Purcell, et al 
designed an injectable hyaluronic acid-dextran sulfate hydrogel sensitive to MMP 
degradation for the delivery of a recombinant tissue inhibitor of MMPs (rTIMP-3), which 
is sequestered in the hydrogel through electrostatic interactions.193 In this way, rTIMP-3 
is released in response to MMP activity. When delivered to the heart in a porcine model 
of MI, there was a significant reduction in MMP activity, preserved ventricular geometry, 
and improved cardiac function after 2 weeks.193 
The release of these molecules from hydrogel carriers is mediated by the size of 
the molecules relative to the hydrogel mesh size (Figure 1.11).194 Molecules that are 
small relative to mesh size diffuse freely from the hydrogel, often on the order of hours to 
days. When molecule size approaches mesh size, steric hindrance prevents the 
molecule from freely diffusing through the material, and slow release can extend 
molecule delivery from days to weeks. Molecules that are larger than the hydrogel mesh 
size are effectively immobilized within the material, and degradation, swelling, or 
mechanical deformation mechanisms can be engineered to control release of the 
therapeutic. Hydrogel mesh size can also change over time through material 
condensation and reorganization.195 Most proteins are smaller than or near the mesh 
size of a typical hydrogel, so combining hydrogel degradation mechanisms with protein-
hydrogel interactions can be effective for controlling growth factor release. For instance, 
hydrogels can be engineered to be degradable in response to enzymatic activity, pH, 
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temperature, or light and common molecule-hydrogel interactions involve covalent 
linkages, electrostatic interactions, or hydrophobic interactions that can sequester 
molecules within the hydrogel.194 
 
Figure 1.11. Relative hydrogel mesh size to drug size mediates diffusion of 
encapsulated therapeutics. Drugs that are small relative to the mesh size diffuse 
rapidly through the hydrogel. As drug size approaches hydrogel mesh size, diffusion is 
slowed. Drugs that are large relative to the mesh size are immobilized in the hydrogel 
and eventually released through degradation, swelling, or deformation mechanisms. 
Adapted from Li, et al.194 
 
Also, the use of composite hydrogel systems of micro- or nano-gels within a bulk 
hydrogel can be used to create complex release profiles of multiple molecules. For 
example, in angiogenesis, VEGF is important for neovessel formation while PDGF-BB is 
crucial for blood vessel stabilization, so the sequential delivery of VEGF and PDGF-BB 
may be desired.196 Awada, et al developed a composite hydrogel consisting of a heparin-
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based coacervate within a fibrin gel and encapsulated VEGF within the fibrin gel and 
PDGF-BB in the heparin-based coacervate.197 In vitro studies showed the varied release 
profiles for VEGF and PDGF-BB, with most of the VEGF released by day 7 and PDGF 
release continuing for at least 3 weeks.197 When delivered to the heart in a rat MI model, 
they found that the delivery of both growth factors in their sequential delivery system 
significantly increased neovessel formation after 3 weeks compared to the free delivery 
of both growth factors but with no delivery system, and they also observed 
improvements for wall thickness, fibrosis, and cardiac function.197 To date, there have 
been no clinical trials that employ injectable hydrogel carriers to deliver proteins, growth 
factors, or cytokines to the heart. Combination therapies with injectable hydrogels, cells, 
and growth factors are also possible to leverage the mechanisms of both therapies.198 
 
1.5 CONCLUSIONS 
Cardiovascular disease and MI exert a tremendous burden on the American 
healthcare system and current available therapies fail to address the physiological 
changes that occur in the myocardium that can lead to HF. Clinical trials for cell 
therapies and cell-derived therapeutics have largely failed to replicate the improvements 
in cardiac function and remodeling observed in preclinical studies. Injectable hydrogels 
alone are useful for myocardial bulking, but recently have been explored as delivery 
vehicles that can be engineered for a range of payloads. This thesis describes the 
development of injectable hydrogel systems to deliver cells and cell-derived therapeutics 
for improved retention and efficacy to increase angiogenesis and modulate inflammation 
for cardiac repair and preserved cardiac function. 
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CHAPTER 2  
RESEARCH OVERVIEW 
 
2.1 SPECIFIC AIMS 
 Heart failure (HF) is a growing cause of morbidity and mortality in the United 
States, where it contributes to 1 in 9 deaths.1 Currently, medical and surgical treatments 
for HF, except for heart transplantation, are merely palliative and do not attempt to 
resolve the underlying disease.2 One cause of HF is ischemic cell death after myocardial 
infarction (MI), which can lead to the loss of a billion or more cardiomyocytes3 and 
initiates a process of adverse remodeling that lessens the ability of the ventricles to 
contract.4 
 A number of therapeutics (e.g., cells, drugs) have been delivered to cardiac 
tissue to improve outcomes after MI. For example, various cell types have been tested 
extensively in preclinical studies with positive outcomes for cardiac repair, but benefits of 
cellular delivery have not translated in clinical trials.5,6 This is likely due to the low 
retention and engraftment of delivered cells which suggests that the benefits of cellular 
therapies are not mediated directly by the delivered cells, but instead indirectly by the 
paracrine signals that the delivered cells produce that act on cells in the endogenous 
tissue to promote regeneration.7,8 
 The paracrine hypothesis of cellular delivery has led to the exploration of cell-
derived therapies for cardiac repair, such as growth factors, cytokines, or extracellular 
vesicles (e.g., exosomes). These factors can help to promote angiogenesis, reduce 
apoptosis, promote cardiomyocyte proliferation, control fibrosis, and modulate 
inflammation.9 Growth factors, such as vascular endothelial growth factor, have been 
tested in numerous preclinical as well as clinical studies.10 Again, clinical results have 
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not recapitulated the positive successes of preclinical models, likely due to the low 
retention of therapeutics at the injection site.11 This leads to the delivery of 
supraphysiological doses of growth factors, which can have deleterious off-target 
effects.12,13 Exosomes are a more recently developed therapeutic, but they have already 
been isolated from various cell types and evaluated in preclinical trials for cardiac 
repair.14,15 However, the delivery of exosomes to the myocardium presents the same 
challenges as cell and growth factor delivery, which is local and sustained delivery at the 
injection site. 
Injectable hydrogels are evolving to improve upon these therapies for cardiac 
repair after MI. They have been used alone as bulking agents to reduce myocardial wall 
stresses, which has been shown to limit left ventricular wall thinning and dilation that 
leads to decreased cardiac function.16–18 Injectable hydrogels can also be used as 
delivery vehicles for cellular and cell-derived therapeutics. Our lab has recently 
developed an injectable hyaluronic acid (HA) hydrogel based on the guest-host 
interactions of b-cyclodextrin and adamantane.19 HA is a non-sulfated 
glycosaminoglycan found in the extracellular matrix and is involved in many cellular 
processes (e.g., proliferation, wound healing).20 Compared to other naturally-derived 
materials such as collagen, elastin, or fibrin, HA lends itself to facile modification with 
functional groups that can mediate a variety of crosslinking mechanisms, varying from 
covalent to supramolecular crosslinks.21 Hydrophobic interactions between these b-
cyclodextrin and adamantane groups form guest-host, supramolecular interactions that 
allow this hydrogel to be both shear-thinning and rapidly self-healing, permitting 
injectability as well as rapid solidification at the injection site.19 
 Our lab has investigated the use of this hydrogel alone in cardiac repair as a 
bulking agent22,23, as well as a delivery vehicle for miRNAs24, small molecule drugs25, 
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and extracellular vesicles26. This thesis describes the design criteria necessary for 
injectable hydrogels, and then applies these design principles to the use of injectable 
hydrogels for the delivery of cellular and cell-derived therapies, such as growth factors 
and extracellular vesicles. In combination, these aims utilize material design and 
characterization to develop novel injectable treatments that will improve the efficacy of 
cellular and cell-derived therapies for cardiac repair. 
 
Aim 1: Develop methods to characterize shear-thinning and self-healing hydrogels 
and their potential for injectability in biomedical applications. 
Hypothesis: Rheological properties, injection forces, and encapsulated cell viability are 
dependent on injectable guest-host hydrogel formulation and injection parameters.  
 Injectable hydrogels when used for therapeutic delivery (e.g., as cell carriers) 
increase therapeutic retention in the heart.5 Toward this, it is important to understand the 
hydrogel properties that relate to injectability and therapeutic applications. For example, 
it has been shown that the viability of cells after ejection using a biomaterial carrier is 
mediated by material properties, such as storage modulus.27 Other factors, such as 
viscosity and injection force, are also important when evaluating the application of 
hydrogels as injectable biomaterials. In this aim, HA is modified separately with b-
cyclodextrin and adamantane groups to form a shear-thinning, injectable guest-host 
hydrogel when mixed. Hydrogel formulations are varied by percent functionalization of 
the HA backbone, material concentration, and molar ratio of b-cyclodextrin and 
adamantane groups and injection parameters include syringe needle gauge, syringe 
needle length, and flow rate. Methods are developed for the quantitative (e.g., rheology, 
injection force) assessment of hydrogels for injectability, and cells are encapsulated in 
these hydrogels and cell viability after ejection is investigated as a function of hydrogel 
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formulation and injection parameters. Techniques for the in vivo delivery of injectable 
hydrogels to the heart are also described. Material formulations identified from this aim 
that are injectable and result in high cell viability after injection are assessed in 
subsequent aims. 
 
Aim 2: Deliver endothelial progenitor cells (EPCs) using an injectable hydrogel to 
the heart after MI. 
Hypothesis: Injectable hydrogels improve EPC localization and therapeutic efficacy (e.g., 
vascularization, cardiac function, geometry) when delivered after MI.  
EPCs are primary, bone marrow-derived cells that can differentiate into mature 
endothelial cells and promote new vasculature through paracrine signals.28–30 Although 
EPC delivery has been shown to be effective for cardiac repair in preclinical models31,32, 
clinical trials have been less encouraging, likely due to the low retention of delivered 
EPCs.33,34 Injectable hydrogels can improve the retention of delivered cells.5 Here, EPCs 
are isolated from the bone marrow of adult male Wistar rats, cultured, and encapsulated 
in an injectable hydrogel formulation found in the previous aim to give high cell viability 
after injection. In a rat model of MI, EPCs are delivered with or without the injectable 
hydrogel carrier via intramyocardial injections to the border zone of the infarct. After 48 
hours, the retention of fluorescently-tagged EPCs is assessed via fluorescent imaging. 
After 4 weeks, cardiac function is measured using an aortic flow probe, 
echocardiography, and an intraventricular pressure-volume catheter. Masson’s trichrome 
staining is utilized to visualize scar tissue, and immunohistochemistry for vascular 
markers and fluorescent microscopy is used to assess new vessel formation. This study 
evaluates the use of our injectable guest-host hydrogel as a cell delivery vehicle for 
EPCs and highlights the benefits of cell delivery to the heart with biomaterial carriers.    
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Aim 3: Design and evaluate injectable microgel/hydrogel composites for 
interleukin-10 (IL-10) delivery to the heart. 
Hypothesis: IL-10 delivery from injectable microgel/hydrogel composites reduces 
inflammation (e.g., macrophage levels) and improves cardiac repair (e.g., 
vascularization, cardiac function, geometry) after MI. 
The paracrine hypothesis for cell delivery suggests that the signals that cells 
produce are important for cardiac repair.7,8 The delivery of these signals, such as growth 
factors and cytokines, can benefit from injectable hydrogel carriers to improve 
therapeutic retention and reduce the need for supraphysiological doses that can cause 
detrimental off-target effects.11–13 However, it may also be advantageous to decouple 
hydrogel injectability from the controlled release of encapsulated therapeutics. Toward 
this, composites of hydrogels (that govern injectability) and encapsulated microgels (that 
control sustained release profiles) are developed.  This includes the same injectable 
hydrogel studied in Aim 1 and microgels fabricated via microfluidics from norbornene-
modified HA, which forms crosslinks with dithiols in the presence of photoinitiator and 
UV light. Microgels are formulated with various dithiol crosslinkers, and microgel 
degradation and therapeutic cargo release are assessed as a function of crosslinker 
degradability. Material properties of composite hydrogels are measured using rheology. 
Finally, the composite hydrogel is evaluated in vivo as a delivery system for IL-10, an 
anti-inflammatory cytokine, in a rat model of MI. After 7 days, immunohistochemistry is 
used to assess the immune response to the therapy. After 4 weeks, cardiac function, 
cardiac remodeling, and new vessel formation are evaluated to assess the treatment in 
both tissue structure and functional outcomes. This study describes an injectable 
microgel/hydrogel composite that can be useful for the targeted and sustained delivery 
of growth factors and cytokines to the heart. 
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Aim 4: Develop pre-condition protocols for the isolation of extracellular vesicles 
(EVs) from mesenchymal stromal cells (MSCs) and deliver to the heart using an 
injectable hydrogel. 
Hypothesis: EVs isolated from pre-conditioned MSCs (e.g., hypoxia, growth factors) will 
have varied protein content and increased vasculogenic potential and EV hydrogel 
delivery will increase vasculature after MI.  
 MSC-derived EVs have been investigated for their potential to improve cardiac 
outcomes after MI in preclinical models.35,36 Additionally, MSCs can be pre-conditioned 
with growth factors37 or cultured in hypoxic conditions38 to be more pro-vasculogenic. In 
this aim, we first pre-condition MSCs by culturing both with angiogenic growth factors 
and under hypoxic conditions. Next, we isolate EVs from these pre-conditioned MSCs 
using polymer precipitation. EV size and concentration are quantified via nanoparticle 
tracking analysis, and EV contents (e.g., proteins) are explored using proteomics. The in 
vitro angiogenic potential of EVs is investigated using a Matrigel angiogenesis assay. 
Finally, the injectable, guest-host hydrogel described in Aim 1 is used as a carrier for 
local, sustained delivery of EVs to the heart in a rat model of MI. The formation of new 
vasculature after EV delivery is evaluated compared to controls of EV injection alone or 
hydrogel delivery alone. This aim evaluates a method of enhancing the efficacy of 
cellular-derived therapeutics, by pre-conditioning cells to direct them to produce desired 
signaling factors, such as EVs. Also, while our group has used this hydrogel before to 
deliver EPC-derived EVs to the heart39, these studies further explore the use of our 
injectable hydrogel as a delivery vehicle for EV therapies.   
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2.2 CHAPTER OUTLINE 
 Chapter 1 provides a detailed description of MI and the adverse remodeling 
processes that occur afterward that can lead to HF. Also, clinically-relevant trials for 
cellular and cell-derived therapies are reviewed, as well as a description of the clinical 
application of injectable hydrogels for cardiac repair and preclinical studies using 
injectable hydrogels as delivery vehicles.  
 Chapter 3 describes the research proposed in Aim 1, which concerns the 
development of methods to assess biomaterials for use as injectable hydrogels as well 
as the application of those methods to evaluate injectable hydrogels for cell delivery. 
 Chapter 4 describes the research proposed in Aim 2, which uses the injectable 
hydrogel evaluated in Aim 1 to deliver EPCs to the heart in a rat MI model. 
 Chapter 5 describes the research proposed in Aim 3, which involves developing 
injectable hydrogel/microgel composites for local and sustained delivery of IL-10 to the 
heart. In this chapter, a microfluidic device is utilized to form microgels, which allow for 
hydrogel injectability to be decoupled from the release of therapeutic cargo.  
 Chapter 6 describes the research proposed in Aim 4, which uses the injectable 
hydrogel from Aim 1 to deliver EVs to the heart in a rat MI model. This chapter 
showcases a method for improving the therapeutic benefit of cell-derived therapies by 
pre-conditioning MSCs prior to EV collection and evaluates our injectable hydrogel for 
EV delivery.  
 Chapter 7 presents a summary of the work presented in this thesis, highlighting 
the contributions of each aim toward developing injectable hydrogels for the delivery of 
cellular and cell-based therapeutics for cardiac repair. Limitations of these studies are 
discussed, as well as possible future directions toward further clinical translation and 
eventual commercialization of these therapies.  
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CHAPTER 3  
METHODS TO CHARACTERIZE INJECTABLE HYDROGELS FOR BIOMEDICAL 
APPLICATIONS  
 
Adapted from: 
1. Chen, M. H., Wang, L. L., et al. Methods to assess shear-thinning hydrogels for 
application as injectable biomaterials. ACS Biomater. Sci. Eng. 3, 3146-3160 
(2017).  
2. Loebel, C., Rodell, C. B., Chen, M. H., & Burdick, J. A. Shear-thinning and self-
healing hydrogels as injectable therapeutics and for 3D-printing. Nature Protocols 
12, 1521-1541 (2017).   
 
3.1 INTRODUCTION 
Hydrogels are water-swollen polymer networks with widespread applications in 
the biomedical sciences, including drug delivery and tissue regeneration.1,2 Their high 
water content and mechanical properties make hydrogels natural mimetics of 
extracellular matrices. Acellular hydrogels can be delivered for tissue bulking or as 
artificial tissue mimetics.3,4 Hydrogels can also be loaded with cells for therapeutic effect, 
and may promote additional infiltration of cells upon implantation.5,6 Therapeutic 
molecules can also be encapsulated within hydrogels and released with highly tunable, 
controlled profiles in response to erosion, swelling, or external stimuli such as enzymes 
or light.7–10  
Over the past few decades, injectable hydrogels have become increasingly 
popular for their ability to be delivered via minimally invasive approaches.1 In this 
context, two major routes for injection have been explored. The first approach is the 
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engineering of hydrogels that gel in situ after injection, through chemical or physical 
crosslinking mechanisms that occur either during or after injection of the hydrogel 
precursors.11 While many hydrogels can be delivered in this fashion, they often require 
the use of multi-barrel syringes for mixing during injection or an external trigger to induce 
gelation.  Gelation is also time sensitive, as crosslinking that occurs too slowly can lead 
to rapid material dispersion upon injection and prior to gelation, leading to cargo loss.12 
Alternatively, crosslinking that occurs too quickly can clog the needle or syringe before 
hydrogel deposition.13  
To overcome limitations of in situ crosslinking systems, hydrogels have also been 
engineered with shear-thinning properties, which are defined as the ability for a material 
to decrease in viscosity with increasing shear.  Such hydrogels can be pre-formed into 
syringes, which allows them to be extruded upon application of shear, and rapidly re-
formed upon cessation of mechanical load, a process known as self-healing. The self-
healing nature of these hydrogels allows for improved material retention upon injection 
and offers advantages to in situ gelation systems, including minimization of potential 
embolization into the systemic circulation. However, these self-healing systems are often 
mediated by physical crosslinks and may not confer the mechanical stability of in situ 
crosslinking covalent systems. To overcome this, secondary crosslinking techniques 
have been explored toward stabilizing physically assembled hydrogels after injection.4,14  
Shear-thinning and self-healing hydrogels have been investigated in various 
biomedical applications including drug delivery,7,15 tissue regeneration,2,16 mechanical 
bulking,3,4,17 and extrusion-based bioprinting.18,19  These systems include hydrogels 
crosslinked through peptide assembly,20,21 recombinant protein assembly,22,23 ionic 
interactions,24 thermal assembly,25 electrostatic interactions between colloidal systems,26  
and supramolecular chemistry.27–31 Dynamic covalent crosslinks have also been 
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explored for injection, where their dynamic nature confers shear-thinning during injection 
and then slow self-healing after injection.32,33 
For translation, the injectability of shear-thinning hydrogels plays a major role in 
enabling minimally invasive delivery (i.e., through percutaneous catheters or via 
standard surgical minimally invasive or robotic means).34,35 For tissue regeneration, the 
encapsulation of cells within hydrogels also requires specific injection parameters that 
can influence viability.6,36 For bioprinting applications, injection parameters are also 
important in modulating both the resolution and stability of printed structures, as well as 
cellular viability.37,38 For these reasons, it is important to engineer and tune hydrogels for 
injection and to understand how various design parameters influence these outcomes, 
using both quantitative and qualitative techniques. In this methods article, we detail 
techniques useful for exploring the mechanical properties that enable shear-thinning and 
self-healing, and demonstrate protocols that can be employed to ensure consistent 
hydrogel injection and retention.  
As a model system, we investigated these properties for hydrogels assembled 
through guest-host chemistry, which we have previously described, including in a 
detailed protocols paper on the synthesis of these hydrogel components.15,30,39 
Specifically, hyaluronic acid (HA) was modified with either b-cyclodextrin (CD, host, 28% 
of disaccharide repeats) or adamantane (Ad, guest, 22% of disaccharide repeats) to 
form CD-HA and Ad-HA, respectively, and assembled through supramolecular 
hydrophobic interactions to form hydrogels that are shear-thinning and self-healing 
(Figure 3.1). These materials are only a representative example of the many types of 
shear-thinning and injectable hydrogels that are available, and the techniques used for 
their characterization can be applied to other injectable hydrogels.  We organize this 
work into five main methods, including (i) synthesis of hydrogel components, (ii) 
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rheological characterization of hydrogels, (iii) measurement of hydrogel injection forces, 
(iv) encapsulated cell viability after injection, and (v) injection of hydrogels into cardiac 
tissue. 
 
Figure 3.1. Guest-host material synthesis and assembly. (a) Schematic of guest-host 
material synthesis through modification of hyaluronic acid with either adamantane (Ad-
HA) or b-cyclodextrin (CD-HA). (b) Graphic showing guest-host assembly of 
adamantane and b-cyclodextrin groups and shear-thinning.  
 
3.2 SYNTHESIS OF HYDROGEL COMPONENTS 
 A step-by-step protocol with characterization of the desired products is provided 
for Ad-HA (guest) and CD-HA (host), which are the components of the injectable guest-
host hydrogel that will be utilized extensively in the rest of this chapter and in the rest of 
this thesis. The synthesis reactions are typically performed for 2.5 g of HA and can be 
scaled to a desired size (reactions using 0.5–5 g of HA have been successfully 
performed in our laboratory by linear scaling of all reagents). 
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For CD-HA, the water-soluble β-cyclodextrin (CD) is aminated via intermediate 
tosylation of one of the primary hydroxyl groups to obtain 6-(6-aminohexyl)amino-6-
deoxy-β-cyclodextrin (CD-HDA). CD-HA is then synthesized by the reaction of CD-HDA 
with the TBA salt of HA, with benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate (BOP) as the coupling reagent in anhydrous DMSO. For Ad-HA, 
the TBA salt of HA is reacted with 1-adamantane acetic acid using 4-
(dimethylamino)pyridine (DMAP) and di-tert-butyl dicarbonate (BOC2O) in DMSO. Both 
products are purified by excessive dialysis, lyophilized for storage, and then rehydrated 
and used to form hydrogels. 
3.2.1. MATERIALS 
Reagents 
CAUTION: When using the chemicals described in this protocol, always wear suitable 
personal protective equipment, including lab coat, gloves, safety goggles and, where 
indicated, face shield, respirator and thermo-insulated gloves. Follow the relevant 
institutional and governmental safety guidelines and refer to the appropriate material 
safety data sheets. All synthesis steps should be performed within a chemical fume 
hood. 
• Sodium hyaluronic acid, 66–99 kDa (Lifecore, cat. no. HA-60K; store it under 
nitrogen at −20 °C) 
o Other molecular weights of sodium hyaluronic acid can be used for this 
protocol. However, this affects the viscosity during synthesis and the 
properties of the resulting hydrogels. 
• Methacrylic anhydride (MA; Sigma-Aldrich, cat. no. 276685; store under nitrogen 
at 4 °C) 
o CAUTION: Contact with methacrylic anhydride can cause skin irritation, 
eye damage and respiratory irritation. Wear a face shield and respirator. 
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• Sodium hydroxide (NaOH; Sigma-Aldrich, cat. no. S8045; store it at room 
temperature (RT; 20–25 °C)) 
o CAUTION: Sodium hydroxide can cause skin corrosion and serious eye 
damage. Avoid any direct contact. 
• Dowex 50W×8 resin (Sigma-Aldrich, cat. no. 217506; store at RT) 
o CAUTION: Dowex is acutely toxic and causes skin and eye irritations and 
presents organ toxicity after a single exposure. Wear a respirator. 
• Tetrabutylammonium hydroxide solution, 40% (wt/vol) in water (TBA-OH; Sigma-
Aldrich, cat. no. 178780; store it at RT) 
o CAUTION: Tetrabutylammonium hydroxide can cause skin corrosion and 
serious eye damage. Avoid any direct contact and wear face shield and 
respirator. 
• 1-Adamantane acetic acid (Acros Organics, cat. no. 331560010; store it at RT) 
o CAUTION: 1-adamantane acetic acid causes skin irritation and serious 
eye irritation, and may cause respiratory irritation if inhaled. 
• 4-(Dimethylamino)pyridine (DMAP; Sigma-Aldrich, cat. no. 29224; store dry at 
RT) 
o CAUTION: DMAP can cause severe skin burns and eye damage. Wear a 
face shield and respirator. 
• Anhydrous DMSO (Sigma-Aldrich, cat. no. 276855; store at RT) 
o CAUTION: Always wear a face shield. 
• Di-tert-butyl dicarbonate (BOC2O; Sigma-Aldrich, cat. no. 361941; store it under 
nitrogen at 4 °C) 
o CAUTION: BOC2O is flammable, causes serious eye damage and is fatal 
if inhaled. Always wear a respirator and face shield. 
• Acetone (Fisher Scientific, cat. no. A18-20; store at RT) 
o CAUTION: Acetone is flammable and may cause irritation of the 
respiratory tract; vapors may cause dizziness. Keep it away from heat 
and hot surfaces. 
• p-Toluenesulfonyl chloride (TCI America, cat. no. T0272; store dry at RT) 
o CAUTION: p-Toluenesulfonyl chloride is highly corrosive and may cause 
severe skin burns and eye damage. It should be directly weighed out in 
the reaction vessel. Avoid any direct contact and wear a face shield. 
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• Acetonitrile (Sigma-Aldrich, cat. no. 271004; store at RT) 
o CAUTION: Acetonitrile is flammable, irritating to the eyes and may cause 
skin and respiratory tract irritation. Wear a face shield and respirator 
when handling. 
• Diethyl ether (Sigma-Aldrich, cat. no. 296082; store at RT) 
o CAUTION: Diethyl ether is flammable and may cause respiratory irritation 
if inhaled and skin dryness if exposed repeatedly. Wear a respirator and a 
face shield. 
• (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
(BOP; Sigma-Aldrich, cat. no. 226084; store it under nitrogen at 4 °C) 
o CAUTION: BOP is flammable and acutely toxic, and causes specific 
organ toxicity upon a single exposure. 
• β-Cyclodextrin (CD; TCI America, cat. no. C0900; store it under nitrogen at 4 °C) 
• Ammonium chloride (Fisher Scientific, cat. no. A661-500; store it at RT) 
o CAUTION: Ammonium chloride is harmful if swallowed and may cause 
skin and respiratory tract irritation. 
• N,N-Dimethylformamide (DMF; Sigma-Aldrich, cat. no. 227056; store it at RT) 
o CAUTION: DMF is flammable and acutely toxic, can cause serious eye 
irritation and is harmful if inhaled. Always wear a respirator and a face 
shield. 
• Liquid nitrogen (Airgas National Welders, cat. no. 160LT22) 
o CAUTION: Contact with liquid nitrogen may cause serious freezing 
injuries. When handling liquid nitrogen, always wear thermo-insulated 
gloves, a full-face shield and a laboratory coat. 
• 1,6-hexanediamine (HDA; TCI, cat. no. D0095; store it at RT) 
o CAUTION: HDA is harmful on contact with skin and if swallowed, and can 
cause severe skin burns and eye damage. 
• Sodium chloride (Sigma-Aldrich, cat. no. S9888; store it at RT) 
• Deuterium oxide (D2O; Sigma-Aldrich, cat. no. 151882; store it at RT in a 
desiccator) 
• DMSO-d6 (Sigma-Aldrich, cat. no. 151874; store it at RT in a desiccator) 
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Equipment 
• Heated stir plate (e.g., RCT Basic; IKA, cat. no. 0003810001) 
• 1-, 2- and 3-neck round-bottom flasks, assorted sizes, with a magnetic stir bar 
• Rubber septa (Sigma-Aldrich, cat. no. Z553980) 
• pH meter (e.g., accumet, Fisher Scientific, cat. no. AB150BCERT) 
• Cannula, 20 gauge (e.g., Chemglass, cat. no. A-0519-08) 
• Glass pipettes with dropper bulbs 
• Beaker with a minimum of 3-liter volume 
• Milli-Q Biocel (Millipore, cat. no. ZMQS60F01) 
• Separatory funnel (e.g., Chemglass, cat. no. CG-1742-04) 
• Dialysis tubing (6,000–8,000 MW cut-off, regenerated cellulose; e.g., Spectra/Por 
1, Spectrum Labs, cat. no. 132670) and tubing closures (e.g., Spectrum Labs, 
cat. no. 142734) 
• Schlenk line with vacuum line, cold trap and oil pump (Liebig condenser (e.g., 
Chemglass, cat. no. CG-1218-03) 
• Bubbler (e.g., Chemglass, cat. no. AF-0513-20) 
• Lyophilizer (e.g., Labconco FreeZone; Thermo Fisher Scientific, cat. no. 
7387020) 
• NMR spectrometer (e.g., Bruker, cat. no. DMX360) 
• Sterile 1.5-, 2-, 15- and 50-ml conical (micro)centrifuge tubes 
• Glass beaker, 200–500 ml 
• Spatula 
• Forceps 
• Micropipettes and tips 
• Disposable Pasteur glass pipettes 
• Pasteur pipette rubber bulbs 
• Sterile syringes and needles 
• Refrigerator set to 4 °C 
• Freezer set to −20 °C 
• Freezer set to −80 °C 
• Standard laboratory bench-top refrigerated centrifuge for 50-ml conical tubes 
(e.g., Thermo Fisher Scientific, cat. no. 75004521) 
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• Microcentrifuge (e.g., Eppendorf Refrigerated Microcentrifuge; Eppendorf, model 
no. 5417R) 
• Vortex mixer (e.g., Fisher Scientific, cat. no. 02-215-414) and tube holder (e.g., 
Fisher Scientific, cat. no 11-676-363) 
 
3.2.2. PROCEDURE 
Overview 
• Step 1: Preparation of tetrabutylammonium salts of HA (HA-TBA) 
• Step 2: Preparation of CD-HA, part 1: synthesis of 6-o-monotosyl-6-deoxy-β-
cyclodextrin (CD-Tos) 
• Step 3: Preparation of CD-HA, part 2: synthesis of CD-HDA 
• Step 4: Preparation of CD-HA, part 3: synthesis of CD-HA 
• Step 5: Preparation of Ad-HA 
 
Step 1: Preparation of tetrabutylammonium salts of HA (HA-TBA) (2 hours, 3 days 
lyophilization) 
Dissolve 3.0 g of HA in 150 ml of deionized water in a 250-ml one-neck round-
bottom flask equipped with a magnetic stir bar.40 Add 9.0 g of Dowex 50W×8 to the HA 
solution and continue stirring for 30 min at RT. 
CAUTION: The hydrogen form of Dowex is a strong acid. Avoid any direct 
contact; always wear appropriate personal protective equipment, including gloves, safety 
goggles and a laboratory coat. 
Critical step: The reaction may be scaled by adjusting the amount of HA while 
maintaining a 2.0% (wt/vol) solution and a 3:1 weight ratio of Dowex/HA. 
Collect the HA from the resin by vacuum filtration using a No. 1 filter paper. 
Prepare 1:1 (20% (vol/vol)) and 1:5 (8% (vol/vol)) dilutions of tetrabutylammonium 
hydroxide (TBA-OH, 40%) in deionized water. Subsequently titrate the HA solution first 
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to pH 5 by adding 40% TBA-OH, then to pH 7 by adding 20% TBA-OH and finally to pH 
7.02–7.05 by adding 8% TBA-OH. 
Critical step: Add the TBA-OH slowly, as the pH of the solution can change 
rapidly near neutral pH values. 
Transfer the HA solution to 50-ml tubes, freeze them in a −80 °C freezer 
overnight and lyophilize the sample until the polymer is fully dry (3–4 d). To maintain a 
barrier, cover the 50-ml conical tubes with gauze and seal them with rubber bands 
before lyophilization. Ensure that samples do not thaw when transferred to the 
lyophilizer. Once dry, store polymers under nitrogen at −20 °C to avoid absorption of 
water and hydrolysis of HA. Lyophilized HA-TBA can be stored for at least 1 year at −20 
°C. 
Confirm the product and the degree of modification using 1H NMR spectroscopy 
and D2O as a solvent. Dissolve 5 mg of HA-TBA in 0.7 ml of D2O with shaking for 30 min 
at RT to ensure complete dissolution. Transfer the solution to an NMR tube using a 
Pasteur pipette, and seal the tube with a cap. Acquire spectra according to the 
manufacturer's instructions. 
Step 2: Preparation of CD-HA, part 1: synthesis of 6-o-monotosyl-6-deoxy-β-
cyclodextrin (CD-Tos) (2 days) 
Critical step: Ensure that all glassware and laboratory equipment are clean to 
avoid chemical contamination. 
The protocol described here is for 50 g of CD and can be scaled accordingly 
(reactions from 10 g–100 g of CD have been successfully performed in our laboratory).41  
Suspend 50 g (44 mmol) of CD in 300 ml of Milli-Q water in a one-neck round-
bottom flask and cool the solution in an ice bath (Figure 3.2). The solution will remain 
cloudy white because of limited CD solubility. Dissolve 10.07 g (53 mmol) of p-
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toluenesulfonyl chloride in 25 ml of acetonitrile under stirring. Use a cannula to gradually 
add the p-toluenesulfonyl chloride solution to the CD solution over 10 min under stirring. 
Alternatively, the solution can be added through a needle using a 50-ml glass syringe. 
Maintain the CD solution on ice for 2 h and continue stirring vigorously. 
 
Figure 3.2. Synthetic route for preparation of CD-Tos and CD-HDA. Reagents and 
conditions are as follows: reaction 1 (CD-Tos): deionized water, p-toluenesulfonyl 
chloride, NaOH, 0 °C → room temperature; reaction 2 (CD-HDA): DMF, HDA, 80 °C. (a) 
Schematic of chemical reaction and (b) reaction setup for the amination reaction, in 
which the dry round-bottom flask containing a stir bar is charged by the tosylated 
intermediate and purged by nitrogen, and DMF and HDA are separately added via a 
syringe through a rubber septa. 
 
Critical step: To achieve the desired pressure difference for cannulation, place 
the flask containing p-toluenesulfonyl chloride under nitrogen pressure, vent the flask of 
the CD solution and connect with the cannula (Figure 3.3). Ensure adequate stirring of 
the CD solution to avoid precipitation during the reaction. 
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Figure 3.3. Reaction setup for synthesis of CD-Tos and CD-HDA. Setup for (a) CD-
Tos and (b) CD-HDA synthesis under anhydrous conditions. 
 
Remove the flask from the ice bath. Dissolve 5.3 g (133 mmol) of sodium 
hydroxide in 20 ml of deionized water and add this dropwise to the CD solution over 10 
min. Continue stirring at RT for 30 min. The solution will turn slightly yellowish and 
become clearer. 
Critical step: Use a glass pipette when handling sodium hydroxide, as alkali 
solutions may corrode plastic pipette tips. 
Add 40 g (748 mmol) of ammonium chloride to the solution to adjust the pH to 9. 
Add additional ammonium chloride in 5-g increments until the pH is stable between 8.5 
and 9. Flocculation of the CD-Tos should occur. 
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 Critical step: Ensure adequate stirring and complete dissolution of the 
ammonium chloride before adding additional ammonium chloride. 
Precipitate the CD-Tos product: Separate the solution into 50-ml conical tubes 
and cool on ice for 15 min. Centrifuge the tubes at 3,200g for 2 min at 4 °C and decant 
the supernatant. Resuspend the crude product in 40 ml of deionized water (per tube) by 
vortexing. Cool the resuspended product on ice for 15 min, centrifuge at 3,200g for 2 min 
at 4 °C and decant the supernatant. Repeat this step twice. 
Critical step: For best yields, ensure that the solution is completely cooled on 
ice before centrifugation. Wash the reaction vessel with deionized water to collect the 
entire product. 
Wash the CD-Tos product: resuspend the product in 40 ml of ice-cold acetone 
(per tube) by vortexing, cool the resuspended product on ice for 15 min, centrifuge at 
3,200g for 2 min at 4 °C and decant the supernatant. Repeat this step twice. Resuspend 
the product in 40 ml of diethylether (per tube), centrifuge at 3,200g for 2 min at 4 °C and 
decant the supernatant. Repeat this step and decant the supernatant. Evaporate organic 
residues by vacuum pressure overnight to obtain a dry CD-Tos product. 
CAUTION: Wear goggles, thermally insulated gloves and a long-sleeved 
laboratory coat to avoid direct contact of liquid nitrogen with eyes and skin. 
Critical step: Vacuum drying should be carried out in a fume hood using a cold 
trap filled with liquid nitrogen. To maintain a barrier, cover the 50-ml conical tubes with 
gauze and seal them with rubber bands. 
Confirm the CD-Tos product using 1H NMR spectroscopy and DMSO-d6 as a 
solvent. CD-Tos can be stored under nitrogen at −20 °C for at least 6 months. 
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Step 3: Preparation of CD-HA, part 2: synthesis of CD-HDA (4 days) 
Add 10 g (8.8 mmol) of CD-Tos to a dry three-neck round-bottom flask and 
connect the flask to a Liebig condenser in-line with a gas bubbler (Figure 3). Purge by 
nitrogen, add 50 ml of DMF using a syringe and stir the mixture at RT until CD-Tos is 
fully dissolved.42 
Critical step: To ensure that glassware is dry, place the vessels in a drying oven 
at 125 °C for 24 h. Remove glassware from oven and stopper immediately. 
CAUTION: Be careful when handling hot glass and allow it to cool to RT before 
use. 
Melt HDA in a 60 °C oil bath and add 40 g (34 ml, 344 mmol) to the CD-Tos 
solution using a syringe. The solution will turn yellowish. Allow the reaction to stir for 18 
h at 80 °C in an oil bath before cooling to RT. 
Critical step: Transfer the HDA solution quickly to ensure that it does not solidify 
in the syringe. 
Precipitate the CD-HDA product: To 50-ml conical tubes holding 45 ml of ice-cold 
acetone (each), add 5 ml of the reaction solution and allow it to precipitate. Centrifuge 
the precipitate at 3,200g for 2 min at 4 °C and decant the supernatant. Re-dissolve the 
precipitate in 5 ml of DMF (per tube) by vortexing. Precipitate by adding 45 ml of ice-cold 
acetone (per tube), centrifuge at 3,200g for 2 min at 4 °C and decant the supernatant. 
Repeat this step three times. 
Critical step: The crude product will agglomerate as a pellet during 
centrifugation, which requires vigorous vortexing to re-dissolve in DMF. Increase the 
volume of DMF and acetone if full dissolution cannot be achieved. 
Wash the product by resuspending the pellet in 45 ml of cold acetone (per tube), 
centrifuge at 3,200g for 2 min at 4 °C and decant the supernatant. Resuspend the pellet 
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in 40 ml of ice-cold diethyl ether (per tube), centrifuge at 3,200g for 2 min at 4 °C and 
decant the supernatant. Repeat this step two times. 
Critical step: To reduce the number of tubes (allowing easier drying and 
collection of the final product), combine multiple fractions while washing with diethyl 
ether. 
Evaporate organic residues by vacuum pressure for 48 h to obtain dry CD-HDA 
as a white powder. Confirm the CD-HDA product using 1H NMR spectroscopy and 
DMSO-d6 as a solvent. CD-HDA can be stored under nitrogen at −20 °C for at least 6 
months. 
Step 4: Preparation of CD-HA, part 3: synthesis of CD-HA (11 days) 
Allow the HA-TBA to warm to RT. Equip a dry one-neck round-bottom flask with 
a magnetic stir bar and stopper. 
Critical step: Keep the HA-TBA in a desiccator, as it is hydroscopic and will 
remove water from the atmosphere. It is essential to exclude moisture while performing 
this reaction, as the presence of water reduces the coupling efficiency of the reaction. 
Add 2.5 g (3.43 mmol, 1 equiv.) of HA-TBA and 2.96 g (4.86 mmol, 0.5 equiv.) of 
CD-HDA to the flask. Purge with nitrogen before adding 125 ml of anhydrous DMSO (2% 
(wt/vol)) via cannulation. Stir the mixture at 350 r.p.m. until it is fully dissolved. Add 1.06 
g (4.86 mmol, 0.5 equiv.) of BOP to a separate dried round-bottom flask, purge with 
nitrogen and add 20 ml of DMSO via cannulation. Once the BOP is fully dissolved, 
transfer the solution to the HA-TBA/CD-HDA solution via cannulation and stir for 3 hours 
at RT. 
Quench the reaction with 10 ml of cold deionized water and transfer the solution 
to dialysis tubing. Dialyze for 5 d at RT and change the water twice daily. During the first 
3d, add sodium chloride (NaCl; 1.5 g per liter of dialysate) to force dialysis of the TBA 
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salt. Remove insoluble by-products from the BOP coupling reaction by vacuum filtration, 
and return to dialysis for an additional 5 d.  
Freeze the dialyzed solution at −80 °C and lyophilize. Confirm the product and 
the degree of modification using 1H NMR spectroscopy and D2O as a solvent. 
Lyophilized CD-HA samples can be stored under nitrogen for at least 1 year at −20 °C. 
Step 5: Preparation of Ad-HA (10–15 days) 
Allow the HA-TBA to warm up to RT. Equip a one-neck round-bottom flask with a 
magnetic stir bar and stopper. Add 2.5 g (3.5 mmol, 1 equiv.) of HA-TBA, 2.04 g (10.5 
mmol, 0.753.0 equiv.) of 1-adamantane acetic acid and 0.32 g (2.63 mmol, 0.75 equiv.) 
of DMAP to the flask and purge with nitrogen before adding 125 ml of anhydrous DMSO 
(2% (wt/vol)) to the vessel via cannulation. Stir at 350 r.p.m. for 20 min, or until the HA-
TBA is fully dissolved. 
Critical step: Secure the stopper with a copper wire to prevent the stopper from 
becoming dislodged because of increased pressure when the reaction is heated. It is 
essential to exclude moisture while performing this reaction, as the presence of water 
reduces the coupling efficiency of the reaction. 
Melt BOC2O in a 37 °C water bath and add 0.35 ml (0.41 equiv.) to the reaction 
using a plastic syringe. Purge the reaction vessel with nitrogen and stir for 20 h at 45 °C 
in an oil bath. 
Critical step: The degree of modification can be controlled by adjusting the 
amount of BOC2O; modifications of 20–50% have been achieved in our laboratory 
(quantity used to afford the desired modification: 20%, 0.41 equiv.; 30%: 0.54 equiv.; 
40%, 0.81 equiv. and 50%, 1.15 equiv.) 
Let the reaction mixture cool to RT, add 10 ml of cold deionized water to quench 
the reaction and transfer the mixture to the dialysis tubing. Dialyze for 3 days at RT and 
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change the water twice daily. Precipitation of excess adamantane is expected and 
should be removed by vacuum filtration using a No. 1 filter paper. Return the filtrate to 
dialysis for an additional 12 d. Change the water twice daily. Freeze the samples in a 
−80 °C freezer overnight and lyophilize. Confirm the product and the degree of 
modification using 1H NMR spectroscopy and D2O as a solvent. Lyophilized Ad-HA 
samples can be stored under nitrogen for at least 1 year at −20 °C. 
3.2.3. TROUBLESHOOTING 
- Low yield of CD-Tos (Step 2). Possible reasons for this include the use of poor 
quality p-toluenesulfonyl chloride. In this case, use a freshly opened p-
toluenesulfonyl chloride. The p-toluenesulfonyl chloride also could have been 
added too quickly, so ensure low nitrogen pressure when using a cannula. 
Alternatively, add dropwise via a syringe over ∼10 min. Poor precipitation during 
water and acetone washes could also lead to low yields. Be certain to keep 
water, acetone, and samples on ice between the washing steps and centrifuge at 
4 °C. 
- High residual water peak on CD-Tos 1H NMR (Step 2, Figure 3.4). This is 
likely due to incomplete drying of CD-Tos. Repeat vacuum drying overnight to 
remove residual water and purge sample with nitrogen before storage.  
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Figure 3.4. 1H NMR spectrum of CD-Tos in DMSO-d6. The product was not fully dried, 
which causes combination of the HOD peak with the hydroxyl groups of the CD ring 
(purple shaded), prohibiting reliable integration of the CD necessary to confirm mono-
tosylation. 
 
- Cloudy acetone supernatant (Step 3). Usually this is the result of poor 
precipitation. Make sure to use low amounts of DMF (ca. 5 mL) to dissolve the 
pellet during washing steps.    
- Low degree of CD or Ad modification on HA (Steps 4-5). Residual water can 
quench the anhydrous reaction. Ensure that the glassware is completely dry and 
purged with nitrogen before starting the reaction. Pre-weigh HA-TBA before 
storage under nitrogen to avoid long exposure to the atmosphere before starting 
CD-HA or AD-HA syntheses. Also, be sure to sufficiently purge by dry nitrogen 
before the reaction.  
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3.2.4. ANTICIPATED RESULTS 
The HA-TBA product should be recovered as a spongy white solid. 1H NMR 
spectroscopy (D2O) HA-TBA δ = 0.9–1.04 (t, 12H), 1.33–1.47 (m, 8H), 1.62–1.76 (m, 
8H), 2.1 (s, 3H), 3.13–3.3 (m, 8H), 3.30–4.20 (10 H) (Figure 3.5). All products derived 
from this intermediate (CD-HA, Ad-HA) should be examined to confirm sufficient dialysis 
for elimination of the TBA salt. 
 
Figure 3.5. 1H NMR spectra of HA-TBA in D2O. Modification of HA with TBA salt is 
determined by the integration of the TBA methyl-groups (12H, shaded brown) relative to 
the N-acetyl group of HA (3H, shaded gray).  
 
The CD-Tos product should be recovered as a white powder, where yields (2.5 g, 
21.1%; 20 g, 22.2%; 50 g, 17.8%) and product characterization are consistent 
regardless of reaction scale and are consistent with literature reports.41 1H NMR 
spectroscopy (300MHz, DMSO-d6) δ = 2.42 (s, 3H), 3.123.80 (m, overlaps with HOD), 
4.124.40 (m, 6H), 4.77 (s, 2H), 4.83 (s, 5H), 5.606.05 (br s, 14H), 7.43 (d, 2H), 7.75 (d, 
2H) (Figure 3.6).  
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Figure 3.6. 1H NMR spectrum of CD-Tos in DMSO-d6. Tosylation of CD is confirmed 
by integration of the methyl (3H, shaded red) and aromatic hydrogens (2H each, shaded 
orange), relative to the secondary hydroxyls of CD (14H, shaded gray). Anticipated 
minor impurities in the spectra may include trace acetone ( = 2.10), ammonium chloride ( 
= 6.98, 7.12, 2.27 (s)), ethyl ether ( = 3.42 (q), 1.13 (t, 3H)), and water (see Figure 4). 
 
CD-HDA should resemble a white powder and the overall yield of this step is 
74.7± 7.4% (n = 3). 1H NMR spectroscopy (DMSO-d6) δ = 1.141.61 (m, 12H), 3.123.45 
(m, overlaps with HOD), 3.483.78 (m, 28H), 4.284.56 (br s, 6H), 4.83 (s, 7H), 5.595.88 
(br s, 14H) (Figure 3.7).  
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Figure 3.7. 1H NMR spectrum of CD-HDA in DMSO-d6. Modification of CD with HDA is 
determined by integration of the hexane linker (12H, shaded red) relative to the 
secondary hydroxyls of CD (14H, shaded gray). Anticipated minor impurities in the 
spectra may include trace dimethlyformamide ( = 7.98, 2.92, 2.08), acetone ( = 2.10), 
and ethyl ether ( = 3.42 (q), 1.13 (t, 3H)).  
 
The CD-HA product should be recovered as a spongy white to off-white solid, 
with typical yields of ∼70%. The modification of HA is ∼30% for CD-HA, which is 
validated by 1H NMR spectroscopy (D2O) based on the integration of the hexane linker δ 
= 1.351.85 (12H) relative to the methyl singlet of HA δ =2.1 (3H) (Figure 3.8).  
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Figure 3.8. 1H NMR spectra of CD-HA in D2O. Modification of HA with pendant CD 
(30.2%) is determined by integration of the hexane linkers (12H, shaded red) relative to 
the N-acetyl singlet of HA (3H, shaded gray).  
 
The Ad-HA product should be recovered as a spongy white solid, with typical 
yields of ∼70%. The modification of HA repeat units is 32.5% for Ad-HA as validated by 
1H NMR spectroscopy (D2O) based on integration of the ethyl multiplet of adamantane (δ 
= 1.501.85, 12H) relative to the HA backbone (δ = 3.204.20, 10H) (Figure 3.9).  
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Figure 3.9. 1H NMR spectra of Ad-HA in D2O. Modification of HA with pendant Ad 
(32.5%) is determined by integration of the ethyl multiplet (12H, shaded blue) relative to 
the sugar ring of HA (10H, shaded gray). 
 
 
 
3.3 RHEOLOGICAL CHARACTERIZATION OF HYDROGELS 
Rheology is a tool that can be used to quantitatively measure parameters of 
hydrogels such as viscosity and storage and loss modulus, which are important 
determinants of hydrogel injectability. Viscosity is a direct measurement of the ability for 
a material to resist deformation in response to stress and is a direct measurement of 
relative ability for hydrogel formulations to respond to changes in shear stress during 
injection. Storage and loss modulus provide information about the elastic and viscous 
response behaviors of a hydrogel, respectively, in response to oscillatory shear. In 
particular, they measure the extent to which a hydrogel is able to respond to stress and 
either absorb energy (storage modulus) or undergo stress relaxation to dissipate energy 
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(loss modulus). This information is relevant for injections to better understand the 
behavior of hydrogels during injection.  
There are certain steps that must be taken in hydrogel sample preparation, 
hydrogel loading onto the rheometer, and rheometer data acquisition that are crucial to 
precise data collection and analysis. In this section, we describe a method for 
rheological analysis of injectable hydrogels that can be used to determine compatibility 
of hydrogels for future injection, including in vivo delivery.  
3.3.1. MATERIALS 
Reagents 
• Adamantane-modified HA (Ad-HA) , ~22% of repeat units modified, synthesis 
described elsewhere with reagents available from sigma (St. Louis, MO)39 
• Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis 
described elsewhere with reagents available from Sigma (St. Louis, MO)39 
• Phospho-buffered saline  (Life Technologies, Carlsbad, CA, cat no: 15710-064) 
• Deionized water 
Equipment 
• Forceps (e.g. Fine Science Tools, Foster City, CA, cat no: 11008-15) 
• 1.5-mL microcentrifuge tubes (e.g. Fisher Scientific, Waltham, MA, cat no: 05-
408-129) 
• Vortex (e.g. Fisher Scientific, Waltham, MA, cat no: 02-215-414) with 
microcentrifuge tube holder (e.g. Fisher Scientific, Waltham, MA, cat no: 11-676-
363) 
• Sonicator (e.g. Branson Ultrasonics, Danbury, CT, model no: CPX5800H) 
• Microcentrifuge (e.g. Eppendorf Refrigerated Microcentrifuge 5417R, Eppendorf, 
Hamburg, Germany)  
• Scoopula (made from a cut 1-mL pipette tip)39  
• Rheometer (AR 2000 EX, TA Instruments, New Castle, DE) 
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3.3.2. PROCEDURE 
Overview 
• Step 1: Hydrogel preparation 
• Step 2: Rheometer set-up and calibration 
• Step 3: Hydrogel loading onto rheometer 
• Step 4: Rheometer data acquisition 
• Step 5: Clean-up and next sample preparation 
• Step 6: Rheometer data analysis 
 
Step 1: Hydrogel preparation (2 hours) 
 Thaw materials (i.e., Ad-HA, CD-HA) from storage as a dry powder at -20°C until 
they reach room temperature. For guest-host hydrogels, the mixing of Ad-HA with CD-
HA in aqueous solution forms an injectable hydrogel. Weigh materials separately into 
two microcentrifuge tubes and dissolve them in PBS at the desired concentration on a 
vortex for at least 30 minutes or until dissolved. Pipette the Ad-HA solution into the CD-
HA solution and mix the components with a pipette until the hydrogel is formed. Vortex 
the hydrogel for 30 minutes. Then, sonicate the hydrogel for at least 10 minutes at 50°C 
to completely dissolve the hydrogel components. Mix the hydrogel again with a pipette, 
and then centrifuge for 2 minutes at 25000 RCF to remove any bubbles. The 
components and concentrations can be varied depending on the shear-thinning hydrogel 
that is being investigated. 
 Critical step: For reproducibility between samples, it is important that the 
hydrogel components are weighed accurately. It is recommended to prepare solutions of 
Ad-HA and CD-HA and aliquot these solutions into microcentrifuge tubes so that each 
tube contains the desired polymer mass. Tubes can then be frozen, lyophilized, and 
stored under nitrogen until needed. Each aliquot serves as an independent preparation 
of hydrogel, and a minimum of three preparations should be tested to achieve statistical 
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significance between different hydrogel formulations. Additional preparations or technical 
replicates should be used if large variability is observed between formulations. In 
addition, both components of the hydrogel must be thoroughly dissolved and mixed 
together, without air bubbles. Any inconsistencies in hydrogel preparation will result in 
poor reproducibility in subsequent experiments. 
Step 2: Rheometer set-up and calibration (15-30 min) 
2-1. Rheometer set-up. The following steps are specific to the AR 2000 EX 
rheometer. These directions are to be taken in addition to steps provided by the 
manufacturer for rheometer set-up and calibration. Close vent and turn on compressor. 
The pressure should reach 30 PSI for rheometer operation. Connect the geometry and 
the Peltier plate stage to the rheometer. Depending on the application, the Peltier plate 
temperature should be set to 25°C or 37°C depending on the property measured. For 
our experiments, temperature is set to 25°C as this is the ambient temperature in which 
an injection would be performed. Experiments are performed at room temperature 
(25°C). 
Critical step: Rheometer geometry is important and is determined by sample 
viscosity, shear rates and shear stresses desired, as well as sample volumes. For these 
studies, a cone and plate geometry was chosen because this geometry normalizes 
shear rates across the entire sample, allowing for an accurate determination of true 
sample viscosity (as opposed to parallel plate geometries, where shear rates vary 
across the sample). Cone angle (0° 59’ 42”) and diameter (20 mm) were chosen based 
on shear rates and shear stresses desired and to minimize sample volumes needed. 
The truncation height or gap for this geometry is 27 µm. The gap height must be greater 
than or equal to ten times the particle size, if particulate-based hydrogels are 
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investigated. Rheometer geometry may need to be adjusted depending on hydrogel 
properties. 
2-2. Calibration. Open the instrument control program on the computer and 
calibrate instrument inertia, geometry inertia, and bearing friction. Use rotational 
mapping to calibrate the geometry, then zero the geometry gap to prepare for sample 
loading. 
Critical step: Because the geometry is removed for cleaning after every sample, 
all calibrations except for the instrument inertia should be repeated between each 
sample. 
Step 3: Hydrogel loading onto rheometer (10 min) 
Remove the hydrogel from the microcentrifuge tube using a scoopula. Load the 
hydrogel onto the Peltier plate, taking care not to introduce air or bubbles into the 
hydrogel. Place the hydrogel in the center of the plate. When centered, use the program 
to set the height of the cone to the gap height (27 µm). Spin the geometry so that it is 
turning while it contacts the hydrogel for more even hydrogel flattening (Figure 3.10a). 
Either right before (~5% higher) or when the gap height is reached, trim the edges of the 
hydrogel with a pipette tip so that the hydrogel correctly fills the geometry (Figure 
3.10b). Place the solvent trap over the geometry and onto the Peltier plate and surround 
the outer edges of the solvent trap with water to keep the hydrogel hydrated during data 
acquisition.  
 Critical step: Correct filling of the geometry by the hydrogel is important for 
accurate rheological data acquisition. An over-filled sample overestimates mechanical 
values, while an under-filled sample underestimates mechanical values. A correctly filled 
sample can be difficult to obtain by trimming. Hydrogel loading volume may need to be 
optimized based on the geometry used.  
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Figure 3.10. Hydrogel loading onto the rheometer stage. (a) When lowering the 
geometry onto the hydrogel, spin the geometry slightly for more even hydrogel loading. 
(b) Over-filling and under-filling of the sample results in increased and decreased forces, 
respectively. The hydrogel sample must fill the space between the geometry and the 
rheometer stage correctly for accurate measurements. 
 
 
Step 4: Rheometer data acquisition (variable) 
 Open the procedure desired and start the protocol. Depending on the tests 
chosen, the procedure length will vary. For these studies, we used the following protocol: 
A. Time sweep (2 min) at 0.2% strain, 10 Hz 
Note that % strain is determined using strain sweeps to select a % strain 
lower than the yield strain. A consistently non-deforming strain in our 
system is <1%. Similarly, the frequency is determined from frequency 
sweeps by selecting a frequency greater than the crossover frequency. 
B. Frequency sweep from 0.01 to 100 Hz at 0.2% strain with a conditioning time of 3 
seconds, a sampling time of 3 seconds, and 10 points per decade 
Note that the % strain is the same as for the time sweep. 
C. Time sweep (2 min) at 0.2% strain, 10 Hz to recondition the hydrogel 
D. Strain sweep from 0.01% to 500% strain at 10 Hz with a conditioning time of 3 
seconds, a sampling time of 3 seconds, and 10 points per decade 
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Note that the frequency is the same as for the time sweep. 
E. Low strain (cyclic strain) time sweep (2 min) at 0.2% strain, 10 Hz 
F. High strain (cyclic strain) time sweep (1 min) at 500% strain, 10 Hz 
G. Repeat E, F 5 times for cyclic strain test 
H. Time sweep (2 min) at 0.2% strain, 10 Hz to recondition hydrogel 
I. Continuous ramp from shear rates of 0 s-1 to 50 s-1 over 2 min 30 seconds with 
20 points per decade 
J. Continuous ramp from shear rates of 50 s-1 to 0 s-1 over 2 min 30 seconds with 
20 points per decade 
Step 5: Clean-up and next sample preparation (10 min) 
 Raise the geometry using controls on the machine. Remove the hydrogel from 
the stage and clean up any excess water around the solvent trap. Remove the geometry 
carefully from the bearing and wipe dry. Repeat steps starting at rheometer calibration 
for all remaining samples.  
Critical step: Be sure to clean the stage and complete all calibration steps fully 
between each sample.  
Step 6: Rheometer data analysis (variable) 
Export data as text files from the computer program. Import files into graphing 
software and create plots based on tests completed.  
Critical step: TA Instruments includes a data analysis program, but this program 
does not allow you to fully manipulate graphs and graph settings. 
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3.3.3. TROUBLESHOOTING 
- Air bubbles within hydrogel prior to loading onto rheometer. After the 
hydrogel is mixed, spin down the hydrogel at 25000 RCF for 2 minutes to remove 
any bubbles accumulated during mixing. Note that centrifugation speeds for 
hydrogels with encapsulated therapeutics should be determined empirically, as 
small molecules or cells may settle in the hydrogel during centrifugation.  
- Difficulties in hydrogel loading or hydrogel trimming on the rheometer 
stage. Change the volume of hydrogel prepared to match the amount of hydrogel 
that is needed for the specific geometry chosen to limit the need to trim the 
hydrogel. Take care to load the hydrogel onto the center of the plate and make 
sure the geometry is slightly spinning when it touches the hydrogel.  
- Hydrogel dries out during testing. Make sure to add water to the top of 
geometry and use the solvent trap. Surround the edges of the solvent trap with 
water to provide a humidified environment for the hydrogel during testing. 
Lowering the temperature of the Peltier stage may also be helpful for longer 
studies, as long as the temperature change does not affect the mechanical 
properties of the hydrogel. 
 
3.3.4. ANTICIPATED RESULTS  
For demonstration, we prepared guest-host hydrogels of varying material 
concentrations for rheological analysis. Using the materials previously described, we 
formed hydrogels with a total (Ad-HA and CD-HA) polymer content of 5 wt% or 7.5 wt%. 
Following hydrogel preparation, we loaded these hydrogels onto the rheometer and ran 
the tests outlined above. The results from these tests are shown in Figure 2. Frequency 
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sweeps (Figure 3.11a), strain sweeps (Figure 3.11b), continuous flow experiments 
(Figure 3.11c), and cyclic strain time sweeps (Figure 3.11d) are highlighted here.  
 
Figure 3.11. Rheological characterization of guest-host hydrogels. Results of (a) 
frequency sweep, (b) strain sweep, (c) continuous flow, and (d) cyclic strain time sweep 
rheology experiments for hydrogels of 5 wt% and 7.5 wt% material concentration, using 
the described method and rheological parameters. For cyclic strain, shaded regions are 
high strain (500%) and unshaded regions are low strain (0.2%). 
 
 The frequency sweep indicates that both hydrogels transition from a primarily 
liquid to a primarily solid state with increasing frequencies, and that the relaxation time 
for the 5 wt% hydrogel is shorter than that of the 7.5 wt% hydrogel (Figure 3.11a). 
Frequency sweeps provide a relative ranking of elastic and viscous properties under 
constant strain. Increasing frequencies decrease relaxation times and favor elastic 
properties (G’, storage modulus) over viscous properties (G’’, loss modulus) as there is 
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minimal time for energy to dissipate or for hydrogels to flow during testing. These results 
indicate that the 5 wt% hydrogel flows more readily than the 7.5 wt% hydrogel.  From the 
strain sweep, we observe that both hydrogels experience a steep drop in storage and 
loss modulus after a certain yield strain, indicating material yielding (Figure 3.11b). This 
yield strain is lower for the 5 wt% hydrogel, indicating that the 5 wt% hydrogel may be 
easier to inject than the 7.5 wt% hydrogel. 
An important factor for injectability from the rheology data is whether the hydrogel 
is shear-thinning. Shear-thinning hydrogels experience decreases in viscosity upon 
application of shear, which are enabled by reversible crosslinking mechanisms. From the 
continuous flow experiments, we observe that the viscosity decreases as shear rate 
increases for both the 5 wt% and 7.5 wt% hydrogels, indicating that both hydrogels are 
shear-thinning (Figure 3.11c). Similarly, the cyclic strain sweeps show that at high 
strains, both of these hydrogels yield and show sharp decreases in storage and loss 
modulus, which are recovered instantly at low strains upon cessation of shear (Figure 
3.11d, Figure 3.12b-c). This displays the ability for hydrogels to transition from a 
predominantly elastic material to a predominantly viscous one, and demonstrates the 
rapidly self-healing properties of this hydrogel. From the continuous flow experiments, 
we can also observe that the 5 wt% hydrogel displays shear banding, or a precipitous 
drop in shear stress for certain shear rates (Figure 3.12a).43 This also indicates 
injectability. 
Hydrogels with a lower viscosity and a lower storage and loss modulus are 
typically easier to inject than hydrogels of a high viscosity and a high storage and loss 
modulus. The viscosity of the 5 wt% hydrogel is lower than that of the 7.5 wt% hydrogel, 
indicating that the 5 wt% hydrogel would be easier to inject (Figure 3.11c). From the 
cyclic strain time sweeps, we observe that the storage modulus of both hydrogels 
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change with strain and that the 5 wt% hydrogel has a lower storage modulus than the 
7.5 wt% hydrogel, indicating that the 5 wt% hydrogel may be easier to inject (Figure 
3.11d). Cyclic strain time sweeps showing both storage and loss modulus for 5 wt% and 
7.5 wt% hydrogels can be found in Figure 3.12b-c. 
 
 
Figure 3.12. Additional rheological characterization of guest-host hydrogels. (a) 
Continuous flow experiments of shear stress by shear rate that show shear banding for 5 
wt% hydrogels, but not 7.5 wt% hydrogels. (b-c) Cyclic strain time sweep experiments at 
10 Hz for 5 wt% (b) and 7.5 wt% (c) hydrogels show storage (G’) and loss (G”) moduli 
over time. Shaded regions represent high strain (500%) and unshaded regions represent 
low strain (0.2%).   
 
 
 
3.4 MEASUREMENT OF HYDROGEL INJECTION FORCES 
While material properties such as viscosity, storage, and loss modulus are 
important for determining injectability, injection force determines whether or not a 
material is clinically relevant for injection. Controlled methods to measure injection force, 
such as a force sensor or a material testing machine, allow us to compare quantitatively 
the injectability of various hydrogels of differing material formulations. In this section, we 
describe a protocol for determining injection force using both a versatile, inexpensive 
force sensor and using an established material testing machine. We also describe 
factors that influence injection force, such as flow rate, needle gauge, and needle length. 
Injection force is not only relevant as a physical property, but also has effects on 
hydrogel contents, such as cells. 
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3.4.1. MATERIALS 
Reagents 
Reagents for hydrogel formation 
• Adamantane-modified HA (Ad-HA) , ~22% of repeat units modified, synthesis 
described elsewhere with reagents available from sigma (St. Louis, MO)39 
• Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis 
described elsewhere with reagents available from Sigma (St. Louis, MO)39 
• Phospho-buffered saline  (Life Technologies, Carlsbad, CA, cat no: 15710-064) 
Equipment 
• Forceps (e.g. Fine Science Tools, Foster City, CA, cat no: 11008-15) 
• 1.5-mL microcentrifuge tubes (e.g. Fisher Scientific, Waltham, MA, cat no: 05-
408-129) 
• Vortex (e.g. Fisher Scientific, Waltham, MA, cat no: 02-215-414) with 
microcentrifuge tube holder (e.g. Fisher Scientific, Waltham, MA, cat no: 11-676-
363) 
• Sonicator (e.g. Branson Ultrasonics, Danbury, CT, model no: CPX5800H) 
• Microcentrifuge (e.g. Eppendorf Refrigerated Microcentrifuge 5417R, Eppendorf, 
Hamburg, Germany)  
• Scoopula (made from a cut 1-mL pipette tip)39  
• Various syringes and needles for gel preparation or testing 
o 1 mL syringe (BD, Franklin Lakes, NJ, cat no: 309628) 
o ½ mL, 27G x ½” tuberculin syringe (BD, Franklin Lakes, NJ, cat no: 
305620) 
o 18G x ¼” needle (McMaster-Carr, Elmhurst, IL, cat no: 75165A121) 
o 25G x ¼” needle (McMaster-Carr, Elmhurst, IL, cat no: 75165A127) 
o 27G x ¼” needle (McMaster-Carr, Elmhurst, IL, cat no: 75165A128) 
o 25G x 1 ½” needle (BD, Franklin Lakes, NJ, cat no: 305127) 
• Force Sensor (Tekscan, Boston, MA, FlexiForce Quickstart Board) 
• myDAQ Data Acquisition Device (National Instruments, Austin, TX) 
• Syringe pump (e.g. New Era Pump Systems Inc, Farmingdale, NY, model no: 
NE-300) 
• Mechanical testing machine (Instron, Norwood, MA, model no: 5848) 
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3.4.2. PROCEDURE 
Overview  
• Step 1: Hydrogel preparation 
• Step 2: Hydrogel loading into syringe for testing 
• Step 3: Force testing by force sensor or mechanical testing machine 
 
Step 1: Hydrogel preparation (2 hours) 
Hydrogels are prepared the same way as described for Method 1. Briefly, weigh 
Ad-HA and CD-HA materials into separate microcentrifuge tubes and dissolve in PBS on 
a vortex. Mix Ad-HA and CD-HA components together using a pipette. Vortex the 
hydrogel for 30 minutes, then sonicate at 50°C for 10 minutes. Mix the hydrogel again 
with a pipette and centrifuge at 25000 RCF for 2 minutes to remove entrapped air. Refer 
to Step 1 of Method 1 for more details and critical steps.  
Step 2: Hydrogel loading into syringe for testing (20 min + overnight incubation) 
Cut the needle off of a ½ mL, 27G x ½” tuberculin syringe. Remove the hydrogel 
from the microcentrifuge tube using a scoopula and load it onto the cut end of the 
syringe. Pull back on the plunger to load the hydrogel into the syringe. After the hydrogel 
is loaded, paraffin the open end of the syringe and cut the excess plunger using wire 
cutters. Centrifuge at 1000 RCF for 3 minutes to remove bubbles. Then, using the cut 
portion of the plunger, depress the plunger to load the hydrogel into a 1 mL syringe for 
testing. We use a 1 mL Luer lock syringe that can be connected to a wide variety of 
needles with different gauges and lengths. After loading the syringe and attaching the 
desired needle, wrap the needle with a hydrated wipe and cover with aluminum foil to 
prevent the hydrogel from drying. Store at 4°C overnight to allow any remaining bubbles 
to rise to the top of the syringe barrel. 
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Critical step: Any imperfections in hydrogel loading and hydrogel preparation 
(bubbles, dust, etc) will affect injection force so take care to load the hydrogel into the 
testing syringe homogeneously. The overnight incubation time is crucial for removing 
any air taken in during the hydrogel loading process. 
Step 3: Force testing (variable by sample number) 
By force sensor (Figure 3.13a). For best results, use a syringe pump to 
standardize the application of force to the syringe. Connect the force sensor to myDAQ 
for data acquisition. Create a  standard curve by placing weights that correspond to the 
injection forces that will be measured onto the sensor. Record voltages and adjust 
sensitivity of the force sensor if the voltages are out of range. Prime syringes, then place 
samples onto the syringe pump, and place the force sensor between the plunger of the 
syringe and the syringe pump. Start the syringe pump and record voltages for 1-2 
minutes. Convert the voltage to force using the standard curve and plot the force over 
time. 
 
Figure 3.13. Injection force using a force sensor. (a) Schematic of the set-up for 
measuring injection force using a force sensor. (b) Plot of injection force over time for 
hydrogels with varying material concentrations (5 wt%, 7.5 wt%) and different flow rates 
(2 mL/hr, 8 mL/hr). 
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By mechanical testing machine (Figure 3.14a). The use of a mechanical 
testing machine negates the use of a syringe pump, since the load cell will apply even 
forces. Prime the syringe and place into the stage of the mechanical testing machine. 
We used the base test frame as a  stage with no accompaniments. Zero the force from 
the load cell and then maneuver the load cell so that it is just touching the syringe, which 
can be detected by an increase in force. Using the tensile extension mode, set the linear 
rate to match a flow rate desired for testing. Start applying displacement and record the 
force over time for 1-2 minutes. Extract data and plot force over time.  
Critical step: For most accurate results, run each trial with the same starting 
volume of hydrogel. The distance traveled by the plunger will affect the forces applied.  
 
 
Figure 3.14. Injection force using a mechanical testing machine. (a) Schematic of 
the set-up for measuring injection force with a mechanical testing machine. (b) Plot 
showing injection force over time for hydrogels injected from a 1 mL syringe with ¼” 
needles of 18G, 25G, and 27G. (c) Injection force over time for hydrogels injected from a 
1 mL syringe with a 25G needle of ¼” and 1 ½” lengths. All measurements were taken at 
a flow rate of 2 mL/hr. 
 
3.4.3. TROUBLESHOOTING  
- Force changes over time. Over time, injection force should plateau for most 
hydrogel samples. If the force continues to rise, let the test run for a longer period 
of time. If the force declines unexpectedly and then increases, there may be 
imperfections in hydrogel loading. Ensure that the hydrogel is adequately mixed 
93 
and that there are no bubbles in the testing syringe for the most accurate 
measurements. 
- Needle detaches from syringe. Because of the nature of Luer-Lock needles, 
they can become detached from the syringe upon the application of extreme 
forces. In these cases, the hydrogel requires a high amount of force for injection. 
While this may not be practical for eventual clinical application, to measure this 
force, use a needle and syringe combination that is not detachable, such as an 
insulin syringe, to obtain measurements. Note that differences in syringes include 
barrel diameter, needle gauge, and/or needle length, all of which are variables 
which can affect injection force and that need to be controlled between samples 
for comparison. 
3.4.4. ANTICIPATED RESULTS 
 We tested the injection force necessary to eject both 5 wt% and 7.5 wt% guest-
host hydrogels from 1 mL plastic syringes at different flow rates and with differing needle 
gauges and needle lengths, using both a force sensor and a mechanical testing 
machine. We observed that, at a flow rate of 2 mL/hr, the injection force required for a 5 
wt% hydrogel was close to 5N. At the same flow rate, the injection force required for a 
7.5 wt% hydrogel was close to 15N (Figure 3.13b). From rheology we know that the 7.5 
wt% hydrogel has a higher viscosity and a higher storage and loss modulus than the 5 
wt% hydrogel, both of which contribute to its higher injection force. 
 Higher flow rates also lead to higher injection forces, and this effect was 
dependent on weight percent. For the 5 wt% hydrogels, increasing flow rate from 2 to 8 
mL/hr minimally increased injection force. For the 7.5 wt% hydrogels, increasing the flow 
rate from 2 to 8 mL/hr increased injection force. Other factors that affect injection force 
include needle gauge and needle length. Increasing needle gauge, and thereby reducing 
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needle diameter, increased injection force. For a 5 wt% hydrogel with a flow rate of 2 
mL/hr, reducing the needle diameter from 18G (0.84 mm) to 25G (0.26 mm) to 27G 
(0.21 mm) increased the injection force from 0.4N to 4N to 7N, respectively (Figure 
3.14b). We also found that increasing the needle length from ¼” to 1 ½” drastically 
increased injection force for a 5 wt% hydrogel at 2 mL/hr from 4N to 13N (Figure 3.14c). 
Blips in the force profile as it builds up can be attributed to heterogeneity in hydrogel 
preparations or improper loading. Care should be taken to ensure hydrogels are 
adequately mixed prior to testing, and that the syringe is properly loaded to ensure even 
contact between the load cell and syringe barrel. New syringes and needles should also 
be used for each independent hydrogel preparation. Single blips may be caused by one 
of the above issues, but multiple blips within the same profile may indicate problems 
such as phase separation.  
 
3.5 ENCAPSULATED CELL VIABILITY AFTER INJECTION 
Injection force is not only an important mechanical measure of hydrogel 
injectability but can also affect the ability of the hydrogel to carry certain types of cargo 
that are sensitive to force, such as cells. Material properties of hydrogels, such as 
storage modulus, can also affect the cell-protective capacity of injectable hydrogels.36 
Standardized techniques for encapsulating cells in hydrogels, especially two-component 
hydrogels such as the guest-host hydrogels described here, are important for 
reproducibility since variations in mixing techniques can alter cell responses and 
ultimately therapeutic efficacy. In this section, we describe a method for encapsulating 
cells within injectable hydrogels, culturing injectable hydrogels in vitro, and assessing 
encapsulated cell viability after injection.   
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3.5.1. MATERIALS 
Reagents  
• Adamantane-modified HA (Ad-HA) , ~22% of repeat units modified, synthesis 
described elsewhere with reagents available from sigma (St. Louis, MO)44 
• Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis 
described elsewhere with reagents available from Sigma (St. Louis, MO)44 
• Mouse 3T3 fibroblasts (e.g., ATCC, cat. no. CRL-1658; store in liquid nitrogen 
and routinely check to ensure that they are not contaminated with mycoplasma) 
• DMEM, high glucose, with GlutaMAXTM (Thermo Fisher Scientific, cat. no. 
10566016; store it at 4 °C) 
• FBS (Thermo Fisher Scientific, cat. no. 1437028; store it at −20 °C) 
• Penicillin–streptomycin, 10.000 U/ml (Life Technologies, cat. no. 15140-122; 
store it at −20 °C) 
• PBS (Life Technologies, cat. no. 10010023; store it at 4 °C) 
• Trypsin–EDTA (Life Technologies, cat. no. 15090-054; store at 4 °C) 
• Acrylonitrile–butadiene–styrene spool (MakerBot 1.75 mm/1.8 mm filament; ABS; 
store it at RT) 
• Agarose (Sigma-Aldrich, cat. no. A9539; store it at RT) 
• Live/Dead Viability/Cytotoxicity Kit for mammalian cells (e.g., Thermo Fisher 
Scientific, cat. no. L3224; store it at −20 °C) 
Equipment 
• Tissue culture hood (e.g., Thermo Fisher Scientific 1300 Series Class II, Type A2 
biological safety cabinet) 
• CO2 cell culture incubator set to 5% CO2 and 37 °C (e.g., Heracell VIOS; 
Thermo Fisher Scientific) 
• Microwave 
• Confocal microscope (e.g., Leica, model no. TCS SP5) 
• Hemocytometer (e.g., Hausser Scientific, cat. no. 0630010) 
• Water bath set to 37 °C 
• Scoopula (made from a cut 1-mL pipette tip)44  
• Sterile 100 cm2 tissue culture dishes (e.g., Sigma-Aldrich, cat. no. Z707694) 
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• Sterile 24-well plates for 3D cell culture (e.g., Corning Costar; Sigma-Aldrich, cat. 
no. CLS3527) 
• 3D printer (e.g., Makerbot Replicator 2) 
• ImageJ (https://imagej.nih.gov/ij/) or CellProfiler (http://cellprofiler.org/releases/) 
software 
• 1.5-mL microcentrifuge tubes (e.g. Fisher Scientific, Waltham, MA, cat no: 05-
408-129) 
• Forceps (e.g. Fine Science Tools, Foster City, CA, cat no: 11008-15) 
• Micropipettes and tips 
• Sterile syringes and needles 
• Refrigerator set to 4 °C 
• Freezer set to −20 °C 
• Freezer set to −80 °C 
• Microcentrifuge (e.g., Eppendorf Refrigerated Microcentrifuge; Eppendorf, model 
no. 5417R) 
• Vortex mixer (e.g., Fisher Scientific, cat. no. 02-215-414) and tube holder (e.g., 
Fisher Scientific, cat. no 11-676-363) 
 
3.5.2. PROCEDURE 
Reagent set-up 
• Mouse 3T3 fibroblast medium: prepare DMEM supplemented with 9% FBS 
and 1% penicillin–streptomycin. This medium can be stored for 1 week at 4 °C. 
• ABS molds: using a 3D-printer, prepare plastic molds designed to fit into a 24-
well plate with inserts of 8-mm length and 5-mm diameter44  
• Solution for live/dead staining: add 0.5 μL of calcein AM (2 μM) and 2 μL (4 
μM) of ethidium homodimer-1 (from Live/Dead Viability/Cytotoxicity Kit) to 1 ml of 
serum-free DMEM and allow the solution to warm to 37 °C. Protect the vial from 
light. Live/Dead staining solution should be freshly prepared at the time of the 
assay and kept at RT. Prepare at least 300 μL per sample, adjusting the volume 
according to the number of samples to be assayed. 
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Overview 
• Step 1: Prepare materials 
• Step 2: Prepare agarose molds 
• Step 3: Encapsulate cells in hydrogel and inject 
• Step 4: Assess cell morphology and viability 
 
Step 1: Prepare materials (2 hours) 
Prepare sterile polymer stock solutions: Sterilize the desired amounts of dry Ad-
HA and CD-HA components by placing them beneath a germicidal UV lamp for 60 min in 
a class II biological safety cabinet. Dissolve the components individually in sterile PBS at 
the desired concentration and shake the polymer solutions overnight to ensure complete 
dissolution of the polymer. 
 Critical step: For cell culture applications, work in a class II biological safety 
hood and use sterile instruments. Clean all working surfaces with 70% (vol/vol) ethanol 
before use. 20% of the final hydrogel volume should be reserved for resuspending the 
cell pellet, to yield the desired final concentration. 
Step 2: Prepare agarose molds (2-3 hours) 
For in vitro experiments, we recommend the use of a well-in-well culture system 
to ensure facile media changes without disruption of the GH hydrogel construct. We 
designed a mold made of acrylonitrile–butadiene–styrene (ABS), which fits into a 24-well 
plate and can be used to fabricate agarose well-in-well molds (Figure 3.15a). Agarose 
represents an ideal material for preparing such molds, as cells do not adhere to the 
agarose surface; therefore, cells do not undergo excessive aggregation or proliferation 
at the gel–gel interface. 
Sterilize the customized plastic mold (Figure 3.15a) by spraying it with 70% 
(vol/vol) ethanol in a class II biological safety cabinet. Dissolve 1.5 g of agarose in 50 mL 
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of PBS by microwaving the agarose solution for 1 min at 600 W. Pipette 2 mL of agarose 
into each well of a sterile 24-well plate, avoiding introduction of air bubbles. Cover the 
24-well plate with the customized plastic mold (Figure 3.15b) and secure with rubber 
bands. Let it cool to RT for at least 60 min to ensure that the agarose is fully solidified. 
Gently remove the plastic mold from the 24-well plate and rinse the agarose-containing 
wells twice with 1 mL of sterile PBS per well (Figure 3.15c). Add 0.5 mL of sterile PBS 
to each well and transfer to a cell culture incubator at 37 °C while preparing the hydrogel 
and processing the cells. 
Critical step: After spraying ABS mold with ethanol, ensure that the plastic mold 
has fully dried before proceeding. Caution: wear thermo-insulated gloves when handling 
the agarose-containing glassware. 
 
Figure 3.15. Agarose molds. (a) Customized plastic mold made of acrylonitrile-
butadiene-styrene (ABS). (b) The mold is designed to fit into a 24-well plate with inserts 
of 8 mm length and 5 mm diameter. (c) After solidification of 2 mL agarose, molds can 
be used to contain injected guest-host hydrogels for culture. 
 
Step 3: Encapsulate cells in hydrogel and inject (3 hours) 
Expand cells of choice (e.g., mouse 3T3 fibroblasts) in tissue culture dishes (e.g., 
100 cm2) using the appropriate cell culture medium. Wash cells with 10 mL of sterile 
99 
PBS, add 3 mL of sterile trypsin–EDTA and incubate for 5 min in a cell culture incubator 
at 37 °C. Add 10 mL of sterile mouse 3T3 fibroblast medium and transfer the cell 
suspension to a sterile 50-mL conical tube. Pellet the cells by centrifuging at 500g for 5 
min at RT. Remove the supernatant and resuspend the cell pellet in a suitable volume of 
medium (e.g., 5 mL) to determine the cell concentration using a hemocytometer. 
Calculate the cell suspension volume for the desired cell number and transfer to a sterile 
1.5 mL microcentrifuge tube. Pellet the cells by centrifuging at 500g for 5 min at RT. 
Critical step: The cell concentration depends on the cell type and its application. 
A typical cell density for the encapsulation of mouse 3T3s is 5 × 106 per mL.  
Aspirate the medium from the cell pellet, resuspend in 20% of the final gel 
volume and separate into the Ad-HA and CD-HA stock solutions. Ensure homogeneous 
cell dispersion by mixing gently with a pipette. Combine the two component solutions by 
gentle mixing in a 1.5-mL tube (Figure 3.16a), briefly centrifuge at 500g for 30s at RT 
and transfer to the syringe barrel using an adequate scoopula. Alternatively, components 
may be combined directly in a 1-mL syringe barrel (Figure 3.16b). Depress the plunger 
slowly and inject the gel (e.g. 30 µL) into the agarose wells. Add 0.5 mL of mouse 3T3 
fibroblast medium and incubate in a culture incubator at 37 °C. 
Critical step: The CD-HA solution can be viscous, depending on the polymer 
concentration. Alternatively, use a positive-displacement pipette for mixing the cell 
suspension. Be very gentle when handling the cell–polymer solutions to ensure low 
shear stress during mixing. We recommend mixing the GH components in the back of a 
syringe to reduce unnecessary shear forces that may be experienced by the cells during 
hydrogel transfer to the syringe. 
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Figure 3.16. Techniques for mixing guest-host hydrogels. (a) Prepare CD-HA and 
Ad-HA solutions in stoichiometric equivalence in PBS and portion the therapeutic cargo 
between the two stock solutions. Mix the two components in a 1.5-mL tube, briefly 
centrifuge to remove entrapped air and transfer the preformed hydrogel to the back of a 
syringe. (b) For cell encapsulation, portion the cell suspension between the two stock 
solutions. To load the syringe with the GH gel, first add the CD-HA solution to the back 
of the syringe, then add the Ad-HA while continuously mixing the two components; 
continue to mix gently until a homogeneous gel is formed.  
 
Step 4: Assess cell morphology and viability (3 hours) 
After a desired culture period, remove the medium from the wells and add 300 μL 
of Live/Dead staining solution per sample in a 24-well plate. Incubate for 30 min in a 
culture incubator at 37 °C. Aspirate the staining solution and replace with 0.5 mL of 
serum-free medium. Image the samples with a confocal laser scanning microscope with 
a 10/20× objective. Quantify cell viability by counting cells that stain positive for live and 
dead stains using ImageJ or CellProfiler. 
Critical step: Protect samples from light before imaging.  
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3.5.3. TROUBLESHOOTING 
- Low cell viability. Avoid air bubbles inside the sample prior to injection. Make 
sure to centrifuge the preformed hydrogel and avoid rupture of the sample when 
transferring. Alternatively, mix guest-host components in the back of a syringe. 
3.5.4. ANTICIPATED RESULTS 
When we encapsulated cells within hydrogels using the established protocol, we 
observed that the viability of cells delivered using a 5 wt% hydrogel was significantly 
higher than that of cells delivered using a 7.5 wt% hydrogel (Figure 3.17a-b).39 We 
determined cell viability after injection using a live/dead assay and CellProfiler to quantify 
cell counts, as previously described.39  However, not all increases in injection force have 
a deleterious effect on cargo. When we assessed cell viability after injection at 2 mL/hr 
or 40 mL/hr, we observed that cell viability was not significantly different at the two flow 
rates, even though injection force increased with flow rate (Figure 3.18a-c).  
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Figure 3.17. Cell viability depends on material concentration. Cell viability 
immediately after injection at 2 mL/hr or without injection for mouse 3T3 fibroblasts 
encapsulated in guest-host hydrogels of 5 wt% and 7.5 wt%. (a) Live cells (calcein AM) 
are green and dead cells (ethidium homodimer-1) are red. Scale bar is 100 µm. (b) Cell 
viability was significantly lower for the 7.5 wt% hydrogels compared to the 5 wt% 
hydrogels after injection. Data displayed is mean ± SE with p<0.05.  
 
 
Figure 3.18. Effect of increasing flow rate on injection force and cell viability. (a) 
For a 5 wt% hydrogel, increasing the flow rate from 2 mL/hr to 40 mL/hr increases 
injection force from 5N to 7.5N. (b) Images of mouse 3T3 fibroblast cells immediately 
after injection at varying flow rates. Scale bar is 100 µm. (c) Quantified cell viability 
shows no significant differences in cell viability after injection at either 2 or 40 mL/hr. 
Data displayed as mean ± SE with p<0.05. 
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 Many factors, such as flow rate, needle gauge, and needle length can affect 
injection force for the same hydrogel in the same syringe. Using a force sensor or 
mechanical testing machine to measure injection force can allow for quantifiable 
measures of injectability that, when other variables are controlled, can be used to 
compare ease of injection between different hydrogels. While these tests were done 
injecting into air, injections into liquids or tissues would more accurately mimic in vivo 
conditions. Clinically relevant injection forces typically are <20N45,46 but actual 
injectability can depend not only on force but also on the ergonomics of the syringe, 
which can affect the force applied. The methods described here for characterizing 
injectable hydrogels using rheology and measurements of injection force can also be 
utilized for applications other than in vivo delivery that include ejection of hydrogels, such 
as 3D printing. 
 
3.6 INJECTION OF HYDROGELS IN RAT MI MODELS 
Injectable hydrogels have been widely investigated for cardiac repair and have 
been used for mechanical bulking,3,4,35 modulating remodeling,7,17 or therapeutic delivery 
(cells, small molecules, RNAs) after MI.6,15,47 Some hydrogel formulations have 
undergone testing in clinical trials.48–52 Especially for the heart, injectable hydrogels are 
advantageous because of their potential for minimally invasive delivery such as through 
a catheter.34,35 Toward their assessment in vivo, hydrogels have been used in small and 
large animal models in which they are injected intramyocardially into the infarct site or 
the border zone region around the infarct. Although delivery through catheters has been 
investigated in larger animal models, most current models of hydrogel injections are still 
through minimally invasive thoracotomy and myocardial injection, which is an open-heart 
surgery and will be the focus of this section.  
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Common small animal cardiac models are mouse and rat. While the mouse has 
been the model organism for studying heart disease in humans and ease in testing 
biocompatibility, it is also the farthest from translatability to humans due to its small size. 
Rats are larger than mice and enable easier hemodynamic modalities (such as 
pressure-volume catheterization) to assess cardiovascular function, and surgical 
techniques are often technically easier than in mice, leading to decreased noise and 
variability in studies. Rat studies also enable greater quantities of myocardial tissue for 
post-mortem histological analyses.53 However, costs associated with rat models may be 
higher and favorable results may not always be reproducible in clinical studies. 
Moreover, while transgenic rat models exist, a high cost is associated with generating 
and maintaining these colonies and there are appreciably fewer models in rats than in 
mice.54–57 
Here, we outline the steps necessary for injection of hydrogels into a rat model of 
MI, which is widely utilized in the rest of this thesis. This protocol focuses on the injection 
of hydrogels, and additional protocols regarding the surgeries themselves (anesthesia, 
intubation, thoracotomy, closure, and post-operative care) can complement these 
methods.58 We have found that the steps listed below lead to reproducible and reliable 
hydrogel injection models. However, these steps should be used as guidelines for other 
hydrogel injections and can be adapted as necessary on a case-by-case basis, where 
variations in the method (e.g., location, number, volume, or timing of injections) are 
desired. We note that investigators should obtain IACUC or similar approval and training 
prior to animal testing.   
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3.6.1. MATERIALS  
Reagents 
• Adamantane-modified HA (Ad-HA) , ~22% of repeat units modified, synthesis 
described elsewhere with reagents available from Sigma (St. Louis, MO)39 
• Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis 
described elsewhere with reagents available from Sigma (St. Louis, MO)39 
• Phospho-buffered saline  (Life Technologies, Carlsbad, CA, cat no: 15710-064) 
• Analgesics as listed below or a comparable and approved pain control regimen 
o Meloxicam (Norbrook Laboratories, Newry, United Kingdom, 5 mg/mL 
solution for injection) 
o Buprenorphine (ZooPharm, Windsor, CO, 1 mg/mL) 
o Bupivacaine (Hospira, Inc, Lake Forest, IL, 0.25%, 2.5 mg/mL)  
• Betadine solution swab stick (Purdue Pharma LP, Stamford, CT) 
• Isoflurane (Piramal Enterprises Ltd, Mumbai, India, 250 mL)  
Equipment 
• Hydrogel preparation 
o Forceps (e.g. Fine Science Tools, Foster City, CA, cat no: 11008-15) 
o 1.5-mL microcentrifuge tubes (e.g. Fisher Scientific, Waltham, MA, cat no: 
05-408-129) 
o Vortex (e.g. Fisher Scientific, Waltham, MA, cat no: 02-215-414) with 
microcentrifuge tube holder (e.g. Fisher Scientific, Waltham, MA, cat no: 
11-676-363) 
o Sonicator (e.g. Branson Ultrasonics, Danbury, CT, model no: CPX5800H) 
o Microcentrifuge (e.g. Eppendorf Refrigerated Microcentrifuge 5417R, 
Eppendorf, Hamburg, Germany)  
o Scoopula (made from a cut 1-mL pipette tip)39  
o ½ mL, 27G x ½” tuberculin syringe (e.g. BD, Franklin Lakes, NJ, cat no: 
305620) 
o ½ mL, 28G x ½” insulin syringe (e.g. BD, Franklin Lakes, NJ, cat no: 
329420) 
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• In vivo rat surgery set-up58,59 
o Rat ventilator with isoflurane (Isoflurane VIP 3000 Vaporizer, Midmark 
Co, Dayton, OH; Anesthesia workstation, Halowell EMC, Pittsfield, MA, 
cat no: 000A5653)  
o Endotracheal tube: 16G x 2” IV catheter (Terumo, Tokyo, Japan, Surflo IV 
Catheter) 
o Electrical clippers/shaver (Wahl Clipper Co, Sterling, IL) 
o 45° Angled Potts scissors (Teleflex, Wayne, PA, Pilling 35-2166 N22) 
o Blunt-tip scissors (Integra Miltex, York, PA, cat no: 5-SC-16) 
o Blunt-tip forceps (Integra Miltex, York, PA, cat no: 6-30) 
o Weitlaner retractor (Fine Science Tools, Foster City, CA, cat no: 17012-
11) 
o Sutures (Medtronic, Fridley, MN, ligation: SurgiProTM II 7-0 VPF-702-X, 
closing: SurgiProTM II 4-0 VP-583-X) 
o Sterile gauze (Fisher Scientific, Waltham, MA, cat no: 22-362-178) 
 
3.6.2. PROCEDURE 
Overview 
• Step 1: Hydrogel preparation and syringe loading   
• Step 2: Anesthesia   
• Step 3: Infarct induction  
• Step 4: Syringe inspection  
• Step 5: Syringe priming  
• Step 6: Stay suture placement  
• Step 7: Needle insertion 
• Step 8: Hydrogel extrusion 
• Step 9: Needle withdrawal  
 
Step 1. Hydrogel preparation and syringe loading (2 hours)  
Polymers should be sterilized under germicidal UV irradiation for at minimum 30 
minutes and subsequently dissolved in sterile PBS solution and loaded into syringes as 
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previously described.39 Cells or therapeutics that are to be encapsulated should be 
included at this step. Hydrogels should be kept on ice if biologics are included. 
Depending on the hydrogel properties, 50-100µL can be injected in 20µL increments 
(Figure 3.19a). Hydrogels are usually prepared for a single rat in a ½ mL, ½”, 27G or 
28G insulin or tuberculin syringe. Separate hydrogels should be made for each animal 
due to concerns for sterility and cross-contamination.  
 
 
Figure 3.19. Intramyocardial hydrogel injections in rat MI models. (a) Schematic of 
ligation and injection sites rat MI models. A representative rat model uses 5 x 20 µL 
injections circumferentially around the infarct. (b) Technique for localizing gel to infarct 
border zone, where needle is angled and inserted into the infarct as parallel as possible 
to the tissue. With the bevel pointing upward toward the epicardium, the hydrogel 
remains in constant view of the operator. (c) Schematic of injection sites and direction of 
arrow insertion in a radial pattern for targeting of the border zone in a rat infarct model. 
(d) Injection of HA hydrogel into a rat heart, demonstrating needle angling, stay suture 
placement, heart elevation from the thoracic cavity, and hydrogel localization.  
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Step 2. Anesthesia (5 minutes) 
A method of anesthesia should be selected in accordance with animal health and 
safety protocols. In our animal models, rats are anesthetized under 1-3% isoflurane, 
intubated with an endotracheal tube, and maintained under 1-3% isoflurane and positive 
pressure ventilation.  
Step 3. Infarct induction (5 minutes)  
The animal should be placed in right lateral recumbency. Shave the left anterior 
and lateral thorax and disinfect with iodine. Incise the skin and subcutaneous tissues 
with heavy scissors to expose the ribcage. The thoracic cavity should be entered 
between the 4th and 5th ribs in the 4th intercostal space. Using the forceps to grab the 4th 
rib, elevate the ribcage to provide room between the chest wall and underlying heart and 
lungs and carefully insert one blade of the Potts scissor, taking care not to injure the 
intrathoracic structures. Extend your incision to provide adequate exposure to the heart. 
Place your retractors between the cut ribs and spread carefully to achieve visualization 
of the target organ. Using blunt forceps, lift the pericardium off the surface of the heart 
and cut a generous window into the tissue using blunt-tip scissors.58 Using anatomic 
landmarks, identify the artery of interest and perform a suture ligation of a major arterial 
branch in as consistent a manner as possible to ensure relatively reproducible regions of 
infarction. This is traditionally done through ligation of the left anterior descending artery, 
1-2mm below the level of the left atrial appendage (Figure 3.19a).59  
Step 4. Syringe inspection (<1 minute)  
Inspect the syringe for damage and air bubbles and ensure that adequate 
volumes have been prepared for injection.  
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Critical Step: Air bubbles in the hydrogel have the potential to cause 
embolization. Thus, routine inspection of syringes for air bubbles and subsequent 
centrifugation is necessary.  
Step 5. Syringe priming (<1 minute)  
Prime the syringe by manually applying pressure until the hydrogel begins to 
extrude from the needle. It is important to be familiar with the forces required prior to the 
cardiac injection.   
Step 6. Stay suture placement (5 minutes)  
Using a stay suture or the ligation suture, manually orient the heart so that the 
injection site is in clear view of the operator. This may require externalizing the heart 
from within the chest cavity, especially for posterior injections that would otherwise be 
inaccessible. Use gentle and controlled movements to prevent tearing of the 
myocardium and bleeding.  
Step 7. Needle insertion (<1 minute)  
While stabilizing the heart in the desired position, insert the needle tip either 
parallel or as close to parallel to the injection site as possible, avoiding any visible 
surface vessels. It may be necessary to introduce a gentle bend in the needle to achieve 
the appropriate angle for insertion (0-45 degrees). This step ensures that any 
penetration by the needle does not lead to ventricular puncture (Figure 3.19b).  
 Critical step: Throughout the duration of needle insertion, the needle tip should 
remain superficial enough to be visible to the operator through the overlying 
myocardium. The bevel should always be inserted face up in clear view of the operator 
so that it is apparent when the hydrogel begins to extrude. During the hydrogel injection, 
a visible wheal should form at the needle tip. If not visible, the needle has been inserted 
too deep and should be repositioned.  
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Critical step: To target the border zone, the needle should be inserted into the 
infarct and directed radially into the border zone. This improves targeting as the infarct is 
akinetic, allowing for easier insertion. This also minimizes any potential damage from the 
needle to non-infarcted myocardium (Figure 3.19c).  
Step 8. Hydrogel extrusion (<1 minute)  
After ensuring that the entire length of the bevel is buried within tissue, inject 
slowly with controlled, manual pressure until adequate volumes have been injected. We 
recommend one hand be used to stabilize the needle in the heart while the other is used 
to inject material. (Figure 3.19d).  
Step 9. Needle withdrawal (<1 minute) 
After the injection is complete, wait for 1-2 seconds before withdrawing the 
needle so that the hydrogel can disperse into the tissue. Withdraw the needle slowly to 
prevent material leakage. Manual pressure can be applied after injection also to limit 
material leakage. 
3.6.3. TROUBLESHOOTING  
- Hydrogel cannot be visualized during injection. The needle is inserted too far 
into the tissue, which increases likelihood of ventricular puncture and 
embolization. Remove the syringe and re-insert as needed. If bleeding occurs, 
apply manual pressure with gauze until bleeding stops.  
- Hydrogel causes excessive bleeding or damage. This is an unlikely scenario 
where there has likely been damage to the ventricle caused by needle movement 
during placement or injection. To prevent this, it is important that the hand 
controlling the syringe be rested on a solid immobile surface to prevent small 
movements during needle insertion and injection. A controlled injection using two 
hands, one to stabilize the syringe in the heart and one to apply pressure, may 
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be necessary for some operators. If this occurs, gentle compression with a dry 
gauze will most often achieve hemostasis. 
- Hydrogel leaking from injection sites. This can occur when needles are too 
quickly removed following injection or if the hydrogel used has slow healing 
properties. To prevent this, slowly withdraw the needle from the injection site 1-2 
seconds after the injection is complete. Manual pressure can be applied over the 
hydrogel as the needle is withdrawn. Occasionally, this is due to the bevel not 
being fully inserted into the tissue during the injection. In this case, re-insert the 
needle and ensure that the bevel is fully buried within the tissue. Leaked 
hydrogel can be easily wiped away with a gauze pad.  
 
3.6.4. TISSUE PROCESSING AFTER HYDROGEL INJECTION  
In addition to assessing functional outcomes of cardiac remodeling after MI, most 
studies involve investigating tissue outcomes of cardiac remodeling. These outcomes 
are often measured through stains, such as Masson’s Trichrome, to assess collagen 
content and scar fraction, as well as immunohistochemistry. All of these outcomes 
involve a tissue preservation step, followed by sectioning, and then a staining process. 
Due to the weak mechanics and hydrophilicity of hydrogels described in these methods, 
typical processing can be challenging.  Guest-host hydrogel was injected into ex vivo 
porcine cardiac tissue and then, for preservation, was embedded into OCT either via 
snap-freezing (Figure 3.20a-c) or via freezing after sucrose infiltration (Figure 3.20d-f). 
Tissue was also embedded in paraffin (Figure 3.20g-i). Next, to compare hydrogel and 
tissue morphology after tissue preservation, hemotoxylin and eosin (H&E), Masson’s 
Trichrome, and Alcian blue stains were performed.  
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Figure 3.20. Hydrogel and tissue preservation after embedding, sectioning, and 
staining. Ex vivo tissue after being snap-frozen in OCT (a-c), frozen in OCT following 
sucrose infiltration (d-f), or embedded in paraffin (g-i). H&E (a, d, g), Masson’s Trichrome 
(b, e, h), and Alcian Blue (c, f, i) staining was done to visualize the hydrogel within the 
tissue. Scale bar: 200 µm. 
 
Tissue preservation was poorest in snap-frozen OCT samples, and improved in 
sucrose infiltration samples. Sucrose infiltration prevents tissue expansion during 
freezing, which can help reduce tissue artifacts. However, tissue morphology was most 
preserved in paraffin-embedded samples. The same trends followed for hydrogel 
morphology. Hydrogel was not observed at all in the snap-frozen OCT samples or 
sucrose infiltration samples and was only visible in the paraffin-embedded samples. 
Alcian blue was used to confirm the presence of glycosaminoglycans, such as the 
hyaluronic acid we would expect from our hydrogel, on our slides. 
 Since paraffin embedding completely dehydrates the tissue and the hydrogel, it 
decreases the likelihood that the hydrogel will be washed away in subsequent staining 
steps, even if it is preserved after sectioning. Placing paraffin slides into a 37°C oven for 
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15 minutes prior to staining can help completely remove any remaining water beneath 
the tissue and the slide, effectively securing the tissue to the slide. However, paraffin 
embedding is much more tedious than the other methods. Snap-freezing is the fastest 
(only a few hours), followed by sucrose infiltration (3 days), and then paraffin embedding 
(4-6 days, depending on tissue size). For paraffin embedding, it is crucial to allow each 
of the many solutions to fully diffuse within the tissue, which can take days. Still, we 
recommend paraffin-embedding tissue when it is preferred to preserve the hydrogel 
within the tissue sections. 
 
3.7 SUMMARY 
Injectable hydrogels are useful delivery vehicles and have been used in many 
clinical applications to improve cargo retention at the injection site. Using rheology and 
injection force measurements to characterize these hydrogels can be helpful to 
determine which material formulation is best suited for an application, as long as 
considerations are taken to carefully prepare hydrogel samples for accuracy and 
reproducibility. However, it can be difficult to definitively establish minimum or maximum 
values for viscosity or storage and loss modulus, for example, that will render the 
hydrogel to be injectable, since those values will vary depending on the shear forces 
applied. While it may be easier to define clinically relevant limits for injection force, every 
clinician will handle these hydrogels differently and the maximum amount of force a 
clinician can apply will depend also on the ergonomics of the syringe.  
The effects of hydrogel material formulation and flow properties on therapeutic 
cargo, such as cells, is also important to consider and techniques described here can be 
used to engineer hydrogels for high cell viability after injection. In our case, a low 
material concentration (5 wt%) guest-host hydrogel was most protective to cells after 
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injection, and this material formulation will be used in subsequent aims to deliver cells 
and other cell-derived factors.  
For delivery in vivo, special care must be taken both to avoid damage to healthy 
native tissue during injection and to retain the hydrogel in the delivery site. These 
considerations are especially important for cardiac delivery, where mechanical forces 
can make it difficult to control injection and to localize the hydrogel where desired. We 
describe techniques here that can be used for cardiac delivery in rat animal models, as 
well as considerations for tissue post-processing if hydrogel visualization is desired. 
Paraffin embedding of tissues, although time-intensive, best preserves hydrogel 
morphology by removing water which can make the hydrogel susceptible to washing 
during staining. 
In conclusion, we describe here quantitative in vitro techniques for characterizing 
injectable hydrogels. These techniques can be valuable for exploring the capabilities of 
an injectable hydrogel or comparing formulations of the same hydrogel prior to in vivo 
studies. We also describe here technical methods for in vivo delivery to the heart in rats. 
The techniques described in this paper can also be applied to the delivery of injectable 
hydrogels in other clinical applications, as well as for the evaluation of injectable 
hydrogels as printing bioinks. 
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CHAPTER 4  
INJECTABLE HYDROGELS FOR ENDOTHELIAL PROGENITOR CELL DELIVERY 
TO THE HEART 
 
Adapted from: 
1. Gaffey, A. C., Chen, M. H., et al. Injectable shear-thinning hydrogels used to 
deliver endothelial progenitor cells, enhance cell engraftment, and improve 
ischemic myocardium. Journal of Thoracic and Cardiovascular Surgery 150, 
1268-1276 (2015).  
2. Gaffey, A. C., Chen, M. H., Delivery of progenitor cells with injectable shear-
thinning hydrogel maintains geometry and normalizes strain to stabilize cardiac 
function after ischemia. Journal of Thoracic and Cardiovascular Surgery 157, 
1479-1490 (2019).  
 
4.1 INTRODUCTION 
Ischemic heart failure is a major global health concern. Within the United States, 
a myocardial infarction (MI) occurs every 34 seconds1, and current therapies for heart 
failure, including both medical and surgical treatments, are merely palliative and only 
result in slight improvements in length and quality of life. Overall, there has been a 
reduction in mortality from acute MI, but treatment strategies for those patients who 
develop ventricular dysfunction are still lacking. As a result, the number of patients who 
progress to heart failure has not improved, and both the incidence and prevalence of 
heart failure have increased.2–5  
Cell-based therapies for treating ischemic myocardium are emerging as a 
treatment option for this ever-growing public health challenge. To date, numerous cell 
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types have been used in experimental models, including fetal myocytes, embryonic stem 
cell–derived myocytes, skeletal myoblasts, endothelial progenitor cells (EPCs), and 
mesenchymal stem cells.6–9 Our lab and others have demonstrated that EPCs are easily 
expanded in vitro and have the ability to engraft, improve cardiac function, and 
attenuate ventricular remodeling when delivered after MI.10–14  
Therapy with EPCs involves postnatal vasculogenesis that can be used to 
revascularize the ischemic myocardium. EPCs are pluripotent, bone marrow–derived 
stem cells with the ability to differentiate into de novo vasculature.15 Initial work was 
focused on cytokine therapies to locally recruit EPCs to the ischemic myocardium, 
because EPCs are known to promote vasculogenesis.12 Unfortunately, translatable 
outcomes were marginal at best. Further studies were focused on directly delivering 
syngeneic EPCs locally to the infarcted myocardium.6,16,17 Both small and large animal 
studies showed significant vasculogenic responses in ischemic myocardium. However, 
the benefit has not been translatable to a sustainable clinical model. 
One of the major challenges for the therapeutic application of EPCs has been 
optimizing cell delivery, dispersal, and engraftment. After direct cell injection into 
the myocardium, <1% of cells are retained, as shown by cell-tracking studies.18–
21 Numerous factors contribute to the poor cell retention, including exposure of the cells 
to ischemia and inflammation, mechanical washout of cells from the beating myocardium 
and coronary vasculature, and leaking of the cell suspension from the targeted injection 
site.22–24 Overall, most cell death occurs within the first few days of cell delivery. 
Consequently, a delivery and stabilization mechanism is likely to promote longer cell 
retention and engraftment.24  
One possible approach involves the use of biomaterials to provide a 
surrogate extracellular matrix to localize cells at the delivery site. Hydrogels in particular 
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may provide an environment for protection from the insults of inflammation 
and ischemia to reduce immediate cell death upon exposure.12,25 Hydrogels are 
biocompatible materials that have gained increasing interest, owing to their ability to 
enhance cell and biomolecule delivery.26–30  
In this chapter, we utilize the injectable guest-host hydrogel described in Chapter 
3 of this thesis to deliver EPCs to the ischemic myocardium. This hydrogel was designed 
to be shear-thinning to allow for flow through a syringe upon the application of force and 
also rapidly self-healing to quickly reassemble at the injection site.30 Hydrogel properties 
were tuned for high cell viability after injection31,32 and cell release through gel 
degradation.31 This injectable hydrogel is based on hyaluronic acid (HA) and assembles 
by the guest-host interactions of adamantane-modified HA (guest-macromer; Ad-HA) 
and β-cyclodextrin–modified HA (host-macromer; CD-HA).30  
As a biomaterial, HA is particularly attractive because it is found abundantly in 
tissues and used in biomedical applications.31 For EPC delivery and cardiac repair, HA 
has been shown to interact with EPCs via membrane protein CD4433–35 and to stimulate 
angiogenesis in vivo in necrotic tissue.36 Furthermore, derivatives of adamantane are 
used in pharmaceuticals, and cyclodextrans are recognized by the US Food and Drug 
Administration as safe and approved for use in pharmaceuticals, cosmetic products, and 
food products.30 We have chosen to use EPCs for this study because they are readily 
available, highly vasculogenic, and have demonstrated clinical potential. We hypothesize 
that, compared to the delivery of EPCs in saline, the delivery of EPCs with injectable 
hydrogel will increase cell retention within the ischemic myocardium and lead to 
robust vasculogenesis, minimization of adverse ventricular remodeling, and improved 
ventricular function after MI. 
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4.2 METHODS 
4.2.1. ANIMAL CARE AND BIOSAFETY 
Adult male Wistar rats (250-300 g) were obtained from Charles River 
Laboratories, Inc. Food and water were provided ad libitum. This investigation adheres 
to the National Institutes of Health guidelines on animal care and use, conforms to 
institutional ethical review, and has been approved by the University of Pennsylvania 
Institutional Animal Care and Use Committee (Protocol 803394). All measurements were 
performed by 2 independent investigators blinded to animal treatment conditions. 
4.2.2. ENDOTHELIAL PROGENITOR CELLS 
EPCs were isolated from the long bones of syngeneic adult male Wistar rats by 
density-gradient centrifugation (Histopaque-1083; Sigma-Aldrich). After isolation, EPCs 
were seeded on vitronectin-coated plates and cultured in endothelial cell basal medium 
supplemented with fetal bovine serum, human epidermal growth factor, vascular 
endothelial growth factor, human fibroblast growth factor-B, R3-insulin-like growth factor, 
ascorbic acid, gentamicin, and amphotericin-B for 6 days (Lonza). The EPC phenotype 
(DiLDL+VEGFR2+CD34+) was previously confirmed by our group.10,37 
4.2.3. HYDROGEL FORMATION AND CELL ENCAPSULATION 
All chemicals were purchased from Sigma-Aldrich unless otherwise noted. 
Protocols for hydrogel formation (Chapter 3.2) and cell encapsulation (Chapter 3.5) are 
described in detail in earlier chapters of this thesis. Briefly, sodium hyaluronate (HA, 90 
kDa) was purchased from Lifecore Biomedical LLC and dissolved in deionized water at 2 
wt%, exchanged against Dowex-100 resin, neutralized 
by tetrabutylammonium hydroxide (TBA), frozen, and lyophilized to form HA-TBA. 
Adamantane-modified HA (Ad-HA) was prepared by coupling 1-adamantane acetic 
acid to HA-TBA via esterification.30 b-cyclodextrin (CD) was first reacted to add 
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a hexane diamine linker to form β-CD-hexane diamine, which was coupled via amidation 
to HA-TBA to form β-cyclodextrin–modified HA (CD-HA) (Figure 4.1). 
 
Figure 4.1. Overview of hydrogel composition. Illustration of hydrogel containing 
EPCs (left) and schematic of hydrogel formation (right), utilizing guest-host complex of β-
cyclodextrin (CD, host) and adamantane (Ad, guest) for initial self-assembly, as well as 
subsequent injection and self-healing in situ. EPC: endothelial progenitor cell.  
  
Percent modification of the HA backbone by adamantane (26%) or β-CD (21%) 
was confirmed by NMR. Hydrogels of 4 wt% total polymer concentration were 
subsequently prepared from stock solutions of Ad-HA and CD-HA in phosphate buffered 
saline. This hydrogel fomulation was tested in a pilot study of the native heart to ensure 
optimal gel dose and tensile properties. To ensure a guest-host assembly mechanism, 
the two component solutions were combined and mixed manually by stirring to ensure a 
homogeneous structure, which was briefly vortexed to remove entrapped air. For 
incorporation of EPCs, the cells were trypsinized and counted before being mixed into 
the hydrogel at a cell density of 700,000 cells per 100 μL of hydrogel. This cellular 
density has been previously used by our group and has demonstrated improvements in 
vasculogenesis.12  
For EPC viability after hydrogel encapsulation, the gel + EPC construct was 
cultured in vitro in agarose wells to allow for ease in handling. Immediately after EPC 
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encapsulation, Live/Dead staining (calcein AM/ethidium homodimer-1, Thermo Fisher 
Scientific) was used to visualize EPC viability. Samples were imaged using confocal 
microscopy and cell viability was quantified using CellProfiler. 
4.2.4. RAT MI MODEL 
The animal model used here was described in Chapter 3.6 of this thesis. Briefly, 
adult male Wistar rats (∼300 g) were anesthetized with 3% isoflurane in an induction 
chamber (Vetequip, Inc), endotracheally intubated, and mechanically ventilated (Harvard 
Apparatus Regenerative Technology) with 1% isoflurane. A left lateral thoracotomy in 
the fourth intercostal space was performed. The proximal left anterior descending (LAD) 
coronary artery was identified approximately 2 mm below the left atrial appendage, and 
a 7-0 polypropylene (Prolene; Ethicon, Inc) suture was placed around the artery and the 
surrounding myocardium. Regional left ventricular ischemia was induced and confirmed 
by discoloration of the myocardium and by changes in cardiac rhythm. The ligation 
induced a consistent and reproducible anterolateral infarction of 35% to 40% of the left 
ventricle.10,38–41 The mortality rate after infarct induction was 18%.  
After infarct induction, animals were randomized to 1 of 4 treatment groups: 
saline (100 μL of phosphate buffered saline), EPC (700,000 EPCs in 100 μL of 
phosphate buffered saline), gel (100 μl of injectable hydrogel), or gel + EPC (700,000 
EPCs in 100 μl of injectable hydrogel). All treatment groups were injected using a 
straight 27G needle intramyocardially in 5 x 20 μL injections along the anterior and 
posterior left ventricular wall in the border zone of the infarct. After injection, the exposed 
heart was monitored for 2 to 5 minutes for stability and return to sinus rhythm. The chest 
was closed in 3 layers with a 3-0 polypropylene suture and the animals were allowed to 
recover. Four weeks after MI, hemodynamic analysis was conducted, and the animals 
were sacrificed for histologic analysis. 
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4.2.4.1. CELL ENGRAFTMENT AND RETENTION 
For fluorescent EPC tracking, EPCs were transduced with enhanced green 
fluorescent protein from Baculovirus vector (enhanced green fluorescent protein+ 
CellLight Reagents BacMam 2.0, Life Technologies). The BacMam 2.0 reagent was 
added directly to the cells, with approximately 90% transduction efficiency at 24 hours. 
Transduced EPCs were delivered either in saline or encapsulated in the injectable 
hydrogel and injected into the ischemic myocardium after MI. At specified timepoints, the 
hearts were explanted, flushed with phosphate buffered saline, and distended with 
optimal cutting temperature embedding compound (Electron Microscopy Sciences). 
Hearts were sectioned along the short axis of the myocardium using a cryostat. Nuclei 
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Inc). 
Samples were imaged at 20x on a Leica DM IL LED fluorescent microscope and 
analyzed using LAS AF 3.2 (Leica Microsystems Inc). Quantitative analysis was 
performed in the peri-infarct border zone, which was defined as 1 microscopic field from 
the infarct. 
For ex vivo imaging, EPCs were labeled with CellVue NIR815 (LI-COR), which is 
an aliphatic near-infrared dye that stably incorporates into the cell membrane lipid bilayer 
without disrupting cell viability or function. EPCs were labeled immediately before 
injection using an iso-osmotic aqueous diluent with 2 µM CellVue NIR815 dye. A trypan 
blue viability test of cells post-labeling confirmed the non-toxic properties of the dye. 
Labeled EPCs were delivered either in saline or encapsulated in the injectable hydrogel 
and injected into the ischemic myocardium after MI, then visualized at indicated 
timepoints using the LI-COR Pearl Small Animal Imaging System. 
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4.2.4.2. ANALYSIS OF GLOBAL VENTRICULAR FUNCTION 
After 4 weeks, transthoracic echocardiography was performed to 
assess myocardial function via ejection fraction (Sonos 5500 revD system with S12 
probe, 12 mHz, 2 cm penetration depth, Philips Healthcare). Technicians were blinded to 
study conditions. Ventricular measurements were performed according to the American 
Society of Echocardiography leading-edge method. Then, a pressure-volume catheter 
(Millar Instruments, Inc.) was inserted into the left ventricle in a retrograde fashion via 
the right common carotid artery for analysis of ventricular function. In addition to steady-
state hemodynamic parameters (maximum pressure, dP/dt max), contractility was 
determined from pressure-volume relationships obtained by reducing preload via 
occlusion of the inferior vena cava. Finally, a sternotomy was performed and a 2.5-mm 
ascending aortic flow probe (Transonic Systems, Inc) was placed for Doppler analysis of 
cardiac output. 
4.2.4.3. ANALYSIS OF MYOCARDIAL FIBROSIS 
At 4 weeks after analysis of global ventricular function, hearts were explanted, 
flushed with phosphate buffered saline, and distended with optimal cutting temperature 
embedding compound (OCT, Tissue-Tek, Sakura Finetek USA, Inc). Hearts were frozen 
in OCT at −80°C. Sections (10 μm thick) were prepared from each heart using a cryostat 
to section along the short axis of the myocardium. Sections at the mid-papillary level 
were stained with Masson's trichrome (Accustain Trichrome Stains Kit) according to 
manufacturer instructions. Sections were imaged and analyzed with ImageJ (NIH) to 
assess scar fraction.  
4.2.4.4. QUANTIFICATION OF MYOCARDIAL VASCULOGENESIS 
Sections at the mid-papillary level were washed 3 times in phosphate buffered 
saline, fixed in 4% paraformaldehyde for 10 minutes at room temperature, and blocked 
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with 10% fetal bovine serum (Gibco BRL, Life Technologies, Inc) for 1 hour at 37°C. 
Primary antibodies were diluted at a ratio of 1:150 in phosphate buffered saline and 
incubated for 2 hours at 37°C. Secondary antibodies were diluted at a ratio of 1:200 in 
phosphate buffered saline and incubated for 2 hours at 37°C. Primary antibodies 
included sheep anti–von Willebrand factor conjugated to fluorescein isothiocyanate and 
rabbit anti–smooth muscle actin (ab8822 and ab5694, respectively; Abcam). Donkey 
anti-rabbit conjugated to Alexa Fluor 594 (ab150068, Abcam) was used as a secondary 
antibody. Nuclei were stained with DAPI. Samples were imaged at 20x on a Leica DM IL 
LED fluorescent microscope and analyzed using ImageJ (NIH). Vascularization was 
quantified in the peri-infarct border zone, which was defined as 1 microscopic field from 
the infarct. 
4.2.5. STATISTICAL ANALYSIS 
Quantitative data are expressed as mean ± standard deviation (SD) unless 
otherwise noted. Statistical significance was evaluated using either an unpaired two-
sample Student’s t-test with unequal variance or a one-way ANOVA with Bonferroni 
correction for multiple comparisons. All analyses were performed using Stata 13.1 (Stata 
Corporation). 
 
4.3 RESULTS 
4.3.1. CELL VIABILITY AFTER HYDROGEL ENCAPSULATION 
 The injectable hydrogel formulation used in this study was previously 
investigated for high cell viability after encapsulation and injection and these studies 
were described in Chapter 3.5 of this thesis. As confirmation, confocal microscopy of 
EPCs in injectable hydrogel stained with Live/Dead showed high viability (98.6%) of 
EPCs immediately after encapsulation, which confirms that EPCs were viable prior to 
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delivery with the injectable hydrogel (Figure 4.2), which validates the use of this 
injectable hydrogel as a delivery vehicle for EPCs.  
 
 
Figure 4.2. EPC viability after injectable hydrogel encapsulation. Confocal 
microscopy of EPCs (live: calcein, green and dead: ethidium, red staining) confirmed 
high viability (98.6%) after injectable hydrogel encapsulation. Scale bar: 200 μm. 
Adapted from Loebel, et al.42  
 
4.3.2. ENDOTHELIAL PROGENITOR CELL ENGRAFTMENT 
The engraftment of eGFP-transduced EPCs in the myocardium after MI was 
evaluated using immunofluorescence microscopy. EPCs were delivered either in saline 
or with injectable hydrogel. After 48 hours, the number of EPCs detected was 
significantly greater after delivery with injectable hydrogel (11.3 ± 4.1 cells per HPF, 
n = 4) compared to delivery in saline (3.2 ± 1.8 cells per HPF, n=4; P < .0001) (Figure 
4.3) and it was noted during sectioning that the injectable hydrogel was still visible in the 
myocardium. After 1 week, there was still a significantly larger number of EPCs detected 
after delivery with injectable hydrogel (17.2 ± 0.8 cells per HPF, n=4) than after delivery 
in saline (3.5 cells ± 1.3 cells per HPF, n=4; P = .0002), although the injectable hydrogel 
was no longer easily visible in sectioned tissue. Overall, this demonstrates a significant 
increase in EPC retention when delivered with injectable hydrogel compared with direct 
cell injections in saline.  
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Figure 4.3. EPC engraftment after 48 hours. Fluorescence imaging of eGFP-
transduced EPCs (green) after delivery (a) with saline or (b) with injectable hydrogel. 
Sections were stained for nuclei (DAPI, blue). EPC: endothelial progenitor cell; scale 
bar: 50 µm. 
 
4.3.3. BIOLUMINESCENT TRACKING OF DELIVERED EPCS 
The retention of NIR815–labeled EPCs was investigated after injection at the 
heart apex after MI either alone (EPC) or when encapsulated in the hydrogel (Gel + 
EPC) (Figure 4.4). After 24 hours, cells are observed within the targeted myocardium for 
both groups. However, after 14 days, cells injected alone were sparse, whereas cells 
delivered with the injectable hydrogel remained within the myocardium. Generally, there 
was a reduction of cells within 24 hours after injection alone and lower cell numbers at 
all observed time points when compared to injection with hydrogel. 
 
 
Figure 4.4. EPC tracking over time. Fluorescently NIR815 tagged EPCs apical view 
(border zone and ischemic myocardium) from day of surgery to 14 days after MI 
comparing gel + EPC delivery with EPC alone delivery. EPC: endothelial progenitor cell; 
scale bar: 1 cm.  
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4.3.4. IMPROVEMENT OF MYOCARDIAL FUNCTION 
After 4 weeks, hemodynamic analysis demonstrated a statistically significant 
improvement in left ventricular ejection fraction, cardiac output, maximum pressure, 
dP/dt max, and contractility generated pressure for the Gel + EPC group compared with 
the EPC group (Figure 4.5, Table 4.1), indicating that the delivery of EPCs with 
injectable hydrogel was able to significantly improve cardiac function compared to the 
delivery of EPCs alone in saline. The improvement in ejection fraction was statistically 
significant for all treatment groups (EPC, Gel, and Gel + EPC), compared with the saline 
control, but the greatest improvement was noted in Gel + EPC group. There was no 
significant difference in ejection fraction between the EPC and Gel groups, but the Gel + 
EPC group had a significantly higher ejection fraction than the Gel group. While the Gel 
+ EPC group had the most improved cardiac function compared to the saline control, 
there were improvements to cardiac function observed for the EPC and Gel groups also. 
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Figure 4.5. Ejection fraction. Plot and table of left ventricular ejection fraction (EF) as 
measured by echocardiography after delivery of saline, EPC, gel, or gel + EPC to the 
heart after MI. Mean ± SD; EPC: endothelial progenitor cell.  
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Group EF (%) P vs saline P vs EPC P vs Gel
Saline (n = 8) 42.1 ± 5.6 .005 .001
EPC (n = 10) 57.3 ± 10.7 .005 .74
Gel (n = 13) 55.6 ± 12.2 .001 .74
Gel + EPC (n = 10) 68.9 ± 12.0 <.00001 .03 .006
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Table 4.1. Left ventricular function. 
Group Saline 
(n = 8) 
EPC 
(n = 10) 
Gel 
(n = 13) 
Gel + EPC 
(n = 10) 
Cardiac output (mL/min) 16.3 ± 4.1 28.3 ± 5.2 24.8 ± 2.1 
(P = .005) 
46.8 ± 7.0 
(P < .00001) 
Maximum pressure 
(mmHg) 
50.8 ± 6.7 74.3 ± 5.6 96.2 ± 7.7 
(P < .00001) 
98.7 ± 17.0 
(P < .00001) 
dP/dt max (mmHg/s) 2037 ± 89.2 2496 ± 65.6 2547.3 ± 248.1 
(P = .52) 
5812.1 ± 237.3 
(P < .00001) 
Contractility (μL/mmHg) 1.2 ± 0.2 1.5 ± 0.08 2.2 ± 0.1 
(P = .003) 
2.8 ± 0.1 
(P = .004) 
Mean ± SD; P values are in relation to EPC treatment; EPC: endothelial progenitor cell.   
 
4.3.5. MINIMIZATION OF MYOCARDIAL FIBROSIS 
After 4 weeks, a significant reduction of myocardial fibrosis and ventricular scar 
fraction was observed for the Gel + EPC treatment group compared to all other 
treatment groups (Figure 4.6a-b), indicating that the delivery of EPCs with injectable 
hydrogel significantly improves ventricular remodeling compared to the delivery of EPCs 
or gel alone. There was also a significantly lower scar fraction for the EPC group 
compared to the saline control. However, the delivery of injectable hydrogel alone 
without EPCs did not significantly reduce the scar fraction compared to the delivery of 
EPCs or the saline control.   
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Figure 4.6. Cardiac remodeling. a) Representative myocardial cross-sectional images 
after trichrome staining to delineate scar (blue) and healthy myocardium (red). Scale bar: 
5 mm. b) Quantification of scar fraction for each treatment group with significant 
differences (p<0.05) in bold. EPC: endothelial progenitor cell. 
 
4.3.6. ENHANCEMENT OF MYOCARDIAL VASCULOGENESIS 
After 4 weeks, the presence of vascular structures in the border zone of the 
infarct was assessed using histological staining for all treatment groups (Figure 4.7a-h). 
Quantification of vascular density demonstrates a statistically significant increase in 
vascular structures within the border zone of the ischemic myocardium for the Gel + 
EPC group compared to all other treatment groups (Figure 4.7i). Interestingly, there was 
no significant improvement in vascular density for the EPC group compared to the saline 
group, indicating that enhanced cell retention may be important for the formation of 
vascular structures.  
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Figure 4.7. Formation of new vascular structures. Representative 
immunofluorescence images of vascular structures in the border zone region after 
delivery of (a-b) saline, (c-d) EPC, (e-f) gel, or (g-h) gel + EPC and i) quantification of 
vascular density. Mean ± SD; ***p<0.001; EPC: endothelial progenitor cell, DAPI: 4′,6-
diamidino-2-phenylindole; vWF: von Willebrand factor; αSMA: α-smooth muscle actin; 
scale bar: 100 μm.  
 
 
 
4.4 DISCUSSION 
Poor cellular retention is implicated in the failure of cell-based therapies for MI 
models. The lack of sustained delivery limits the achievement of clinically significant and 
translatable treatment methods.43,44 Much research over the past decade has focused on 
bioengineered, chemically modified materials to improve delivery of treatment modalities 
(biochemical and cellular) to ultimately preserve left ventricular function.6,45–47  
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In the present study, the delivery of EPCs in an injectable hydrogel addresses 
the issue of mechanical dispersion of cells delivered to the heart. We have shown high 
EPC viability after encapsulation in the injectable hydrogel, and a significant increase in 
EPC retention with injectable hydrogel delivery compared with direct EPC injection in 
saline using both fluorescent EPC tracking and histological techniques and ex vivo 
imaging. Our results are consistent with previous findings that biomaterial delivery 
vehicles can enhance cellular retention.25,48–52 Specifically, Liu and colleagues51 reported 
a 1.5-fold increase in acute cell retention of adipose-derived mesenchymal stem 
cells encapsulated in chitosan/β- glycerophosphate-hydroxyethyl cellulose 24 hours 
post-administration compared with cells delivered in saline.51 The use of biomaterials 
may improve cell retention at the injection site by reducing cell washout due to 
mechanical forces, and the injectable hydrogel used in this study allows for the targeted 
delivery of a high concentration of cells to ensure adequate engraftment. 
The improved retention of cells led us to assess the implications of increased 
retention on ventricular remodeling and function as noted in prior studies.25,51,53–56 Our 
in vivo studies demonstrated that the Gel + EPC therapy significantly improved 
ventricular function, reduced scar fraction, and increased vascular density compared to 
the EPC therapy, showcasing the benefits of improved retention on cardiac repair. The 
delivery of EPCs in saline still led to significant improvements in ejection fraction and 
scar fraction compared to the saline control, but no change in vascular density, further 
highlighting the importance of cell retention for the formation of vascular structures. In 
this study, the delivery of gel alone did not lead to significant changes in cardiac 
remodeling or vasculature but did significantly increase ejection fraction compared to the 
delivery of saline. Prior studies have shown that the delivery of materials alone can help 
to maintain left ventricular geometry and preserve cardiac function by limiting adverse 
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remodeling and preventing infarct expansion through structural support to 
the myocardium46,47, which could explain the benefits of gel delivery alone.  
 While EPCs were utilized in this study to improve vasculogenesis, other cell 
types or even cell-derived therapies could also be useful for cardiac repair. For instance, 
Korf-Klingebiel and colleagues have shown that mesenchymal stem cells release 
cytokines, growth factors, and chemokines that are beneficial after MI.57 Future work 
could also incorporate a myogenic therapy, or a combination of angiogenic and 
myogenic therapies.6,58 In addition to the direct cellular effects of EPCs on the 
myocardium, a paracrine influence from the delivery of cells may occur, suggesting that 
transplanted cells release soluble factors that help regenerate the heart.57,59,60 This 
hypothesis is supported by Gnecchi and colleagues, who demonstrated the ability to 
recreate the effects of cell therapy with conditioned media.59 Proposed mechanisms for 
paracrine signals include modulation of inflammatory responses, up-regulation of 
vasculogenesis, and protection of cardiac cell cycle re-entry.61 Injectable hydrogels could 
also be used for the local and sustained delivery of these factors.  
Compared with our prior work with a fibrin gel patch12, as well as work by Roche 
and colleagues25, one of the benefits of the injectable hydrogel was its ability to target 
multiple small infarct areas. While this study still utilized direct intramyocardial injections 
and therefore required invasive thoracotomies for delivery, injectable hydrogels could be 
designed to be delivered via catheters using a percutaneous approach. In addition, the 
injectable hydrogel utilized in this study could be further tuned by adjusting macromer 
concentrations, percent modifications, or molar ratios of guest and host groups for 
desired material properties, while maintaining injectability and retention at the target 
site.30,62 For the delivery of cells or other cargo, rates of gel degradation could also be 
designed for a variety of applications and tissue targets. Further studies could also 
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investigate the use of hydrogels to alter the hypoxic/ischemic environment of the infarct 
to improve cell viability after delivery.  
 
4.5 CONCLUSION 
An injectable guest-host HA hydrogel was used as a delivery vehicle for EPCs to 
improve EPC retention after delivery to the heart for cardiac repair after MI. The delivery 
of EPCs using an injectable hydrogel enhanced cell retention in the border zone of the 
ischemic myocardium compared to the delivery of EPCs in saline. In a rat model of MI, 
the delivery of EPCs with injectable hydrogel significantly improved cardiac function, 
decreased scar fraction, and increased vascular density in the myocardium after 4 
weeks compared to the delivery of EPCs in saline, emphasizing the benefits of 
enhanced cell retention for cardiac repair. The use of injectable hydrogels as cell 
delivery vehicles can help to improve the efficacy of cell therapies for MI for more 
effective clinical translation. 
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CHAPTER 5  
INJECTABLE SUPRAMOLECULAR HYDROGEL/MICROGEL COMPOSITES FOR 
THERAPEUTIC DELIVERY 
 
Adapted from: 
1. Chen, M. H., et al. Injectable supramolecular hydrogel/microgel composites for 
therapeutic delivery. Macromolecular Bioscience. 19 (1), (2018). 
 
5.1 INTRODUCTION 
Hydrogels are being developed for a wide range of biomedical applications, due 
to the diverse properties that are possible with hydrogel design1. Supramolecular 
hydrogels represent a specific class of hydrogels with reversible, non-covalent crosslinks 
that permit injectability2–4. Examples of supramolecular chemistry include molecular self-
assembly5–8, host-guest complexes9–11, and mechanically-interlocked molecular 
structures12. Supramolecular hydrogels have been used in a variety of biomedical 
applications, including but not limited to imaging13,14, tissue engineering6,15,16, and 
therapeutic delivery17,18. The injectable nature of supramolecular hydrogels makes them 
particularly attractive for clinical translation since they can be delivered using minimally 
invasive approaches. 
Strategies for therapeutic delivery from supramolecular hydrogels include the 
direct encapsulation of growth factors or cells19–21, which may contain enzymatically or 
hydrolytically degradable crosslinks to control release22. Interactions between small 
molecules and components of the supramolecular complex can also be used to 
sequester cargo and control molecule release23. Additionally, nanoparticles can be 
assembled into networks through interactions with polymers to deliver therapeutics24. In 
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this way, molecule release can be controlled through nanoparticle design, allowing for 
extended release over direct encapsulation in a hydrogel.  
Injectable hydrogels are of particular interest in the treatment of tissue after 
myocardial infarction (MI)25,26.  Almost 800,000 Americans each year suffer from a heart 
attack or MI, which occurs when an occlusion in a coronary artery causes inadequate 
blood flow to the heart27. Depending on the severity of MI, adverse remodeling can lead 
to significant decreases in cardiovascular function and heart failure (HF)28. HF affects 
almost 5.7 million Americans and has a 50% mortality rate within 5 years29. Current 
medical and surgical treatments aim to improve the quality and length of life for patients 
with HF, but are primarily targeted to the tissue after remodeling. Thus, a clinical need 
exists to develop a therapy for ischemic MI that can attenuate remodeling and resulting 
tissue damage.  
Numerous hydrogel therapies have been developed that can improve tissue 
properties after infarction30,31.  In some cases, the hydrogel is used to directly thicken the 
ventricle wall in approaches that have been evaluated in preclinical studies and in US 
clinical trials32,33. According to the Law of Laplace, wall thickness is inversely 
proportional to wall stress, so thickening the left ventricle wall leads to reduced wall 
stress, preventing further wall thinning and ventricular dilation which can lead to 
decreased cardiac function34,35.  In other approaches, hydrogels are used to deliver 
therapeutics (e.g. cells, drugs) to the tissue for a local and sustained response, with 
targets that include improved vascularization20,36,37 and cardiomyocyte proliferation38.  
Specifically, shear-thinning hydrogels have been introduced alone and for therapeutic 
delivery to the heart, through direct injections from syringes to percutaneous delivery 
from catheters26,35,39. 
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To utilize the benefits of supramolecular hydrogels for injectability and retention 
and to decouple the delivery of encapsulated therapeutics from the supramolecular 
hydrogel design, we demonstrate here the development and application of an injectable 
supramolecular hydrogel/microgel composite for localized and sustained therapeutic 
delivery.  The supramolecular hydrogel is based on our previous work in which 
hyaluronic acid (HA) is modified separately with adamantane (guest) and ß-cyclodextrin 
(host) to form an injectable supramolecular hydrogel upon mixing11 and the microgels 
are fabricated from covalently-crosslinked HA hydrogels using a high-throughput 
microfluidic device40. As a model therapeutic, we chose to deliver interleukin-10 (IL-10), 
an anti-inflammatory cytokine41,42 to address excessive inflammation that can cause 
extensive damage to the myocardium after MI42. Although shown here to treat MI, such a 
composite hydrogel/microgel system could be used for the delivery of a wide range of 
therapeutics to treat numerous clinical indications.  
 
5.2 EXPERIMENTAL SECTION 
5.2.1. MATERIALS 
 All chemicals were purchased from Sigma-Aldrich unless otherwise noted.  
5.2.2. MATERIAL SYNTHESIS 
5.2.2.1. HA-TBA, AdHA, and CDHA 
HA-TBA, adamantane-modified HA (AdHA), and ß-cyclodextrin-modified HA 
(CDHA) were synthesized as previously described11. For HA-TBA, sodium hyaluronic 
acid (HA, 74 kDa, Lifecore) was dissolved at 2% w/v in DI water and exchanged with 
Dowex 50W x 200 resin (3 g resin/1 g HA) for 2 hours at room temperature. The resin 
was filtered and then the solution was titrated to pH 7 with tetrabutylammonium 
hydroxide, frozen, and lyophilized. 
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For AdHA synthesis, HA-TBA was coupled to 1-adamantane acetic acid (Acros 
Organics) in the presence of di-tert-butyl dicarbonate and 4-methylaminopyridine in 
anhydrous dimethyl sulfoxide (DMSO) under nitrogen for 20 hours at 45°C. Reaction 
products were dialyzed for 2 weeks in DI water, filtered, frozen, and lyophilized. 
Functionalization of HA by adamantane was approximately 20% as quantified via 1H 
NMR (Figure 5.1A). 
 
Figure 5.1. NMR Spectra. 1H-NMR of A) Ad20HA, B) CD20HA, and C) Nor30HA.  
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For fluorescent labeling, a standard solid phase peptide synthesizer (PS3, Gyros 
Protein Technologies) with glycinol 2-chlorotrityl resin was used to synthesize 
fluorescent peptides GCDDD-rhodamine B (for gel labeling) or GCDDD-5(6)-
carboxyfluorescein (for microgel labeling). Peptides were cleaved from the resin using a 
solution of 95% trifluoroacetic acid, 2.5% triisopropylsilane, and 2.5% water, precipitated 
twice in cold diethyl ether, dissolved in water, frozen, and lyophilized before use. Peptide 
synthesis was confirmed using MALDI-TOF mass spectrometry. For gel visualization, 
AdHA was methacrylated (15% modification) via esterification with methacrylic 
anhydride (1 mL/1 g AdHA) at pH 8.5 for 3 hours, dialyzed for 3 days in DI water, 
filtered, frozen, and lyophilized to form AdMeHA. AdMeHA was dissolved at 2 mg/mL in 
triethanolamine buffer (0.2 M in PBS, pH 10) and reacted with fluorescent peptide 
(GCDDD-rhodamine B, 0.015 mol eq) for 2 hours at 4°C. Reaction products were 
dialyzed for 4 days at 4°C, frozen, and lyophilized to form AdMeHA-Rho.  
For CDHA synthesis, ß-cyclodextrin (ß-CD) was conjugated with a hexane 
diamine linker to form ß-CD-HDA as previously described11. HA-TBA was coupled with 
ß-CD-HDA in the presence of benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate (BOP) in anhydrous DMSO under nitrogen for 3 hours at room 
temperature. The reaction was quenched with cold DI water, dialyzed in the presence of 
NaCl for 3 days, dialyzed in DI water for 5 days, filtered, frozen, and lyophilized. 
Functionalization of HA by ß-cyclodextrin was approximately 20% as quantified via 1H 
NMR (Figure 5.1B).  
5.2.2.2. NorHA 
Norbornene-modified HA (NorHA) was synthesized as previously described43. 
Briefly, HA-TBA was coupled with 5-norbornene-2-methylamine (TCI Chemicals) in the 
presence of BOP in anhydrous DMSO under nitrogen for 2 hours at room temperature. 
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The reaction was quenched with cold DI water, dialyzed in the presence of NaCl for 3 
days, dialyzed in DI water for 5-7 days, filtered, frozen, and lyophilized. Functionalization 
of HA by norbornene was approximately 30% as quantified via 1H NMR (Figure 5.1C).  
5.2.2.3. HepSH 
Thiolated heparin (HepSH) was synthesized based on previously described 
reports44,45. Briefly, heparin (5 mg/mL) was dissolved in DI water and reacted with 
cystamine-dihydrochloride (30 mol/mol heparin) in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide-HCl (EDC, 20 mol/mol heparin) and 1-
hydroxybenzotriazole hydrate (HOBt, 20 mol/mol heparin) at pH 6.8 for 5 hours at room 
temperature. Reaction products were purified by dialysis for 3 days, frozen, and 
lyophilized, then re-reacted with tris (2-carboxyeethyl) phosphine-HCl (TCEP, 10 
mol/mol heparin) to reduce oxidized disulfide groups at pH 7.5 for 3 hours at room 
temperature. After 3 hours, the pH was adjusted to 5.0 with 1.0 N HCl and the solution 
was dialyzed against dilute HCl (pH 3-3.5) with 100 mM NaCl for 3 days at 4ºC and then 
without NaCl for an additional 4 days at 4ºC. Reaction solution was aliquoted into 1.5 mL 
tubes, frozen, and lyophilized overnight. Percent conjugation of thiol groups to heparin 
was determined to be approximately 45% via Ellman assay.  
5.2.3. MICROGEL FORMATION AND CHARACTERIZATION 
5.2.3.1. Microgel Formation 
Microgels were formed via water-in-oil emulsion using a microfluidic device with 
parallel flow-focusing particle generators as previously described40,46. The aqueous 
phase (1 mL) consisted of NorHA (30 mg, 3% w/v), thiol crosslinker (pentaerythritol 
tetrakis(mercaptoacetate), PETMA, TCI Chemicals or 1,4-dithiothreitol (DTT)) at 0.95 
mol thiol per 1 mol norbornene, Irgacure-2959 (I2959, 0.05% w/v), HepSH (0.05 mol 
thiol per 1 mol norbornene), and (if indicated) rat IL-10 (R&D Systems, 12 µg) and was 
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attached to an in-line 0.22 µm filter with a flow rate of 0.6 mL/hr. For visualization 
purposes, if indicated, fluorescein isothiocyanate-dextran (FITC-dextran, 2 MDa, 1 mg) 
or fluorescent peptide (GCDDD-5(6)-carboxyfluorescein, 0.05 mol thiol per 1 mol 
norbornene) was incorporated in the aqueous solution. The oil phase consisted of 2% 
w/w Span 80 in mineral oil and was filtered using a 0.45 µm filter prior to use at a flow 
rate of 3.5 mL/hr. Microgels were crosslinked via UV light (OmniCure Series 1500, 
Excelitas, 320-390 nm, 20 mW/cm2) as they flowed out of the device and into a 
collection vial. Microgels were washed with water and then isopropanol to remove oil, 
dried overnight on vacuum, and stored at -20ºC. 
5.2.3.2. IL-10 Encapsulation Efficiency and Zeta Potential 
 Microgels loaded with IL-10 and crosslinked with PETMA were formed either with 
(n=3) or without HepSH (n=3) to determine the effect of heparin on IL-10 sequestration. 
Heparin has a high negative charge density that can attract positively charged cytokines 
such as IL-10. Following microgel formation, microgels were rehydrated at 1 mg 
microgel/1 mL release buffer with hyaluronidase (1 mg/mL). After microgels were fully 
degraded at 48 hours, IL-10 content was quantified via ELISA (DuoSet kit, R&D 
Systems) and encapsulation efficiency was determined as the ratio of the detected 
amount of IL-10 to the expected amount of IL-10.  
 For zeta potential measurements, solutions of NorHA (1 mg/mL in filtered water, 
pH 8) and NorHA with HepSH (0.05 mol thiol per 1 mol norbornene, pH 8) were 
prepared and the zeta potential of these microgel precursor solutions was measured 
using a Zetasizer Nano ZS90 (Malvern Panalytical) at 25°C. 
5.2.3.3. Characterization of Microgel Size, Degradation, and IL-10 Release 
To characterize size, microgels were rehydrated in PBS and imaged at 10x using 
brightfield microscopy. The straight line tool in ImageJ (NIH) was used to measure 
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microgel diameters (n=22).  For degradation and release quantification, microgels 
loaded with IL-10 and crosslinked with either a stable (DTT, n=3) or degradable 
(PETMA, n=3) crosslinker were rehydrated in release buffer (1% bovine serum albumin 
in PBS) at 1 mg microgel/1 mL release buffer and washed via centrifugation at 1200 x g 
for 15 minutes. Release buffer was replaced and collected every other day and stored at 
-20ºC. After 2 weeks, microgel samples were fully degraded in hyaluronidase (1 mg/mL). 
HA release was determined using an uronic acid assay and IL-10 release was quantified 
via ELISA (DuoSet kit, R&D Systems).  
5.2.4. COMPOSITE HYDROGEL FORMATION AND CHARACTERIZATION  
5.2.4.1. Composite Hydrogel Formation 
 Bulk guest-host hydrogel (4% w/w, 1 mol Ad: 1 mol CD) and degradable 
microgels (low concentration: 6.7 mg/mL bulk hydrogel or high concentration: 13.3 
mg/mL bulk hydrogel) were combined to form a composite hydrogel. Guest-host 
hydrogel materials (AdHA and CDHA) and microgels were weighed and CDHA was 
combined with microgels in the same microcentrifuge tube. Following sterilization with a 
germicidal lamp (40 minutes; turn materials at 20 minutes), hydrogel components were 
dissolved in sterile PBS. To mix, the AdHA solution was added to the CDHA/microgel 
solution with a pipette. For rheology samples, hydrogels were further sonicated at 60ºC 
for 10 minutes, vortexed, and centrifuged to promote more homogeneous mixing and to 
remove air bubbles. Using a scoopula, the composite hydrogel was loaded either onto 
the rheometer or into 27G x ½” insulin syringes (BD) for animal studies.  
5.2.4.2. Volume Fraction of Microgels in Composite Hydrogel  
 Composite hydrogels were prepared as described above using rhodamine-
labeled bulk guest-host hydrogel components (AdMeHA-Rho) and fluorescein-labeled 
microgels at both low (6.7 mg/mL bulk hydrogel) and high (13.3 mg/mL bulk hydrogel) 
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concentrations. Confocal microscopy was used to image the composite hydrogel and the 
3D Viewer plugin (ImageJ, NIH) was utilized to create a 3D projection of the composite 
hydrogel. For each composite hydrogel image stack, regions of interest were selected 
and smoothed and a binary mask was created for each stack using an appropriate 
thresholding method in ImageJ. The 3D Objects Counter plugin (ImageJ, NIH) was used 
to determine the volume of objects in each image stack, and these volumes were 
combined to determine the volume fraction of microgels in the composite hydrogel.  
5.2.4.3. Rheological Characterization 
 Oscillatory shear rheometry was used to characterize the material properties of 
the bulk hydrogel alone and of the composite hydrogels with low and high microgel 
concentrations. Hydrogels were prepared as described above, and rheometer 
experiments were conducted as previously described47 with a flat plate geometry and a 
gap size of 600 µm (10 times average microgel diameter). Briefly, time sweep (0.2% 
strain, 10 Hz), frequency sweep (0.01 to 100 Hz, 0.2% strain), strain sweep (0.01% to 
500% strain, 10 Hz), continuous flow (shear rates from 0 s-1 to 50 s-1 over 2 min 30 sec), 
and cyclic strain (low: 0.2% strain, high: 500% strain, 10 Hz) experiments were 
completed for all samples (300 µL)  at 25°C.  
5.2.4.4. IL-10 Release 
Composite hydrogels were formed with a high concentration of degradable 
microgels (50 µL bulk gel, n=3) and release buffer (1% bovine serum albumin in PBS) 
was added at 50 µL bulk gel/1 mL release buffer. Every other day, release buffer was 
collected via centrifugation at 1200 x g for 15 minutes, replaced, and stored at -20ºC. 
After 2 weeks, composite hydrogels were fully degraded in hyaluronidase (1 mg/mL) and 
IL-10 release was quantified via ELISA (DuoSet kit, R&D Systems).   
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5.2.5. RAT MI MODEL 
5.2.5.1. Infarct Induction and Hydrogel Injection 
 Using a previously established protocol, a left lateral thoracotomy in the fourth 
intercostal space was performed to allow for ligation of the left anterior descending artery 
to induce an infarct of approximately 30% of the left ventricle in a rat20,47. Animals were 
randomly assigned to one of three treatment groups: PBS (saline control), without IL-10 
(composite hydrogel with high concentration of microgels without IL-10), and with IL-10 
(composite hydrogel with high concentration of microgels with IL-10). PBS and 
composite hydrogels were loaded into 27G x ½” insulin syringes (BD) and delivered to 
the infarct in the border zone region in approximately 5 x 20 µL equally spaced 
injections. Animals were recovered and evaluated at either 1 week or 4 week timepoints. 
Prior to explant at 4 weeks, cardiac function was assessed using a 12-mm pressure-
volume loop catheter (Millar). Following explant at 1 or 4 weeks, hearts were washed in 
PBS, and frozen in O.C.T. Compound (Tissue-Tek) at -80ºC. From the apex to above 
the papillary muscles, tissue sections of 10 µm thickness were obtained using a cryostat. 
Animal procedures were approved by the University of Pennsylvania Institutional Animal 
Care and Use Committee.  
5.2.5.2. Immune Response 
 After 1 week, immune response was assessed via immunohistochemical staining 
of tissue sections at the mid-papillary level for CD68 (MCA341GA, Bio-Rad, 1:500) with 
goat anti-mouse AF647 secondary (ab150115, Abcam, 1:300) and DAPI (D1306, 
ThermoFisher Scientific, 1:1000). Images were acquired on a Leica DM5000b 
fluorescent microscope using a DFC350 FX monochrome camera. At least 4 images of 
the border zone of the infarct, defined as one high-powered field away from the infarct, 
were quantified and averaged per animal for one biological replicate. 
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CD68 positive area fraction was quantified using ImageJ (NIH). A region of interest was 
selected for each image that included the tissue area only and excluded the composite 
hydrogel if applicable to assess immune response only in the surrounding tissue. 
Composite hydrogel areas were defined by large regions of sparse DAPI staining. A 
binary mask was created using the default thresholding method and then the area 
fraction of CD68+ staining was measured for each image.  
5.2.5.3. Tissue Remodeling 
 After 4 weeks, tissue remodeling was evaluated by staining tissue sections at the 
mid-papillary level with Masson’s Trichrome Stain Kit using manufacturer provided 
instructions. Scar fraction was quantified using the freehand line tool in ImageJ (NIH) to 
measure the endocardial circumference of the left ventricle, the epicardial circumference 
of the left ventricle, the length of the endocardial infarct, and the length of the epicardial 
infarct, with “infarct” defined by portions of the left ventricular wall in which at least 50% 
of the thickness of the wall is scar. The scar fraction was calculated as follows: 
 
For scar thickness, the same tool was used to measure the width of 5 evenly spaced 
points of the infarct and averaged. At least 2 images were quantified and averaged per 
animal for one biological replicate.  
5.2.5.4. Vascular Structures  
 After 4 weeks, vascular structure density and size were assessed via 
immunohistochemical staining of tissue sections at the mid-papillary level for von 
Willebrand factor (vWF-FITC, ab8822, Abcam, 1:400) and  -smooth muscle actin ( -
SMA-AF594, ab202368, Abcam, 1:400) with wheat germ agglutinin (WGA-AF647, 
W32466, ThermoFisher Scientific, 1:300) and DAPI (D1306, ThermoFisher Scientific, 
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1:1000). Images were acquired on a Leica DM5000b fluorescent microscope using a 
DFC350 FX monochrome camera. At least four images of the border zone of the infarct, 
defined as one high-powered field away from WGA-bright scar, were quantified and 
averaged per animal to represent one biological replicate.  
 vWF+ area and vWF+a-SMA+ structure size was determined using ImageJ (NIH). 
For vWF+ structures and a-SMA+ structures, a binary mask was created via 
thresholding. Thresholded images were processed with the Dilate and Erode functions to 
improve connectivity. Particles greater than or equal to 3.5 µm2 in area were counted 
and measured. The Otsu auto-thresholding method was used unless 1) the area fraction 
of particles counted was greater than 10% or 2) the number of structures counted was 
over 200 for vWF+ or 75 for a-SMA+. These cases were empirically determined to be 
indications that the Otsu auto-thresholding method was unsatisfactory; in these cases, 
the Triangle auto-thresholding method was used instead. For the number and size of 
vWF+a-SMA+ structures, the result of using the AND operator in the Image Calculator 
function on the binary masks of the vWF and a-SMA channels was counted and 
measured using the parameters described above.  
5.2.6. STATISTICS 
 All graphs and statistical analyses were completed using GraphPad Prism 7 
software. Outliers were removed using the ROUT test with Q=5% and statistical 
significance was determined using a two-tailed Student’s T-test or a one-way ANOVA 
with post-hoc Tukey’s multiple comparisons test.  
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5.3 RESULTS AND DISCUSSION 
5.3.1. MATERIAL SYNTHESIS AND MICROGEL FABRICATION 
A supramolecular hydrogel was first fabricated using guest-host interactions of 
modified HA. Separately, HA was modified with adamantane (guest, ~20% modification) 
to form AdHA and ß-cyclodextrin (host, ~20% modification) to form CDHA (Figure 5.2A). 
AdHA and CDHA components, upon mixing, have been previously shown to assemble 
due to hydrophobic interactions to form supramolecular, host-guest complexes that 
disassemble upon the application of shear but also rapidly re-assemble to form a stable 
hydrogel after injection (Figure 5.2B-C)48. The injectable properties of this hydrogel have 
been previously explored47 as injectable hydrogels are particularly attractive for clinical 
translation because they can improve the retention of delivered therapeutics and be 
delivered using minimally invasive approaches like catheters35. Variations of this bulk 
guest-host hydrogel have been previously investigated in our lab to deliver cells20, 
exosomes49, small molecules23, growth factors19,21, and RNAs38,50.   
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Figure 5.2. Material synthesis. A) Reaction schematics for the synthesis of 
adamantane-modified HA (AdHA, ~20% modification), cyclodextrin-modified HA (CDHA, 
~20% modification), and norbornene-modified HA (NorHA, ~30% modification). B) AdHA 
and CDHA assemble into a hydrogel through guest-host complexes upon mixing that 
disassemble upon the application of shear, resulting in an C) injectable guest-host 
hydrogel (dyed blue) that can be extruded from a syringe and rapidly self-heals after 
injection. D) NorHA crosslinks through a thiol-ene reaction in the presence of a di-thiol 
crosslinker, photoinitiator, and UV light and can be processed into E) covalently-
crosslinked NorHA microgels (visualized with encapsulated FITC-dextran).  
 
To form microgels, HA was modified with norbornene groups (~30% modification) 
to form NorHA (Figure 5.2A). Norbornenes react to form covalent bonds via thiol-ene 
reactions with thiols in the presence of UV light and a photoinitiator (Figure 5.2D)51, 
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which can be used to form microgels (Figure 5.2E). There are numerous techniques that 
can be used to fabricate covalently-crosslinked microgels, primarily through water-in-oil 
emulsion techniques52,53.  Here, microgels were fabricated using a recently developed 
microfluidic device40 to generate particles that were crosslinked with UV light as they 
flowed out of the device and into a collection vial (Figure 5.3A-C).  Microgels were 
spherical and generally uniform in size with a diameter of 59 ± 7 μm (Figure 5.3D-E).  
 
Figure 5.3. Microgel formation. A) Schematic of high-throughput microfluidic device for 
water-in-oil droplet formation and screenshots (scale bars = 100 µm) of droplets B) being 
formed and C) flowing through the device. After crosslinking with UV light, microgels 
were washed from the oil, dehydrated for storage, and then rehydrated to form relatively 
uniform spherical microgels as D) visualized with light microscopy and E) quantified as a 
histogram with an average microgel diameter of 59 ± 7 μm (mean ± SD). 
 
To encapsulate a therapeutic, such as IL-10, the therapeutic was simply added to 
the aqueous phase during microgel processing. Thiolated heparin, which has a high 
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density of negative charge, was also incorporated into the microgels to sequester 
positively-charged IL-10 prior to release. When we compared the encapsulation 
efficiency, or the ratio of the amount of IL-10 detected to the amount of IL-10 expected, 
we found that the encapsulation efficiency of microgels formulated with HepSH (17.3% ± 
7.2) was significantly higher than that of microgels formulated without HepSH (2.6% ± 
0.3) (Figure 5.4A). The remaining IL-10 could have been lost during the microgel 
formation process or during ELISA analysis. The zeta potential of microgel precursor 
solutions of NorHA with HepSH (-21.5 ± 1.2 mV) was significantly more negative than 
the zeta potential of solutions of NorHA alone (-10.0 ± 1.6 mV) (Figure 5.4B). Thus, 
HepSH was deemed important for IL-10 encapsulation and was used in all subsequent 
studies.  
 
Figure 5.4. Effect of HepSH. A) Thiolated heparin (HepSH) significantly improves IL-10 
retention during microgel formation. The percentage of expected IL-10 detected was 
measured via ELISA. The remaining IL-10 not detected was lost either during the 
microgel formation process or during the ELISA. B) HepSH significantly reduces the zeta 
potential of microgel precursor solutions. (mean ± SD; *p<0.05, **p<0.01, ***p<0.001).  
 
Microgels crosslinked with either a stable (DTT) or hydrolytically degradable 
(PETMA) crosslinker were fabricated and assessed for degradation and IL-10 release 
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over 2 weeks (Figure 5.5A). The degradable microgels were fully degraded after 2 
weeks, while stable microgels were still largely intact (Figure 5.5B). Similar trends were 
observed for IL-10 release (Figure 5.5C), with IL-10 completely released within 2 weeks 
from the degradable microgels, whereas stable microgels still retained much of their IL-
10 content. Thus, we observed that microgel stability and the rate of therapeutic delivery 
can be tailored by changing the stability of the thiol crosslinker within the microgels. For 
more complex growth factor cocktails and delivery profiles, microgels of varying stability 
could be combined. For IL-10 delivery in our study, we desired the steady release of IL-
10 from microgels over a few weeks to match doses from previous IL-10 delivery studies 
and to correspond to detected expression patterns of IL-10 in various animal MI models; 
thus, for animal studies we selected degradable microgels 54–56.  
 
Figure 5.5. Microgel degradation and IL-10 release. A) Schematic for microgel 
degradation and release studies.  Microgels were fabricated with either stable (DTT as 
crosslinker) or hydrolytically degradable (PETMA as crosslinker) crosslinks, washed, and 
incubated in release buffer for up to 14 days.  At each sample point, microgels were 
centrifuged at 1200 x g for 15 minutes and then releasate was collected for analysis of 
HA degradation products and IL-10 release. After 14 days, the microgels were fully 
degraded in hyaluronidase for analysis of any remaining uronic acid or IL-10.  B) Uronic 
acid and C) IL-10 cumulative release over 14 days (mean ± SD). 
 
5.3.2. COMPOSITE FABRICATION AND CHARACTERIZATION 
 To combine the benefits of injectability from the bulk guest-host hydrogel and the 
controlled release of microgels, they were combined to fabricate composites (Figure 
5.6A).  With this approach, microgels can be designed with differing levels of stability 
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and added at different loading amounts and even with mixed compositions to control 
release, independent of the design of the bulk guest-host hydrogel. Others have 
previously explored the use of nano-scale particles (<1 µm) for drug delivery from 
composites24,57; here, we use micro-scale particles and investigate the material 
properties of these composite hydrogels to learn more about the network interactions 
between the bulk guest-host hydrogel and covalently-crosslinked microgels. 
Microgels were combined with the bulk guest-host hydrogel to form a composite 
hydrogel at low (6.7 mg microgels/mL bulk hydrogel) or high (13.3 mg microgels/mL bulk 
hydrogel) concentrations and characterized through confocal microscopy to visualize 
fluorescently labeled microgels (Figure 5.6B). The volume fraction of microgels within 
the bulk hydrogel for the low concentration was 0.08 ± 0.02 and for the high 
concentration was significantly higher at 0.29 ± 0.05 (Figure 5.6C). This illustrates our 
ability to alter the loading of microgels and encapsulated therapeutics. Although there is 
no specific interaction intended between the bulk guest-host hydrogel and the 
covalently-crosslinked microgels, entanglement of the bulk hydrogel within the covalent 
network during encapsulation or non-specific interactions between the b-cyclodextrin 
and norbornene groups are possible.  
 
Figure 5.6. Composite hydrogels. A) Schematic of supramolecular hydrogel/microgel 
composite, consisting of bulk guest-host hydrogel (purple) with encapsulated microgels 
(green). B) 3D projections of microgels (green) in bulk guest-host hydrogels (red) at low 
(left, 6.7 mg/mL bulk hydrogel) or high (right, 13.3 mg/mL bulk hydrogel) concentrations. 
C) Volume fraction of microgels in the bulk guest-host hydrogel at low and high 
concentrations (mean ± SD, n=3, *p<0.05, **p<0.01).  
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The material properties of the bulk guest-host hydrogel, the low microgel 
composite hydrogel, and the high microgel composite hydrogel were evaluated using 
oscillatory shear rheometry. All groups behaved as hydrogels (G’ > G”) (Figure 5.7A) 
that were viscoelastic, as indicated by changes in the moduli with variations in frequency 
(Figure 5.7B). The high microgel composite hydrogel had the lowest crossover 
frequency (~0.1 Hz) and therefore the longest relaxation time, indicating that this 
hydrogel flows less than the low microgel composite hydrogel or the bulk guest-host 
hydrogel, which had similar crossover frequencies  (~2 Hz for bulk hydrogel, ~ 1 Hz for 
the low microgel composite hydrogel). The granular nature of the composite hydrogels 
and the covalent-crosslinking of the microgels likely contributes to the longer relaxation 
times.  
All groups behaved rheologically as shear-thinning injectable materials. The 
strain sweeps indicated material yielding, or a decline in storage and loss moduli at 
particular strains (Figure 5.7C). Interestingly, the composites yielded at lower strains 
than the bulk hydrogel, likely due to failure at interfaces between the supramolecular 
hydrogel and covalently-crosslinked microgels.  Continuous flow experiments also 
showed a decrease in viscosity for all groups with increasing shear rate, indicative of 
shear-thinning (Figure 5.7D). Both composite hydrogels showed evidence of shear 
banding, a phenomenon in which portions of the hydrogel undergo shear and are 
liquidized while other portions of the hydrogel remain solid, allowing the same shear 
stress to be achieved at 2 or more shear rates58 (Figure 5.7E). At high strains, the 
storage and loss moduli for all groups decreased, but then recovered upon the cessation 
of strain, indicative of self-healing (Figure 5.7F). 
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Figure 5.7. Rheology of composite hydrogels. Bulk guest-host hydrogels alone (Gel) 
or as microgel composites at a low (6.7 mg/mL bulk hydrogel) or high (13.3 mg/mL bulk 
hydrogel) microgel concentration characterized using oscillatory shear rheometry, 
including: storage (G’, closed symbols) and loss (G’’, open symbols) moduli A) over time 
at 0.2% strain and 10 Hz, B) across a range of frequencies at 0.2% strain, C) across a 
range of % strains at 10 Hz, D) viscosity with increasing shear rate, E) shear stress with 
increasing shear rate, and F) cyclic strains over time (low = 0.2% strain at 10 Hz, high 
(shaded) = 500% strain at 10 Hz). 
 
Hydrogels with lower storage and loss moduli (at high strains relevant for 
injection), lower yield strain, and lower viscosity are typically easier to inject than 
hydrogels with higher storage and loss moduli, higher yield strain, and higher viscosity. 
Based on these criteria and observations during handling, the composite hydrogels are 
easier to inject than then the bulk guest-host hydrogel. The granular nature of these 
composite hydrogels potentially makes them more prone to shear banding59,60, which 
also improves injectability. To balance injectability and therapeutic dosage, the high 
microgel composite hydrogels were used in animal studies to assess them for use in the 
delivery of IL-10.  
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Additionally, we investigated the release of IL-10 from these high microgel 
composite hydrogels compared to microgels alone (Figure 5.8). After 2 weeks, only 
~15% of the encapsulated IL-10 was released in the composite hydrogels, whereas the 
microgels alone were fully degraded at the end of 2 weeks with 100% of the 
encapsulated IL-10 released. This suggests that the bulk gel can further modulate IL-10 
release, and can be engineered to further tune the release profile of encapsulated 
therapeutics. Encapsulation of microgels within the bulk gel also eliminated burst release 
effects. However, in vivo and in vitro release kinetics may differ due to the contractile 
nature of the heart. For example, in previous studies we have observed that the bulk 
hydrogel is 90% eroded at the end of 1 week in vivo, but persists for over 3 weeks in 
vitro38. Ultimately, it is necessary to entrap microgels within the bulk hydrogel to improve 
localization of the therapy to the injection site and prevent the dispersion of microgels if 
delivered alone57.  
 
Figure 5.8. IL-10 release from composite hydrogels. Release of IL-10 from composite 
hydrogels with a high concentration of degradable microgels compared to the release of 
IL-10 from degradable microgels alone.  
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5.3.3. RAT MI MODEL 
Following MI, PBS, composites without IL-10, or composites with IL-10 were 
injected into the border zone region of the infarct (Figure 5.9A-B). IL-10 is produced by 
activated T cells and monocytes after MI41 and reduces inflammation by both mediating 
the transition of macrophages from a pro-inflammatory M1 phenotype to an anti-
inflammatory M2 phenotype61,62 and by downregulating the production of inflammatory 
cytokines such as IL-1α, IL-1β, TNF-α, IL-6, IL-8, and IL-12 by monocytes and 
macrophages via the STAT3 pathway41,42,63. To better understand the influence of 
exogenous IL-10 delivery on treating MI, the immune response was evaluated with 
CD68 staining for macrophages after 1 week and remodeling, cardiac function, and 
vasculature outcomes were assessed after 4 weeks (Figure 5.9C). 
 
Figure 5.9. Rat MI model. Schematic of the analysis of composite hydrogels in a rat MI 
model, including A) injection sites in border zone of MI after LAD ligation, B) treatment 
groups of saline control (PBS), composites without IL-10, and composites with IL-10, C) 
experimental design timeline showing injection at day 0 and outcome measures after 7 
and 28 days.  
 
Representative images of immunohistochemistry for CD68 after 1 week are 
shown (Figure 5.10A-F). CD68 is a marker commonly expressed by activated or 
inflammatory macrophages, which play a critical role in the acute inflammatory response 
after MI, but excess activity can lead to increased tissue damage41,64. CD68 staining 
showed the presence of macrophages in the border zone region of the infarct for all 
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treatment groups. When quantified, CD68+ area fraction showed that delivery of 
composites with IL-10 significantly decreased the presence of CD68+ macrophages 
when compared to saline delivery, which indicates that IL-10 delivery can mitigate 
inflammation near the injection site (Figure 5.10G). There was a non-statistically 
significant decrease in CD68+ staining with the composite releasing IL-10 when 
compared to the composite without IL-10.   
 
Figure 5.10. Inflammatory response. A-F) Immunohistochemistry for CD68+ cells (red) 
in the border zone and G) quantification of area fraction of cardiac tissue outside of the 
composite hydrogel that is CD68+ after delivery of (A, D) PBS (n=4), (B, E) composites 
without IL-10 (n=4), or (C, F) composites with IL-10 (n=5). (mean ± SD; *p<0.05). 
 
 After 4 weeks, Masson’s trichrome staining was used to visualize scar tissue 
after the delivery of saline, composites without IL-10, or composites with IL-10 (Figure 
5.11A-C). Notably, HA composite hydrogel/microgel structures were still visible (Figure 
5.11D-E), which was confirmed to be glycosaminoglycans (i.e., HA) through Alcian blue 
staining (Figure 5.12A-D). Quantification of scar fraction showed no difference among 
groups (Figure 5.12E); however, there was increased scar thickness with the delivery of 
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composites, and this improvement was significant for the delivery of composites with IL-
10 compared to saline delivery (Figure 11F).  
 
Figure 5.11. Cardiac remodeling. A-E) Masson’s trichrome staining of cardiac tissue 
28 days after delivery of PBS (n=11), composites without IL-10 (n=8), or composites with 
IL-10 (n=10) to rat MI. F) Quantification of scar thickness of these same treatment 
groups (mean ± SD; *p<0.05).  
 
 
 
Figure 5.12. Composite hydrogel in cardiac tissue. A-B) Masson’s trichrome and C-
D) Alcian blue staining of cardiac tissue 28 days after delivery of composites without IL-
10 (n=8) or composites with IL-10 (n=10) to rat MI. Quantification of E) scar fraction of 
these same treatment groups with PBS control (n=11) (mean ± SD). 
 
Scar thickening in the presence of the composite hydrogels is likely due to them 
acting as bulking agents. Previous work by our group has shown that the bulk guest-host 
hydrogel by itself is not intact and almost completely eroded after 4 weeks38,65; however, 
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the microgels likely remain longer in the tissue.  Microparticles have been introduced via 
biomaterials into infarcted tissue previously and have improved functional outcomes 
through a bulking response, likely through altering the inflammatory response66,67. In 
addition to a response of the microgels alone, IL-10 has been found to have inhibitory 
effects on matrix metalloproteinases and increase production of tissue inhibitor matrix 
metalloproteinases by human macrophages in cell culture models, indicating the role of 
IL-10 in limiting the adverse remodeling of native tissues68. Combined, the effect of the 
composite hydrogel as a bulking agent with the therapeutic delivery of anti-inflammatory 
IL-10 showed significant improvements in scar thickness over the saline control, which 
may correspond to improvements in cardiac function.  
 After 4 weeks, pressure-volume catheterization was used to assess cardiac 
function by measuring hemodynamics after the delivery of saline, composites without IL-
10, or composites with IL-10 (Figure 5.13A-D). The delivery of composites without IL-10 
showed significant improvements in ejection fraction and dP/dtmax, a measure of cardiac 
contractility, compared to saline delivery. The delivery of composites with IL-10 showed 
significant improvements in ejection fraction, cardiac output, dP/dtmax, and preload 
recruitable stroke work (PRSW; another index of myocardial contractility) compared to 
saline and in PRSW when compared to the composites without IL-10. For ejection 
fraction, cardiac output, dP/dtmax, and PRSW, the delivery of composites with or without 
IL-10 also improved the value of these outcomes to healthy baseline levels. 
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Figure 5.13. Cardiac function. A) Ejection fraction, B) cardiac output, C) dP/dTmax, and 
D) preload recruitable stroke work (PRSW) 28 days after delivery of PBS (n=15), 
composites without IL-10 (n=8), or composites with IL-10 (n=10) to rat MI and measured 
via pressure-volume catheterization (mean ± SD; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001; healthy range in shaded boxes).  
 
 The improvement of cardiac function with the delivery of composites without IL-
10 indicates that the material itself has a positive effect, likely due to its ability to act as a 
bulking agent and thicken the left ventricular wall. According to the Laplace’s law, wall 
thickness is inversely proportional to wall stress, so thickening of the left ventricular wall 
can decrease wall stress and prevent further ventricular dilation that can lead to poor 
cardiac function34,35. The additional improvements in cardiac function exhibited by the 
delivery of composites with IL-10 indicate that the anti-inflammatory effect of IL-10 may 
help to mitigate the tissue damage that can be caused by excessive inflammation and 
initiate the healing process42,69. 
 After 4 weeks, immunohistochemistry was used to assess the density and size of 
vascular structures after the delivery of saline, composites without IL-10, or composites 
with IL-10 and representative images are shown (Figure 5.14A-C). Von Willebrand 
170 
factor, or vWF, is a glycoprotein produced by endothelial cells and is present in the 
lumen of vascular structures of all sizes, from capillaries to arterioles70,71, whereas alpha-
smooth muscle actin (a-SMA) is expressed by smooth muscle cells and is only present 
in more mature vasculature71. Both vWF+ and vWF+a-SMA+ vascular structures 
contribute to enhancing perfusion in the border zone region after MI. Quantification of 
vWF+ area showed that the delivery of composites without or with IL-10 significantly 
increased vWF+ area compared to the delivery of saline (Figure 5.14D). Quantification 
of vWF+a-SMA+ structure sizes showed that the delivery of composites without or with 
IL-10 increased structure size but only the delivery of composites with IL-10 significantly 
increased structure size compared to the delivery of saline (Figure 5.14E).  
 
Figure 5.14. Formation of new vascular structures. Immunohistochemistry for 
vascular markers 28 days after delivery of A) PBS, (n=9), B) composites without IL-10 
(n=8), or C) composites with IL-10 (n=10) to rat MI. Quantification of D) vWF+ area and 
E) size of vWF+a-SMA+ structures for these same groups (mean ± SD; *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001). 
 
These results indicate that the composite hydrogel alone has a positive effect on 
vascular density, and that the effects of the composite hydrogel and IL-10 can combine 
to have an even greater result. Larger vessel diameters are often correlated with more 
mature vessels that are more constructive for improved remodeling and functional 
outcomes, which makes the influence of IL-10 delivery on vessel size important72. 
Systemic IL-10 has also been shown to increase the number of vascular structures after 
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delivery of endothelial progenitor cells (EPCs) in MI compared to the delivery of EPCs 
without IL-10, further emphasizing the role of IL-10 in vascularization73.  HA has also 
been shown to improve vascularization, largely due to the role of HA in cell migration 
and proliferation74–76. 
 
5.4 CONCLUSIONS 
An injectable bulk guest-host hydrogel was combined with covalently-crosslinked 
microgels to create a composite hydrogel/microgel for therapeutic delivery, combining 
the beneficial properties of both systems. By encapsulating therapeutics within 
microgels, the release of therapeutics from this composite hydrogel was decoupled from 
the degradation of the bulk hydrogel. The composite hydrogel was shear-thinning, self-
healing, and injectable. As a model therapeutic, IL-10 was delivered using this 
composite hydrogel after MI. The delivery of composites with IL-10 significantly 
decreased the presence of macrophages after 1 week and increased scar thickness, 
improved cardiac function, and enhanced vascular density after 4 weeks compared to 
saline delivery. The composite hydrogel/microgel system described here could be tuned 
for the delivery of multiple therapeutics with complex release profiles for broad 
applications.  
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CHAPTER 6  
INJECTABLE HYDROGEL DELIVERY OF EXTRACELLULAR VESICLES ISOLATED 
FROM PRE-CONDITIONED MSCS TO THE HEART 
 
6.1 INTRODUCTION 
 Recently, there has been increased interest in the application of extracellular 
vesicles (EVs) produced by cells, to treat damaged and diseased tissues, particularly as 
a cell-free therapeutic.1–4 There are different types of EVs (e.g., exosomes, 
microvesicles, apoptotic bodies) that are characterized by their biogenesis and size.5 
Exosomes are a subset of EVs that are approximately 100 nm in diameter and have 
membranes that originate from the plasma membrane but are formed from invaginations 
of multivesicular bodies.5,6 EVs can carry cargo such as proteins, RNA, and lipids to 
other cells, and are therefore an important component of the paracrine signaling 
mechanisms that cells use to communicate with each other.5  
 Mesenchymal stromal cells (MSCs) have been explored in several pre-clinical 
and clinical studies and were found to be beneficial for cardiac repair after myocardial 
infarction (MI).7,8 However, low rates of cell engraftment and retention after cell delivery 
suggest that the paracrine signals that MSCs produce, rather than their direct 
integration, are responsible for their positive therapeutic effects.8,9 An important 
component of these paracrine signals are EVs. In 2010, Lai, et al. showed that 
exosomes isolated from human embryonic stem cell-derived MSCs reduced infarct size 
in a mouse model of MI.10 Since then, other groups have also shown that MSC-derived 
EVs can improve cardiac repair after MI by enhancing angiogenesis11,12, reducing 
inflammation12, and limiting cardiomyocyte apoptosis13, and several reviews have been 
published outlining the benefits of MSC-derived EVs as cell-free therapies for MI and 
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other indications.14–17 In the majority of these studies, EVs are directly injected into the 
myocardium after MI. 
Since EVs are cell-derived, altering cell culture conditions has been explored as 
a method to both boost EV production levels18 and to produce EVs with desired 
therapeutic properties. For instance, both hypoxia and pro-angiogenic growth factors 
have been explored as methods for MSC pre-conditioning to enhance the pro-
angiogenic phenotype of MSCs. Human MSCs cultured in hypoxic (1% O2) conditions 
have been shown to release pro-angiogenic factors such as vascular endothelial growth 
factor (VEGF), fibroblast growth factor 2 (FGF-2, also known as basic fibroblast growth 
factor or bFGF), insulin-like growth factor 1 (IGF-1), and hepatocyte growth factor 
(HGF).19 Besides secreted factors, Bian et al found that EVs isolated from human MSCs 
cultured in serum-free growth media under hypoxic (1% O2) conditions for 72 hours had 
significantly higher protein content than EVs isolated from MSCs cultured under 
normoxic (21% O2) conditions.11 Also, EVs isolated from hypoxic MSCs significantly 
improved formation of new vascular structures in vitro and in vivo after MI in a rat when 
compared to saline controls.11 Hypoxia has long been shown to be involved in the 
regulation of angiogenesis, primarily through pathways mediated by hypoxia-inducible 
factors (HIFs).20 
Pro-angiogenic factors, such as epidermal growth factor (EGF)21, bFGF22, IGF23, 
VEGF22, and ascorbic acid24 are positive regulators of angiogenesis that are implicated 
in endothelial cell (EC) proliferation, differentiation, and migration or the stabilization of 
nascent blood vessels. At certain concentrations, heparin22 and hydrocortisone25 have 
also been shown to increase angiogenesis. All of these factors are found in a variant of 
endothelial cell growth medium, commercially available as EGM-2 from suppliers such 
as Lonza and PromoCell. Priming MSCs with EGM-2 for 72 hours was shown to 
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decrease the basal cell death rate, and the delivery of primed MSCs via intraperitoneal 
injection was shown to significantly increase microvascular density in skeletal muscle in 
rats when compared to the delivery of non-primed MSCs.26 Other groups have shown 
that the treatment of adipose-derived MSCs with the same factors increased the release 
of angiogenic factors secreted by cells after one week in culture.27 MSCs cultured in the 
presence of VEGF have also been observed to differentiate into endothelial-like cells.28 
This suggests that culturing MSCs with pro-angiogenic growth factors can alter cell 
behaviors and potentially enhance the pro-angiogenic potential of EVs that these cells 
produce.  
As reported in this chapter, rat MSCs were pre-conditioned with one of four 
treatment conditions involving combinations of culture in hypoxic and normoxic 
environments with and without pro-angiogenic growth factors. EVs were isolated from 
pre-conditioned MSCs and the effect of treatment conditions on EV production and in 
vitro angiogenesis was investigated. Our hypothesis is that priming MSCs with both pro-
angiogenic growth factors and culture in hypoxic conditions, which has not been done 
previously, will alter EV contents and that these EVs will promote angiogenesis in vitro 
and in vivo. For targeted and sustained EV delivery in vivo, EVs were encapsulated in an 
injectable hydrogel and delivered in a rat MI model that was described in Chapter 3 of 
this thesis. Previously, our group has shown that the delivery of endothelial progenitor 
cell-derived EVs in an injectable hydrogel to the heart improves cardiac function and 
remodeling outcomes compared to the delivery of EVs in saline.29 The move toward 
MSC-derived EVs is likely to improve the clinical potential and sourcing of EVs for 
potential therapies. Through pre-conditioning MSCs to increase their pro-angiogenic 
potential and then delivering isolated EVs using an injectable hydrogel, we aim to 
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develop a local and sustained cell-free EV therapy for improved cardiac remodeling 
through increased vascularization after MI. 
 
6.2 METHODS 
6.2.1. INJECTABLE HYDROGEL 
 An injectable, guest-host, hyaluronic acid-based hydrogel formed by the 
supramolecular interactions between adamantane (Ad, guest) and b-cyclodextrin (CD, 
host) functional groups was utilized in this chapter for EV delivery. Synthesis of this 
hydrogel was described extensively in Chapter 3 of this thesis. Briefly, sodium hyaluronic 
acid (HA, 74 kDa, Lifecore) was converted to the tetrabutylammonium salt of HA (HA-
TBA). HA-TBA was modified separately with Ad to form AdHA through the coupling of 1-
adamantane acetic acid (Acros Organics) in the presence of di-tert-butyl dicarbonate 
and 4-methylaminopyridine or with CD to form CDHA through the coupling of b-CD-HDA 
in the presence of benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate. Approximately 20-25% of HA repeat units were functionalized by 
Ad (for AdHA) as quantified by 1H NMR and approximately 20-25% of HA repeat units 
were functionalized by b-CD-HDA (for CDHA) as quantified by 1H NMR. All chemicals 
were purchased from Sigma-Aldrich unless otherwise noted. 
For subsequent studies, the hydrogel used had a total material concentration of 
4.5 wt% (AdHA and CDHA components combined) with an equal molar ratio of Ad to CD 
groups. For hydrogel assembly, AdHA and CDHA were dissolved separately in equal 
volumes of PBS (or in PBS with EVs when noted) and then mixed to form the injectable 
hydrogel. Prior to being dissolved in solution, AdHA and CDHA components were 
sterilized with UV light for in vivo applications.  
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6.2.2. MSC PRE-CONDITIONING 
 Wistar rat mesenchymal stem cells (rMSCs, Cyagen, batch no: 130730H31) 
were subcultured to passage 6 on tissue culture plastic in MSC growth media (a-MEM 
with 16.7% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine) 
and media was changed every other day until rMSCs reached 80% confluence. Cells 
were rinsed twice with phosphate-buffered saline (PBS) and, for pre-conditioning, rMSCs 
were either cultured in hypoxic (1% O2) or normoxic (21% O2) environments and with 
either serum-free MSC growth media (a-MEM with 1% penicillin-streptomycin and 1% L-
glutamine) or serum-free pro-angiogenic growth factor-supplemented media (PromoCell; 
EBM-2 with 5 ng/mL recombinant human epidermal growth factor (EGF), 10 ng/mL 
recombinant human basic fibroblast growth factor (FGF), 20 ng/mL insulin-like growth 
factor (R3 IGF-1), 0.5 ng/mL recombinant human vascular endothelial growth factor 165 
(VEGF), 1  µg/mL ascorbic acid, 22.5 µg/mL heparin, and 0.2 µg/mL hydrocortisone). 
Serum-free media was used to avoid contamination with serum-derived EVs. 
 The pre-conditioning treatment conditions were as follows: standard (normoxia 
with serum-free MSC growth media), hypoxia (hypoxia with serum-free MSC growth 
media), growth factor (GF, normoxia with serum-free pro-angiogenic growth factor-
supplemented media), or growth factor + hypoxia (GF+hypoxia, hypoxia with serum-free 
pro-angiogenic growth factor-supplemented media) (Figure 6.1). Treatment conditions 
were applied for 72 hours during the EV collection time period. Following, conditioned 
media was collected from cells and centrifuged at 2000 x g for 30 minutes at 4°C and 
clarified using a 0.22 µm PVDF filter to remove dead cells and cellular debris. 
Conditioned media containing EVs was frozen and stored at -80°C until EV isolation.  
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Figure 6.1. rMSC pre-conditioning regimen. Passage 6 (p6) rat mesenchymal stromal 
cells (rMSCs) were grown to 80% confluence and then cultured in one of four conditions 
(A-D). After 72 hours, conditioned media was collected for extracellular vesicle (EV) 
isolation. rMSCs were imaged before and after pre-conditioning. GF: growth factor.  
 
Before and after the 72 hour pre-conditioning and EV collection period, cell 
images were taken using a brightfield light microscope at 10x magnification. Using 
ImageJ (NIH), binary masks were created using default intensity-based thresholding 
methods for each image to count the number of cells per area and to calculate cell 
spread area, cell shape index, and cell aspect ratio. Cell shape index is calculated as 
(4pA)/P2, where A is the area of the cell and P is the perimeter of the cell. Using this 
formula, a line has a cell shape index of 0 and a circle has a cell shape index of 1. Cell 
aspect ratio is calculated by taking the length of the longest side of the bounding 
rectangle encompassing the cell and dividing it by the length of the shortest side of the 
bounding rectangle encompassing the cell.  
6.2.3. EV ISOLATION AND CHARACTERIZATION 
6.2.3.1. EV ISOLATION 
 EVs were isolated using a previously described polyethylene glycol (PEG)-based 
polymer precipitation method.30 For the PEG isolation reagent, a solution of 36% 6 kDa 
PEG and 1.5 M NaCl was made in water, filtered with a 0.22 µm filter, and stored at 4°C 
until use. Frozen conditioned media was thawed at 37°C and vortexed. PEG isolation 
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reagent was added to conditioned media at a 1:2 ratio to achieve a working 
concentration of 12% PEG, 0.5 M NaCl. Samples were thoroughly mixed and then 
incubated for 12-24 hours overnight at 4°C. The following day, samples were centrifuged 
at 10,000 x g at 4°C for 2 hours at low brake to collect EVs. EVs were washed and 
resuspended with PBS and then stored at -80°C until use. 
6.2.3.2. EV SIZE, CONCENTRATION, AND PROTEIN CONTENT  
 EVs suspended in PBS were analyzed via nanoparticle tracking analysis (NTA) 
to determine EV size, size distribution, and concentration using a NanoSight NS500 (532 
nm laser; Malvern Instruments) by the Nanomedicines Characterization Core Facility at 
The University of North Carolina at Chapel Hill. Samples were diluted and then injected 
manually. Data acquisition was performed at room temperature and data was analyzed 
using NTA 3.0 software (Malvern Panalytical). EV protein content was quantified using a 
Micro BCA Protein Assay Kit (ThermoFisher Scientific) per manufacturer instructions. 
6.2.3.3. MATRIGEL ANGIOGENESIS ASSAY 
 EV angiogenic potential was quantified in vitro using a Matrigel angiogenesis 
assay. 10 µL of Matrigel (Corning) was plated into each 0.125 cm2 inner well of a µ-slide 
for angiogenesis (Ibidi). Human umbilical vein endothelial cells (hUVECs, passage 4, 
grown to 100% confluence) resuspended in EBM-2 with 1% FBS were seeded onto 
Matrigel at a density of 10,000 cells/well (51,000 cells/cm2). EVs isolated from MSCs 
pre-conditioned with all four treatment groups were suspended in PBS and were added 
to each well at a concentration of 80 µg protein/mL, with EV protein content quantified as 
described above (e.g., for 50 µL volume/well, 4 µg EV were added to each well). EV 
samples with varying protein concentrations were diluted such that the volume of PBS 
added to each well was the same. For a negative control, the same total volume of PBS 
without EVs was added to wells. Samples were incubated for 14 hours and imaged at 4x 
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using brightfield microscopy. Images were analyzed using the Angiogenesis Analyzer 
plug-in (Gilles Carpentier) and ImageJ (NIH).  
6.2.3.4. PROTEOMICS 
Sample preparation 
EVs isolated from MSCs pre-conditioned with standard (n=4) and GF+hypoxia 
(n=5) treatments were evaluated for protein content using mass spectrometry. Biological 
replicates were defined as separate EV isolations, and each sample consisted of 400 µg 
of EVs by protein content. Further sample preparation, mass spectrometry analysis, and 
sequence database search and statistical analysis were completed in collaboration with 
The Proteomics Core Facility at The Children’s Hospital of Philadelphia.  
EV samples were run on a polyacrylamide gel for 0.8 cm and stained with 
Coomassie blue. Each gel band was then excised and further cut into 1 mm cubes, 
which were destained with 50% methanol/1.25% acetic acid, reduced with 5 mM 
dithiothreitol, and alkylated with 20 mM iodoacetamide. Gel pieces were washed with 20 
mM ammonium bicarbonate, dehydrated with acetonitrile, and digested with trypsin 
(Promega, 5 ng/mL in 20 mM ammonium bicarbonate) overnight at 37ºC. Peptides were 
extracted with 0.3% trifluoroacetic acid and 50% acetonitrile. Extracts were combined 
and the volume was reduced by vacuum centrifugation. 
Mass spectrometry analysis 
Peptides were analyzed on a Q Exactive HF mass spectrometer (ThermoFisher 
Scientific) coupled with an UltiMate 3000 Nano UHPLC system and EASY-Spray source. 
Whole proteome samples were collected using data dependent acquisition (DDA) and 
data independent acquisition (DIA). Enriched acetylome peptides were analyzed by 
DDA.  Tryptic digests were spiked with iRT standards (Biognosys) and separated by 
reverse phase (RP)-HPLC on a PepMap RSLC C18 nano column (2 µm particle size, 75 
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μm ID, 50 cm length) at 50°C. Mobile phase A consisted of 0.1% formic acid and mobile 
phase B of 0.1% formic acid/acetonitrile. Peptides were eluted into the mass 
spectrometer at 210 nL/min with each RP-LC run comprising of a gradient from 1 to 5% 
B in 15 min, then 5-45% B in 110 min for DDA and 140 min for DIA.  
For DDA, the mass spectrometer was set to repetitively scan m/z from 300 to 
1400 for one full MS scan followed by data-dependent MS/MS scans on the twenty most 
abundant ions. For full MS scans, the resolution, AGC target, and maximum injection 
times were set at 120,000, 3e6, and 32 ms, respectively. For MS/MS scans, the 
resolution, AGC target, maximum injection time, and isolation window were set at 15000, 
2e5, 32 ms, and 1.4 m/z, respectively. 1 microscan was used for each MS/MS scan with 
rejection of singly charged ions and unassigned charge states and a normalized collision 
energy of 27.  
For DIA, the mass spectrometer completed 1 full MS scan from 300 to 1650 m/z 
with a resolution, AGC target, and maximum injection time of 120,000, 3e6, and 60 ms, 
respectively. This was followed by 22 (DIA) isolation windows with varying sizes at 
30,000 resolution, an AGC target of 3e6, injection times set to auto, and loop count and 
MSX count of 1. The default charge state was 4, the first mass was fixed at 200 m/z and 
the normalized collision energy (NCE) for each window was stepped at 25.5, 27, and 30.  
Sequence database search 
The DDA raw files were searched against a rat protein sequence database 
including canonical and manually reviewed isoform sequences from the Uniprot 
Knowledgebase using MaxQuant version 1.6.1.0 with the following set parameters: fixed 
modifications: carbamidomethyl (C); decoy mode: revert; MS/MS tolerance: FTMS 20 
ppm; false discovery rate for both peptides and proteins: 0.01; minimum peptide length: 
7; modifications included in protein quantification: acetyl (protein N-term), oxidation (M); 
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peptides used for protein quantification: razor and unique. The search result from 
MaxQuant was used to generate a spectral library for DIA analysis. A separate spectral 
library was generated for each DIA raw file using DirectDIA mode in Spectronaut. 
Subsequently, the DIA raw files were searched against a merged library using the 
default settings in Spectronaut. Protein intensity values measured at the MS2 level were 
then exported for downstream statistical analysis using Perseus 1.6.6.0 (Max Planck 
Institute of Biochemistry).  
Statistical analysis 
Protein intensity values were log2 transformed and normalized by subtracting the 
median for each sample. Exploratory analysis of protein contents was completed to 
determine the number of proteins detected in each group and the variance between 
groups was plotted using a principal component analysis plot. Differentially expressed 
proteins were determined using a Student’s t-test and volcano plots were generated to 
visualize affected proteins while comparing different groups of samples. Further 
enrichment analysis was completed using heat maps to show hierarchical clustering of 
differentially expressed proteins. For functional analysis, Fisher’s exact test with 
Benjamini-Hochberg FDR (false discovery rate) to control for multiple hypothesis testing 
was used to determine biological processes that were found to be significantly enriched 
or depleted. Values of the enrichment factor less than 1 indicate depletion.  
6.2.4. EV RETENTION AND BIODISTRIBUTION 
  The retention of EVs in the heart and biodistribution of EVs after cardiac 
injection using either saline or an injectable hydrogel as a delivery vehicle for EVs was 
assessed in vivo. EVs were isolated from MSCs treated with the standard pre-
conditioning regimen (21% O2, serum-free MSC growth media) and characterized using 
NTA as described above. 1 dose of EVs per rat corresponded to 9.33 x 109 particles in 
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110 µL saline. EVs were labeled with ExoGlow-Vivo EV Labeling Kit (near IR, System 
Biosciences) according to manufacturer instructions. Free dye was removed using 
exosome spin columns (MW 3000; ThermoFisher Scientific). For EVs delivered in saline, 
solutions of labeled EVs were loaded into ½ mL, 27G x ½” syringes (BD). For EVs 
delivered with the injectable hydrogel, AdHA and CDHA components were prepared as 
described above with solutions of labeled EVs, mixed, and then loaded into ½ mL, 27G x 
½” syringes (BD). 
A left lateral thoracotomy in the fourth intercostal space was performed as 
described in Chapter 3.6 to allow for the delivery of labeled EVs in saline or 
encapsulated in an injectable hydrogel to the apex of the heart in delivery sites that 
would mimic delivery after MI. For this study, EV retention and biodistribution was 
investigated without MI. Animals were recovered and at specified timepoints after 
injection (5 minutes, 1 day, 7 days, or 14 days), organs (heart, lungs, spleen, kidneys, 
liver, stomach, small intestine, and large intestine) were explanted and epi-fluorescence 
was quantified by imaging explanted organs using an IVIS Spectrum (PerkinElmer). For 
the initial timepoint (day 0), hearts that were explanted earlier that day were injected with 
EVs and immediately imaged. For each timepoint and delivery system (saline or 
injectable hydrogel), 4 biological replicates were used. Images were analyzed using 
Living Image 4.5.2 (PerkinElmer). After background correction, regions of interest 
around each organ were selected for each image, measured, and fluorescence in units 
of radiant efficiency were analyzed. Fluorescent signal was blanked with readings from 
hearts without any labeled EV injections. All animal protocols were approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee. 
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6.2.5. RAT MI MODEL 
 EVs isolated from MSCs pre-conditioned with GF+hypoxia were delivered in a rat 
MI model in either saline or with an injectable hydrogel and cardiac remodeling was 
assessed after 4 weeks. Using a previously established MI model described in detail in 
Chapter 3.6 of this thesis, ligation of the left anterior descending artery was used to 
induce a permanent infarct encompassing approximately 30% of the left ventricle in a 
rat. Animals were divided into one of four treatment groups: PBS (saline), PBS + EVs 
(EVs delivered in saline), Gel (injectable hydrogel alone without EVs), and Gel + EVs 
(injectable hydrogel with encapsulated EVs). EV dosage per animal was 80 µg of EVs as 
quantified by protein content in 110 µL saline. All treatment groups were prepared in ½ 
mL, 27G x ½” syringes (BD) and injected in equally spaced 5 x 20 µL injections into the 
border zone of the infarct immediately after confirmation of infarct induction. After 4 
weeks, animals were sacrificed and hearts were explanted, washed in PBS, and frozen 
in O.C.T. Compound (Tissue-Tek) at -80°C. Tissue sections of 10 µm thickness were 
obtained using a cryostat starting at the apex of the heart to above the papillary muscles 
and then further evaluated for tissue remodeling and vascular structures. All animal 
protocols were approved by the University of Pennsylvania Institutional Animal Care and 
Use Committee. 
6.2.5.1. TISSUE REMODELING 
To assess tissue remodeling, sections of cardiac tissue at the mid-papillary level 
were stained with Masson’s Trichrome Stain kit (Sigma-Aldrich) per manufacturer 
instructions. After staining, slides were imaged using a flatbed scanner and images were 
analyzed using ImageJ (NIH). For scar fraction, the freehand line tool was used to 
measure the endocardial circumference of the left ventricle, the epicardial circumference 
of the left ventricle, the length of the endocardial infarct, and the length of the epicardial 
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infarct. Only transmural infarct lengths were measured, and a transmural infarct was 
defined as a portion of the left ventricular wall with at least 50% of the thickness of the 
wall delineated as scar. Scar fraction was then calculated as the average of the infarct 
length as a proportion of circumference for the epicardial and endocardial sides. For scar 
thickness, the width of five evenly spaced points of the transmural infarct was measured 
and averaged. At least three images were quantified and averaged per animal for one 
biological replicate.  
6.2.5.2. VASCULAR STRUCTURES 
For quantification of vascular structure density and size, sections of cardiac 
tissue at the mid-papillary level were assessed via immunohistochemical staining for von 
Willebrand factor (vWF-FITC, ab8822, Abcam, 1:400) and a-smooth muscle actin (a-
SMA-AF594, ab202368, Abcam, 1:400) with wheat germ agglutinin (WGA-AF647, 
W32466, ThermoFisher Scientific, 1:300) to delineate scar and the infarct region and 
DAPI (D1306, ThermoFisher Scientific, 1:1000) for cell nuclei. Sections were imaged at 
10x on a fluorescent microscope and at least 6 images of the infarct, 12 images of the 
border zone, and 6 images of the remote region were quantified and averaged per 
animal for one biological replicate. Images were analyzed using ImageJ (NIH).  
The number of vWF+ structures, vWF+ structure size, and vWF+ area was 
determined by first creating a binary mask via thresholding with the Otsu method, then 
using the Close function to improve connectivity between structures. Particles greater 
than or equal to 7.5 µm2 in area were counted and measured. For the number of 
vWF+aSMA+ structures, vWF+aSMA+ structure size, and vWF+aSMA+ area, a similar 
analysis was completed but prior to counting particles, an image representing vWF and 
aSMA co-localization was created using the “AND” operator in the Image Calculator 
function on the binary masks of the vWF and aSMA channels. 
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6.2.6. STATISTICS 
 All statistical analyses were conducted using GraphPad Prism 8 software. 
Outliers were removed using the ROUT test with Q = 5% and statistical significance was 
determined using a two-tailed Student’s t-test or one-way ANOVA with post-hoc Tukey’s 
multiple comparisons test when appropriate.  
 
6.3 RESULTS AND DISCUSSION 
6.3.1. MSC MORPHOLOGY AFTER PRE-CONDITIONING 
 Rat MSCs were pre-conditioned in one of four treatment conditions: standard (A, 
21% O2 with serum-free MSC growth media), hypoxia (B, 1% O2 with serum-free MSC 
growth media), growth factor (GF, C, 21% O2 with serum-free pro-angiogenic growth 
factor-supplemented media), or GF+hypoxia (D, 1% O2 with serum-free pro-angiogenic 
growth factor-supplemented media). Treatment conditions were applied for 72 hours. 
Before and after the pre-conditioning regimen, images were taken of MSCs (Figure 
6.2a) and cell number and morphology (cell spread area, cell shape index, and cell 
aspect ratio) were quantified (Figure 6.2b-e). 
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Figure 6.2. MSC number and morphology after pre-conditioning. (a) Brightfield 
images of pre-conditioned rat mesenchymal stem cells (rMSCs) before and after 72 
hours of pre-conditioning treatments. Quantification of (b) cell number per area, (c) cell 
spread area, (d) cell shape index, and (e) cell aspect ratio before and after pre-
conditioning for all treatments. Solid fill: before pre-conditioning; Pattern fill: after pre-
conditioning; Mean ± SD; Scale bar: 200 μm; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001; GF: growth factor. 
 
 The number of cells per area was significantly lower after treatment for all 
conditions except for GF (Figure 6.2b). Cell death was expected in all conditions 
because MSCs were cultured without serum to facilitate EV collection, a requirement to 
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eliminate the introduction of EVs from serum into the experimental sample. Specifically, 
for EV collection cells must either be cultured in serum-free conditions or with EV-
depleted serum, which can still differ from normal serum in its cell proliferative 
capacity.31 Cells cultured under serum-free conditions have been shown to undergo 
apoptosis.32 These results suggest that culturing MSCs with pro-angiogenic growth 
factors can help maintain cell viability under serum-free conditions; however, hypoxic 
conditions reduces viability, even in the presence of growth factors.  
 Changes in cell morphology were also observed after the various treatment 
conditions were applied to MSCs. For all treatment groups, cell spread area significantly 
decreased, indicating that cells became more compact (Figure 6.2c). For the standard 
treatment group, cell shape index decreased, while hypoxia and GF treatments led to 
increases in cell shape index, indicating that cell shapes became more circular (Figure 
6.2d). Standard, hypoxia, and GF treatments led to decreases in cell aspect ratio 
(Figure 6.2e). GF+hypoxia treatment led to no change in cell shape index or cell aspect 
ratio. Decreases in cell spread area taken together with the changes in cell shape index 
and cell aspect ratio suggest that standard, hypoxia, and GF treatments resulted in more 
rounded cells, while GF+hypoxia treatment resulted in more compact cells of similar 
shape. MSC cell shape has been shown to be related to MSC differentiation33, so 
changes in cell morphology could be indicative of a changing MSC phenotype induced 
by the pre-conditioning treatments.  
6.3.2. EV CHARACTERIZATION 
 MSC EVs were isolated from conditioned media by polymer precipitation, and 
NTA was used to evaluate EV size, size distribution, and concentration. All treatment 
groups produced EVs with similar mode diameters of 90-110 nm (Figure 6.3a-b). 
Exosomes, a subset of EVs, are characterized as particles with diameters ranging from 
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50-150 nm6, and a majority of particles from all treatment groups were within this size 
range (Table 6.1). The total number of EVs isolated from each treatment group during 
one EV isolation was similar (Figure 6.3c), and did not seem to trend with the number of 
cells present after treatment shown in Figure 6.2b.  
 However, the amount of protein per EV varied between groups, and the amount 
of protein in EVs isolated from MSCs pre-conditioned with GF+hypoxia was significantly 
higher than that from MSCs pre-conditioned with hypoxia or GF alone (Figure 6.3d, 
Table 6.1). EVs, and specifically exosomes, are thought to contain proteins, RNAs, and 
lipids but exert their therapeutic efficacy primarily through proteins, so high protein 
concentrations could be beneficial depending on actual protein content.34 On average, 
the GF+hypoxia group had the highest protein content, followed by the standard 
treatment group.  
 
 
 
195 
 
Figure 6.3. EV characterization: size, yield, protein content. Extracellular vesicles 
(EVs) isolated from pre-conditioned rat mesenchymal stromal cells (rMSCs) were 
characterized using nanoparticle tracking analysis (NTA) for EV (a) size, (b) size 
distribution (shaded region represents typical exosome size, 50-150 nm), and (c) yield. 
(d) EV protein content quantified using a bicinchoninic acid (BCA) assay. Mean ± SE; 
*p<0.05, **p<0.01; GF: growth factor. 
 
Table 6.1. Exosome size and protein content for all pre-conditioning regimens. 
 
 
GF: growth factor. 
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6.3.2.1. IN VITRO ANGIOGENESIS 
 A Matrigel angiogenesis assay was used to evaluate the in vitro angiogenic 
potential of EVs isolated from MSCs pre-conditioned with all four treatment conditions, 
and saline was used as a negative control. Representative images of hUVEC tubule 
formation for all samples (Figure 6.4a) and quantification of the number of nodes and 
tubules per area (Figure 6.4b-c) show that treating hUVECs with MSC-derived EVs from 
standard, GF, and GF+hypoxia groups significantly increased the formation of vascular 
structures compared to the control group. On average, the GF+hypoxia group had the 
highest number of nodes and tubules per area, followed by the standard group. For 
further evaluation of EV contents using proteomics, only the GF+hypoxia and standard 
groups were evaluated based on in vitro results from the Matrigel angiogenesis assay 
and assessment of amount of protein in EVs. For in vivo studies of EV therapeutic 
efficacy for cardiac repair, only the GF+hypoxia group was evaluated.  
 
 
Figure 6.4. Matrigel angiogenesis assay. (a) Representative images of hUVEC tubule 
formation after treatment with EVs from all pre-conditioning groups. Quantification of (b) 
number of nodes and (c) number of tubules per area. Mean ± SD; Scale bar: 500 μm; 
*p<0.05, **p<0.01 compared to control; GF: growth factor, hUVEC: human umbilical vein 
endothelial cell, EV: extracellular vesicle.  
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6.3.2.2. PROTEOMICS 
 EVs isolated from MSCs pre-conditioned with standard and GF+hypoxia 
treatments were further characterized using mass spectrometry techniques and 
proteomics to determine the protein contents of these groups of EVs. 1675 proteins were 
identified in the standard group, and 1277 proteins were identified in the GF+hypoxia 
group; of these proteins, 1244 were common between both groups (Figure 6.5a). 
However, a principal component analysis (PCA) found two distinct protein populations, 
noted by their separation (green: GF+hypoxia; red: standard) dots on the PCA plot, 
especially with regard to component 1 which accounts for 69.5% of variance in the data 
(Figure 6.5b). This suggests that pre-conditioning MSCs with different treatments alters 
protein content in EVs isolated from these MSCs.  
 A Student’s t-test was used to compare proteins found in EVs isolated from 
standard treatment and GF+hypoxia treatment and a volcano plot was used to visualize 
the results (Figure 6.5c). In this plot, the negative log of the p-value is plotted versus the 
difference in expression between the two groups expressed as the log (base 2) of the 
fold change, so positive values indicate that a protein is over-expressed in standard EVs 
and negative values indicate that a protein is over-expressed in GF+hypoxia EVs. On 
this plot, red dots represent proteins that are statistically significantly over-expressed in 
standard EVs, and green dots represent proteins that are statistically significantly over-
expressed in GF+hypoxia EVs. Some of the greatest differences include proteins 
associated with the genes Adamts1, Lama435, and Col4a1, all of which have been 
implicated in angiogenesis. For example, Adamts1 is upregulated by VEGF and may be 
an endogenous regulator of endothelial cell proliferation36, while mutations in Col4a1 
have been shown to cause defects in blood vessel formation.37 This suggests that 
specific proteins related to angiogenesis are over-expressed in GF+hypoxia EVs.  
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Figure 6.5. Exploratory proteomics analysis. (a) Venn diagram of the number of 
proteins detected in each group. (b) Primary component analysis (PCA) plot showing 
variance between groups. (c) Volcano plot of significantly differentially expressed 
proteins (some gene labels shown). Red and green dots represent proteins significantly 
more expressed in standard or GF+hypoxia group, respectively. GF: growth factor. 
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GF+hypoxia
1.25 StandardGF+hypoxia 431124433
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 The results from the Student’s t-test can also be visualized using a heat map to 
show hierarchical clustering of proteins that are differentially expressed in each group 
(Figure 6.6a). As a result of hierarchical clustering, proteins that are more similarly 
expressed are grouped near each other in the dendrogram. This leads to the formation 
of two separate clusters of proteins- one that is over-expressed in standard EVs (Cluster 
2) and one that is over-expressed in GF+hypoxia EVs (Cluster 1). Profile plots of protein 
expression levels by sample show these similar patterns in the expression levels of 
protein from each cluster (Figure 6.6b). By annotating proteins using a gene ontology 
database, a Fisher’s exact test was used to determine biological processes that were 
enriched in each of these clusters and the biological process, enrichment factor, and 
false discovery rate (FDR) are reported here (Figure 6.6c). For enrichment factor, 
values less than 1 indicate depletion and the FDR is used instead of a p-value to correct 
for multiple comparisons, with FDR < 0.05 to indicate significant differences. Biological 
processes associated with extracellular matrix organization, cell adhesion, wound 
healing, positive regulation of cell migration, and regulation of cell proliferation are 
examples of processes enriched in GF+hypoxia EVs (Cluster 1), while actin nucleation, 
amino acid activation, actin cytoskeleton organization, intracellular protein transport, and 
vesicle-mediated transport are enriched in standard EVs (Cluster 2). GF+hypoxia EVs 
are enriched with proteins related to angiogenesis-related processes, while standard 
EVs are enriched with proteins related to protein synthesis and transport. While these 
lists are not exhaustive and there are many other biological processes, molecular 
functions, and cellular component categories that are enriched in proteins found in these 
clusters, these results continue to indicate that pre-conditioning treatment can change 
EV protein contents, and that priming MSCs with GF+hypoxia results in EVs that contain 
proteins that are enriched in angiogenesis-related processes.  
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Figure 6.6. Enrichment proteomics analysis. (a) Heat map showing hierarchical 
clustering of proteins that are differentially expressed in each group. High expression is 
shown in red and low expression is shown in green. Clusters of interest are highlighted 
in the dendrogram (pink, blue). (b) Profile plots of proteins within each cluster are distinct 
for each treatment group: Cluster 1 (pink) shows proteins strongly expressed in 
GF+hypoxia group (n=5); Cluster 2 (blue) shows proteins strongly expressed in standard 
group (n=4). Intensity scale represents distance from center. (c) List of relevant 
biological processes that are enriched in each cluster. GF: growth factor; EF: enrichment 
factor; FDR: false discovery rate. 
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6.3.3. IN VIVO RETENTION AND BIODISTRIBUTION 
 EV retention in rats was compared for near IR-labeled EVs delivered to the heart 
using either saline or an injectable hydrogel as a delivery vehicle. While the initial 
fluorescent signal was similar for ex vivo rat hearts injected with labeled EVs in both 
saline and gel, after 14 days more signal was detected from hearts that were injected 
with labeled EVs in gel than in saline (Figure 6.7a). Fluorescence signal is measured in 
units of radiant efficiency, which normalizes efficiency (the ratio of photons emitted to 
photons absorbed) by illumination power and allows for the comparison of images taken 
at varying instrument settings. The average radiant efficiency is the total radiant 
efficiency for a specific region of interest divided by the area of that region of interest.  
Quantifying fluorescence intensity in units of average radiant efficiency showed 
that the fluorescence intensity of labeled EVs decreased over time for both the injectable 
hydrogel and saline groups, but that the signal for the injectable hydrogel group was 
higher at each measured timepoint (Figure 6.7b; for gel vs saline groups, p=0.10 at 5 
minutes and p=0.14 at day 14). After only 5 minutes, EV fluorescence intensity in the 
heart decreased dramatically for both gel and saline groups, and the average radiant 
efficiency at 5 minutes for the saline group was significantly lower than at the initial 
timepoint (for gel p=0.09). As with cells, this is likely due to mechanical ejection of 
therapeutics from the beating heart and leakage into the coronary vasculature.8 The 
delivery of EVs with injectable hydrogels showed trends for improved EV retention, and 
targeted, sustained EV delivery may be important for therapeutic efficacy.38,39   
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Figure 6.7. in vivo EV retention. (a) Representative images of rat hearts injected with 
near IR-labeled EVs in saline or an injectable hydrogel at day 0 and day 14. (b) 
Quantification of fluorescence signal over time in units of average radiant efficiency for 
near IR-labeled EVs delivered to the heart in saline or an injectable hydrogel.  Mean ± 
SE. 
 
Biodistribution of EVs after cardiac delivery was also explored for different 
timepoints for EVs delivered with saline or with an injectable hydrogel. Representative 
images of organs showing fluorescent signal from labeled EVs delivered to the heart 
showed that the distribution of labeled EVs in other organs varied based on delivery 
vehicle and time after injection (Figure 6.8a). At day 1, EVs delivered in saline were 
found in high quantities in the kidneys, stomach, small intestine, and large intestine, 
suggesting that since these EVs were not well-retained in the heart, they accumulated in 
the kidneys. By day 7, the strongest EV signal was in the stomach and at day 14, EV 
signal concentration was localized to the stomach, small intestine, and large intestine 
(Figure 6.8b). In general, saline delivery of EVs showed high localization initially to the 
kidneys followed by localization to the digestive tract over time.  
For EVs delivered with an injectable hydrogel, EV signal patterns were similar at 
day 1 but there was a larger portion of EVs remaining in the heart. At later day 7 and day 
14 timepoints, EVs were again distributed similarly to saline and concentrated in the 
stomach, small intestine, and large intestine, but also in the heart (Figure 6.8c). Here, 
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EV distribution was spread more evenly, with some localization to the kidneys initially 
and to the digestive tract but also retention in the heart. For the translation of EV 
therapies, it is important to understand the localization of EV therapies after delivery to 
anticipate off-target effects. Studies by other groups have shown that a number of 
factors such as EV cell source, EV dose, and even mode of EV delivery can affect 
biodistribution and tissue localization.40  
 
 
Figure 6.8. in vivo EV biodistribution. (a) Representative images of biodistribution of 
near IR-labeled EVs after delivery to the heart in saline or injectable hydrogel at day 1, 
day 7, and day 14 timepoints. Quantification of fluorescence signal in organs in units of 
average radiant efficiency for near IR-labeled EVs delivered in (b) saline or (c) injectable 
hydrogel to the heart at day 1, day 7, and day 14 timepoints. Mean ± SE; 1: heart, 2: 
lungs, 3: spleen, 4: kidneys, 5: liver, 6: stomach, 7: small intestine, 8: large intestine. 
 
6.3.4. RAT MI MODEL 
 Following MI, EVs isolated from MSCs pre-conditioned with GF+hypoxia were 
delivered to the heart using either saline or an injectable hydrogel as a delivery vehicle. 
Saline and injectable hydrogel alone were also investigated as controls. The mortality 
rate after MI and injection of any of the four treatment groups (PBS, Gel, PBS + EVs, or 
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Gel + EVs) was 21.3% (10 of 47 animals). However, 27% of the remaining animals (10 
of 37 animals) did not have transmural infarcts, which was discovered upon staining 
sections of cardiac tissue with Masson’s trichrome; these animals were excluded from 
further analysis. At least 4 biological replicates remained for each of the treatment 
groups (PBS: n=5, Gel: n=11, PBS + EVs: n=4, Gel + EVs: n=7).  
 Masson’s trichrome staining showed a large variation in scar fraction and scar 
thickness for all treatment groups (Figure 6.9). For instance, within the gel group, there 
were some sections which showed a very thin ventricular wall and an infarct fraction of 
greater than 50%, while other sections were thicker and had infarct fractions of less than 
25%. Quantification of scar fraction (Figure 6.10a) and scar thickness (Figure 6.10b) 
yielded no significant differences in either metric for any of the treatment groups. The 
largest range in scar fraction was found in the gel group, which had values from about 
0.1 to 0.7. Variations in infarct induction likely led to a large range in infarct severity, 
which is represented here by scar fraction. Future studies should focus on creating 
repeatable infarcts to provide a reliable baseline for testing therapeutic efficacy. 
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Figure 6.9. Cardiac remodeling. Representative images of tissue sections taken from 
the mid-papillary level of all rats from all treatment groups after staining with Masson’s 
Trichrome. In these images, red is healthy muscle tissue and blue is infarct tissue or 
scar. Note the large variations in infarcts across a group, likely indicating variable infarct 
reduction, which then limited the ability to quantify remodeling outcomes. 
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Figure 6.10. Quantification of cardiac remodeling. (a) Scar fraction and (b) scar 
thickness 4 weeks after delivery of treatment groups. Mean ± SD; EVs: extracellular 
vesicles. 
 
 While there were no differences in global cardiac remodeling for any of the 
treatment groups, there were variations in the density and size of vascular structures. 
Immunohistochemical staining for vascular structures probed for vWF, an endothelial cell 
marker, and aSMA, which is expressed by smooth muscle cells. While vWF is present in 
the lumens of most vascular structures ranging from capillaries to arteries, aSMA is 
generally only present in more mature vascular structures such as arterioles and 
arteries.41,42 However, both vWF+ and vWF+aSMA+ structures contribute to enhanced 
perfusion of the myocardium. Representative images from all treatment groups of 
immunohistochemical staining in the infarct (Figure 6.11a-d), border zone (Figure 
6.11e-h), and remote (Figure 6.11i-l) regions for vascular structures are shown here.  
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Figure 6.11. Vascular structures. Representative images of staining for vascular 
structures in the infarct (a-d), border zone (e-h), and remote (i-l) regions after delivery of 
PBS (a, e, i), gel (b, f, j), PBS + EVs (c, g, k), or gel + EVs (d, h, l) to the heart. EVs: 
extracellular vesicles.  
 
Quantification of the number and size of vascular structures is shown in Figure 
6.12. Interestingly, there was often increased vWF+ or vWF+aSMA+ staining and larger 
vascular structures located in the infarct region than in the border zone and remote 
regions, irrespective of treatment group. For instance, vWF+ area was significantly 
greater in the infarct region than in the border zone or remote regions for all treatment 
groups (Figure 6.12e). Except for PBS, vWF+ structure size was also significantly 
greater in the infarct region than in the border zone or remote regions for all treatment 
groups (Figure 6.12c). vWF+aSMA+ area was significantly greater in the infarct than 
remote regions for the Gel group and significantly greater in the infarct than border zone 
or remote regions for the Gel + EVs group (Figure 6.12f). vWF+aSMA+ structure size 
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was also significantly larger in the infarct region than in the border zone and remote 
regions for the Gel + EVs group (Figure 6.12d).  
 
 
Figure 6.12. Quantification of vascular structures. Number of (a) vWF+ and (b) 
vWF+⍺SMA+ structures, (c) vWF+ and (d) vWF+⍺SMA+ structure size, and (e) vWF+ and 
(f) vWF+⍺SMA+ area in infarct, border zone (BZ), and remote regions after delivery of 
PBS, gel, PBS + EVs, or gel + EVs. Mean ± SD; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001; vWF: von Willebrand factor; ⍺SMA: ⍺-smooth muscle actin, EVs: 
extracellular vesicles.  
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A study by Gkontra, et al tracked microvascular changes in the infarct region 
after MI and found that in a pig ischemia/reperfusion model of acute MI, an initial dilation 
of vessels in the infarct region after 1 day is followed by constriction of vessels at 3 days, 
and then a pruning of microvessels and dilation or arterialization of the remaining 
vasculature at 7 days.43 They also found that changes in microvasculature in remote 
regions are not as drastic. This suggests that the majority of changes in vascular 
structure after MI may occur in the infarct region as a response to the ischemic injury, 
which could account for the increased vWF+ area and vWF+ structure size.  
Vascular structures in the infarct region also differed in size and density among 
treatment groups. vWF+ structure size was significantly larger in the infarct region for the 
PBS + EVs than the PBS group, and for the Gel + EVs group than the PBS or Gel 
groups (Figure 6.12c). vWF+ area was also significantly greater in the infarct region for 
the Gel + EVs group compared to the PBS group (Figure 6.12e). For the analysis of 
more mature vascular structures, vWF+aSMA+ structure size was significantly larger in 
the infarct region for the Gel + EVs group compared to the PBS or Gel groups (Figure 
6.12d).  
Taken together, these results suggest that therapeutic delivery to the border 
zone can impact the size and density of vascular structures in the infarct region, which 
may be due to the increase in microvascular changes that happen in the infarct region 
when compared to more remote regions of the myocardium.43 These results also 
suggest that the delivery of MSC-derived EVs in saline or an injectable hydrogel 
increases vasculature compared to the delivery of saline or an injectable hydrogel alone 
and that the delivery of EVs specifically increases the size of both vWF+ and 
vWF+aSMA+ structures, which is important because larger vascular structures can be 
more constructive for increased perfusion. The in vivo angiogenic potential of MSC-
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derived EVs corroborates the in vitro results shown by the Matrigel angiogenesis assay, 
and other groups have shown that the delivery of MSC-derived EVs can promote 
neovascularization after MI.12 
 
6.4 CONCLUSION 
 Rat MSCs were pre-conditioned in one of four treatment conditions- standard, 
GF, hypoxia, and GF+hypoxia. Pre-conditioning MSCs led to changes in cell number per 
area and cell morphology, generally resulting in more compact and rounded cells for all 
treatment conditions. EVs isolated from MSCs pre-conditioned with aforementioned 
treatment conditions had varying protein content, and EVs isolated from MSCs pre-
conditioned with GF+hypoxia had significantly greater protein content than EVs isolated 
from MSCs pre-conditioned with hypoxia or GF. EVs isolated from MSCs treated with 
standard, GF, and GF+hypoxia conditions significantly increased tubule formation in a 
Matrigel angiogenesis assay. Proteomics analysis of EV protein contents determined 
that EVs isolated from MSCs pre-conditioned with standard or GF+hypoxia conditions 
had statistically different expressions of many proteins, and that EVs produced in these 
conditions contributed to two different populations of EVs, with GF+hypoxia EVs being 
enriched for proteins involved in biological processes related to angiogenesis. Injectable 
hydrogel delivery of EVs improved EV retention in the heart when compared to saline 
delivery of EVs, and the delivery of EVs isolated from MSCs treated with GF+hypoxia 
significantly increased vascularization in the infarct region when delivered after MI. 
Further studies should more carefully explore differences in EV content for pre-
conditioning treatment conditions, including analyzing miRNA content using sequencing, 
and focus on investigating changes in cardiac function with injectable hydrogel delivery 
of EVs after MI.  
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CHAPTER 7  
CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS 
 
7.1 OVERVIEW 
 This dissertation describes the use of an injectable, hyaluronic acid (HA) 
hydrogel for the improved retention of cells and cell-derived therapeutics delivered to the 
heart after myocardial infarction (MI). The injectable hydrogel utilized in this thesis is 
comprised of HA that is modified separately with adamantane (guest) and b-cyclodextrin 
(host) molecules, which form supramolecular hydrophobic interactions upon mixing that 
disassemble upon the application of shear forces.1 This allows the hydrogel to be shear-
thinning and rapidly self-healing, which permits injection and immediate stabilization of 
the gel at the injection site, respectively. Synthesis and characterization of this injectable 
hydrogel is described in Chapter 3, followed by the application of this hydrogel for the 
delivery of endothelial progenitor cells (EPCs) in Chapter 4. In Chapter 5, this injectable 
hydrogel is combined with covalently crosslinked microgels for the delivery of IL-10, and 
in chapter 6, the injectable hydrogel is used as a delivery vehicle for mesenchymal 
stromal cell (MSC)-derived extracellular vesicles (EVs) to the heart. The rest of this 
chapter will describe the major conclusions of each of these studies, as well as the 
limitations of the studies and potential future directions for further exploration.  
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7.2 SPECIFIC AIM 1 
DEVELOP METHODS TO CHARACTERIZE SHEAR-THINNING AND SELF-HEALING 
HYDROGELS AND THEIR POTENTIAL FOR INJECTABILITY IN BIOMEDICAL 
APPLICATIONS. 
7.2.1. CONCLUSIONS 
 In this chapter, we developed methods for the synthesis and characterization of 
the guest-host injectable hydrogel that was used in subsequent chapters for the delivery 
of cell-based therapeutics. Further, we described general methods for the rheological 
characterization of injectable hydrogels, and showed that material properties such as 
modulus, yield strain, viscosity, and shear stress could be varied by changing hydrogel 
formulation. Two methods for measuring the injection force required to extrude an 
injectable hydrogel from a syringe were developed and used to investigate how hydrogel 
formulation, flow rate, needle gauge, and needle length modulated injection force. A 
protocol for cell encapsulation and cell culture of injectable hydrogels was also 
developed, along with methods for evaluating cell viability after encapsulation and 
injection from a syringe, and used to illustrate how hydrogel formulation and injection 
parameters affect cell viability. Finally, best practices for hydrogel injection in a rat MI 
model were developed, including identification of injection locations and needle 
placement to prevent hydrogel leakage from the myocardium and methods for tissue 
processing to best preserve hydrogels in tissues.  
 An enumeration of these methods is important because careful hydrogel 
characterization is crucial for the clinical translation of injectable hydrogel therapies. 
Practically, hydrogels that require too much force for a typical operator to inject are not 
going to be testable in preclinical animal models, much less in clinical trials. Also, 
injectable hydrogels designed for cell delivery need to be tested for cell viability after 
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injection, since forces that cells experience during injection can lead to cell death.2 
Especially for cell delivery, changes in seemingly unimportant injection parameters such 
as flow rate, needle gauge, and needle length lead to variations in injection forces that 
could greatly affect cell viability and need to be considered in preclinical studies. In 
addition, small animal models are challenging, and techniques need to be established 
for the delivery of injectable hydrogels to the heart to ensure reproducibility in both 
injection location and volume. We describe these methods here for the characterization 
of injectable hydrogels and use in an in vivo model to highlight the considerations that 
need to be made when engineering an injectable hydrogel for any clinical application.  
7.2.2. LIMITATIONS AND FUTURE DIRECTIONS 
 One of the key limitations of this thesis is the use of the same injectable hydrogel 
and nearly the same material formulation for all studies. While this initial formulation was  
optimized for cell delivery, other material formulations may be better suited for growth 
factor or EV delivery, and considerations for those factors will be described later in this 
chapter in sections 7.4.2 and 7.5.2, respectively. In addition, the range of material 
properties (e.g., modulus) that can be obtained with this injectable hydrogel was 
relatively small (~1-10 kPa), so to increase the stiffness of this hydrogel, secondary 
crosslinking mechanisms could be considered.3,4 In general, stiffer hydrogels (20-40 
kPa) have been shown to be more beneficial for limiting infarct expansion than softer 
hydrogels (1-10 kPa), so the incorporation of a secondary crosslinking mechanism may 
be desired.3,5 
 Also, the injectable hydrogel described was tuned for high cell viability through 
trial-and-error permutations of material formulations and injection parameters that were 
tested for high cell viability. However, it may be useful to create a model that correlates 
flow properties of the injectable hydrogel to cell viability. For instance, Yan et al 
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determined that b-hairpin peptide-based hydrogels have a central wide plug flow region 
that allows for high cell viability after injection.6 In this way, the flow profiles of injectable 
hydrogels could be used to screen material formulations and injection parameters prior 
to the encapsulation of cells, which could greatly improve the time required to screen a 
large number of hydrogel conditions. Unfortunately, due to technical limitations (the 
technique described requires a confocal microscope with a high speed camera) we were 
unable to develop this model, but being able to screen a large number of hydrogel 
conditions would still be useful, especially as the incorporation of cells in bioinks for 3D 
printing grows in popularity.  
 Finally, there are many limitations to the rat MI model described in this chapter. 
Since the same model is also utilized in subsequent chapters, these limitations also 
apply to those chapters but will be described once here. For infarct induction, permanent 
ligation of the left anterior descending artery has little clinical relevance for humans, 
since acute MI is often treated with thrombolytics or angioplasty to restore blood flow.7 
Thus, an ischemia/reperfusion injury much more closely models MIs and their clinical 
standard of care in humans.7 Also, in rat MI models, infarcts can vary from 4-59% of the 
left ventricle even with no discernible variation in surgical technique, likely due to 
variations in anatomy from animal to animal.8 Differences in baseline infarct size can 
make treatment comparisons difficult or even impossible if variation in infarct size is too 
large. Using echocardiography, it can be possible to measure baseline cardiac function 
after infarct induction for all animals to reduce infarct variability9, but this technique is not 
possible if the therapeutic is injected immediately after infarct induction, as it is in this 
model. Immediate delivery of a therapeutic after MI also has little to no clinical relevance, 
as it does not match the clinical scenario, and other groups have shown that delaying 
the delivery of therapeutics can improve their efficacy, likely due to improved targeting of 
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the phases of ventricular remodeling after MI.10,11 Also, depending on the therapeutic 
mechanism of action, the ideal delivery window may vary. 
 Toward clinical translatability, the use of injectable hydrogels as delivery vehicles 
allows for minimally invasive, percutaneous delivery, but hydrogel formulations need to 
be tuned for flow through a catheter. In addition, considerations need to be made for 
delivery method (e.g., intracoronary vs intramyocardial) and the risks associated with 
each of these methods (e.g., embolization, myocardial injury). In addition, subsequent 
experiments in large animals such as pigs will improve the clinical relevance of these 
studies since pig cardiac anatomy and physiology much more closely resembles that of 
humans, but these models are costly and are not appropriate for therapeutic screening.7 
Also, studies of immune response, hydrogel degradation byproducts, and potential 
toxicity should be investigated, particularly for hydrogels formed from derivations of 
naturally-occurring materials. 
 
7.3 SPECIFIC AIM 2 
DELIVER ENDOTHELIAL PROGENITOR CELLS (EPCS) USING AN INJECTABLE 
HYDROGEL TO THE HEART AFTER MI. 
7.3.1. CONCLUSIONS 
 In this chapter, we used the injectable hydrogel described in the previous aim to 
deliver EPCs to the heart in a rat model of MI, particularly as EPCs have been previously 
shown by our group to promote vascularization.12 We found that the delivery of EPCs 
with an injectable hydrogel significantly improved EPC localization to the border zone 
region of the infarct when compared to the delivery of EPCs in saline, and that this 
improved localization was correlated with significant improvements in vascularization, 
cardiac geometry, and cardiac function. In this study, we were able to validate the use of 
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our injectable hydrogel as a cell delivery vehicle, and also show that improved cell 
retention at the injection site improves cardiac outcomes after MI, which is useful for 
improving the efficacy and thereby the translatability of cell therapies to the clinic.  
7.3.2. LIMITATIONS AND FUTURE DIRECTIONS 
 The EPCs used in this study were primary cells isolated from the bone marrow of 
syngeneic rats, and isolation from, on average, one rat was required to obtain enough 
EPCs for one dose. While EPCs are already a heterogenous cell population13, the use of 
primary cells means that multiple EPC isolations from multiple rats needed to be pooled 
for each surgery date in this study. In the future, utilizing an alternate cell type, such as 
mesenchymal stromal cells, which can be subcultured and delivered allogeneically14, 
may reduce cell heterogeneity and be more applicable for clinical translation.  
 While the injectable hydrogel used in this study was optimized for cell viability, 
mechanisms for cell-mediated hydrogel degradation could be engineered into the gel to 
allow for more effective cell delivery. For instance, matrix metalloproteinases (MMPs) 
are up-regulated in the heart after MI15 and are expressed by EPCs.16 An MMP-
degradable peptide could be incorporated into the injectable hydrogel to allow for MMP-
mediated hydrogel degradation and cell delivery.17 
 Further studies could also investigate the efficacy of multimodal therapies 
whereby cells are combined with other factors to improve their therapeutic effect. For 
instance, Saif et al delivered pro-angiogenic growth factors (vascular endothelial growth 
factor, hepatocyte growth factor, and angiopoietin-1) with human cord blood 
vasculogenic progenitor cells in a murine hindlimb ischemia model, and found that the 
combined therapy was more effective for vascularization and increased perfusion than 
either therapy alone.18 In addition to pro-angiogenic factors, pro-survival factors such as 
insulin-like growth factor-1 may also be useful to improve the viability of delivered 
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cells.19,20 However, more complex therapies would likely have a more complicated 
regulatory pathway, so the benefits of combination therapies should be significant.  
 
7.4 SPECIFIC AIM 3 
DESIGN AND EVALUATE INJECTABLE MICROGEL/HYDROGEL COMPOSITES 
FOR INTERLEUKIN-10 (IL-10) DELIVERY TO THE HEART. 
7.4.1. CONCLUSIONS 
 In this aim, injectable microgel/hydrogel composites were designed for IL-10 
delivery to the heart. In this case, the injectable hydrogel described in Aim 1 was used 
as a bulk injectable hydrogel to encapsulate microgels and improve microgel retention at 
the injection site.21 IL-10, an anti-inflammatory cytokine22,23, was used as a model 
therapeutic. Covalently crosslinked microgels were designed for IL-10 release, 
incorporating factors such as dithiol crosslinkers with varying stability to control microgel 
degradation and IL-10 release and thiolated heparin for IL-10 sequestration during the 
microgel formation process. The delivery of the composite hydrogel with IL-10 to the 
heart after MI significantly reduced inflammation (macrophage levels) and improved 
cardiac repair (vascularization, function, geometry) compared to the delivery of saline. 
The injectable composite hydrogel delivery system described in this aim decouples 
hydrogel injectability from sustained therapeutic delivery, and could be modified for the 
release of multiple growth factors with complex release profiles toward more effective 
molecular therapies.  
7.4.2. LIMITATIONS AND FUTURE DIRECTIONS 
 For growth factor encapsulation in bulk hydrogels, engineering growth factor-
hydrogel interactions as well as tailoring the mesh size of the bulk hydrogel are 
important when designing hydrogels for growth factor release. In the case of composite 
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hydrogels, it can be important to tailor the relationship between the mesh size of the bulk 
hydrogel and the diameter of the microgels. In most cases, microgel diameter is much 
larger than hydrogel mesh size to allow for entrapment of microgels within the bulk 
hydrogel. In this case, the release of encapsulated therapeutics from the microgel are 
mediated either by release first from the microgels and then diffusion through the bulk 
gel, or by release of microgels from the bulk gel.24 Therefore, to further control 
therapeutic release from the composite hydrogel system, mechanisms of degradation for 
the bulk gel could also be designed. For example, the incorporation of MMP-degradable 
crosslinks could be useful for hydrogel degradation, especially when delivered to the 
heart after MI.17 
 For varying therapeutic release from microgels, crosslinker degradability, 
molecule tethering, and microgel size could be explored. For crosslinker degradability, 
we evaluated both a stable crosslinker and a hydrolytically-degradable crosslinker, but 
there are many other types of crosslinkers that could be used depending on the 
application (e.g., proteolytically degradable, light sensitive25) to control molecule release. 
IL-10 was sequestered in microgels via charge using thiolated heparin, but there are 
many other protein-peptide or protein-protein interactions that could be leveraged for 
growth factor encapsulation.26 Additionally, the microgels we studied were of one size 
(60 µm diameter). Varying microgel size could alter microgel degradation and molecule 
release kinetics by changing the surface area to volume ratio, and change composite 
material properties due to differences in packing. Microgel size can be varied by either 
changing the geometry of the microfluidic device or by modifying fluid flow rates through 
the device.  
 The injectable composite hydrogel delivery system described in this aim could be 
used for the complex delivery of factors in situations when the temporal or spatial27 
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control of growth factor delivery is important, such as in angiogenesis.28,29 The modular 
nature of this system allows for the incorporation of varying amounts of multiple 
microgels of different sizes. As with any growth factor therapy, a dosing study is also 
important for clinical translation. 
 
7.5 SPECIFIC AIM 4 
DEVELOP PRE-CONDITION PROTOCOLS FOR THE ISOLATION OF 
EXTRACELLULAR VESICLES (EVS) FROM MESENCHYMAL STROMAL CELLS 
(MSCS) AND DELIVER TO THE HEART USING AN INJECTABLE HYDROGEL. 
7.5.1. CONCLUSIONS 
 In this aim, EVs isolated from pre-conditioned MSCs were delivered to the heart 
using the injectable hydrogel described in Chapter 3. MSCs were treated with pro-
angiogenic growth factors and cultured in hypoxic conditions to improve their 
vasculogenic potential. EVs isolated from pre-conditioned MSCs increased the formation 
of vascular structures in vitro compared to saline. Pre-conditioned EVs also had altered 
protein contents when compared to standard EVs, and proteins found in pre-conditioned 
EVs were involved in biological processes related to angiogenesis. Injectable hydrogel 
delivery of EVs to the heart improved EV retention compared to the delivery of EVs in 
saline, and, in a rat MI model, the delivery of pre-conditioned EVs to the heart using an 
injectable hydrogel significantly increased the formation of vascular structures. In this 
study, we were able to alter MSC EV contents through pre-conditioning, which had 
implications for improving the efficacy of cell-derived therapeutics for cardiac repair. In 
addition, this aim further showcased the use of this injectable hydrogel for EV delivery to 
the heart.11,30 
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7.5.2. LIMITATIONS AND FUTURE DIRECTIONS 
 A large barrier for EV translation is EV heterogeneity and the diversity of 
methods in EV isolation, which can greatly affect EV purity. In this study, great care was 
taken to ensure that each EV isolation produced EVs of similar quality- for example, 
mode size, size distribution, quantity of protein, and metrics of in vitro angiogenesis were 
compared for each isolation and only isolations that were similar to each other and met 
set standards were used downstream in proteomics and in vivo experiments. Currently, 
there is no standard in the field for EV isolation, and the method used for EV isolation in 
this study, polymer precipitation, has benefits for cost and ease but also generally leads 
to the isolation of non-EV proteins and contamination from the polymer precipitation 
reagent.31 Other EV isolation methods, such as ultracentrifugation coupled with density 
gradient centrifugation, could be explored to reduce the presence of contaminants and 
isolate more pure EVs. For scale-up of EV production, bioreactors have been shown to 
increase EV yield by 100-fold compared to traditional cell culture methods through 
enhancements in cell culture surface area, medium perfusion, and mass transport.32   
Additional characterization of EV contents could also be useful for understanding 
the mechanisms driving the therapeutic benefits of EV delivery. While proteomics 
studies are becoming more commonplace for EV analysis33, using miRNA-seq34 or RNA-
seq35 to investigate RNA contents of EVs may also be useful, and a careful examination 
of EV contents is important toward developing standards for EVs in a therapeutic 
context.  
 Typically, the release of molecules from hydrogels is dependent on the hydrogel 
mesh size in relation to the size of the encapsulated molecule, with release mediated 
through diffusion and potential degradation mechanisms.24 Release can also be affected 
by affinity between the hydrogel and encapsulated molecule, so that EV-hydrogel 
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interactions could be engineered to further sustain EV delivery. For example, in the case 
of our guest-host hydrogel, EVs could be functionalized with adamantane (guest) groups 
that could interact with excess b-cyclodextrin (host) groups on HA and sequester EVs.36 
Further studies should also investigate the effects of EV dose on therapeutic efficacy. 
 
7.6 OVERALL SUMMARY 
Injectable hydrogels can improve the targeted delivery of cells, cytokines, and 
EVs to the heart after MI to enhance outcomes of cardiac repair (vascularization, 
function, geometry). This thesis describes the development of more effective therapies 
for cardiac repair through the use of an injectable hydrogel for improved retention, and 
enumerates techniques that can be applied for the translation of these therapies to the 
clinic, where delivery challenges, such as the local and sustained release of 
therapeutics, have often precluded success in clinical trials. While the work described in 
this thesis contributes to the body of knowledge surrounding the use of biomaterials as 
therapeutic delivery vehicles, some of the greatest challenges remaining for clinical 
translation include the development of a catheter-based, minimally invasive delivery 
method for the delivery of hydrogels to the heart and manufacturing and reproducibility 
of cell-based therapies. As cell-based therapies and biomaterials evolve, we anticipate 
that the work featured in this thesis can help guide the development of more effective 
therapeutics for the heart, as well as toward widespread biomedical applications where 
injectable therapies are useful. 
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